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Early detection by X-ray mammography allows for timely treatment of breast cancer, thus preventing
disease progression and improving patient outcome. However, the sensitivity of mammography is
reduced in women with dense breasts, which may lead to delayed diagnosis, more advanced stage upon
detection, and reduced survival. Thus, a dual energy technique has been implemented to improve the
diagnostic sensitivity of mammography. Dual energy mammography (DEM) employs k-edge imaging to
separate iodine contrast materials and distinguish iodinated tumors from surrounding tissue. However,
iodine agents have drawbacks such as potential adverse reactions and low contrast generation for DEM.
Recently, silver has been identified as an element that has superior DEM contrast properties. In this thesis,
we present the development of silver sulfide nanoparticles (Ag2S-NP) as a low-cost, biocompatible
contrast agent specialized for DEM. Hydrophobic Ag2S-NP were encapsulated in phospholipid micelles
with iron oxide nanoparticles and a near-infrared fluorophore to create a multimodality nanoprobe. This
agent showed negligible cytotoxicity and allowed breast tumors to be detected in vivo with DEM and other
imaging methods, thus providing a safe and flexible screening option. To increase the likelihood of
translation, sub-5 nm, hydrophilic Ag2S-NP were formulated to be renally-clearable with 85% of the
injected dose being excreted within 24 hours of intravenous injection. This is amongst the best clearance
of similarly sized nanoparticles reported thus far. To further improve the clearance efficiency, we
employed a novel microfluidics approach to synthesize Ag2S-NP under ambient conditions and to
maintain the integrity of surface ligands. Intact coating shell improved the clearance of Ag2S-NP by
lowering uptake in the liver and shifting nanoparticle distribution into the hepatocytes. This initial finding
highlights the impact of synthetic conditions on ligand integrity and subsequent clearance and nano-bio
interactions. Finally, small core Ag2S-NP were loaded in biodegradable polymers to form a
multifunctional, theranostic agent, which can be used for multimodality tumor detection, image-guided
surgery, and localized tumor ablation via phototherapy. This work expands the list of potential DEM
specific contrast agents and represents a significant advancement in the biomedical uses of Ag2S-NP.
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ABSTRACT

SILVER SULFIDE NANOPARTICLES FOR BREAST CANCER IMAGING WITH DUAL
ENERGY MAMMOGRAPHY AND OTHER MODALITIES
Jessica C. Hsu
David P. Cormode

Early detection by X-ray mammography allows for timely treatment of breast
cancer, thus preventing disease progression and improving patient outcome. However,
the sensitivity of mammography is reduced in women with dense breasts, which may lead
to delayed diagnosis, more advanced stage upon detection, and reduced survival. Thus,
a dual energy technique has been implemented to improve the diagnostic sensitivity of
mammography. Dual energy mammography (DEM) employs k-edge imaging to separate
iodine contrast materials and distinguish iodinated tumors from surrounding tissue.
However, iodine agents have drawbacks such as potential adverse reactions and low
contrast generation for DEM. Recently, silver has been identified as an element that has
superior DEM contrast properties. In this thesis, we present the development of silver
sulfide nanoparticles (Ag2S-NP) as a low-cost, biocompatible contrast agent specialized
for DEM. Hydrophobic Ag2S-NP were encapsulated in phospholipid micelles with iron
oxide nanoparticles and a near-infrared fluorophore to create a multimodality nanoprobe.
This agent showed negligible cytotoxicity and allowed breast tumors to be detected in vivo
with DEM and other imaging methods, thus providing a safe and flexible screening option.
To increase the likelihood of translation, sub-5 nm, hydrophilic Ag2S-NP were formulated
to be renally-clearable with 85% of the injected dose being excreted within 24 hours of
iii

intravenous injection. This is amongst the best clearance of similarly sized nanoparticles
reported thus far. To further improve the clearance efficiency, we employed a novel
microfluidics approach to synthesize Ag2S-NP under ambient conditions and to maintain
the integrity of surface ligands. Intact coating shell improved the clearance of Ag2S-NP by
lowering uptake in the liver and shifting nanoparticle distribution into the hepatocytes. This
initial finding highlights the impact of synthetic conditions on ligand integrity and
subsequent clearance and nano-bio interactions. Finally, small core Ag2S-NP were loaded
in biodegradable polymers to form a multifunctional, theranostic agent, which can be used
for multimodality tumor detection, image-guided surgery, and localized tumor ablation via
phototherapy. This work expands the list of potential DEM specific contrast agents and
represents a significant advancement in the biomedical uses of Ag2S-NP.
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Chapter 1 : Introduction to breast cancer,
mammography and nanoparticle contrast agents

dual

energy

1.1 Introduction
Medical imaging aims to improve patient outcomes by providing key information
that leads to early detection, diagnosis, and appropriate treatment of diseases. X‐ray
based imaging techniques, such as computed tomography (CT), remain the most
frequently used diagnostic technology in medicine. Mammography is an X-ray imaging
method that is used extensively to screen for breast cancer. This is the only modality that
has been shown to reduce mortality from this disease.1 However, it is widely recognized
that mammography has poor efficacy for women with dense breasts.2 As a result, a dual
energy technique has been introduced to improve the diagnostic sensitivity of
mammography.3

Dual

energy

mammography

(DEM),

or

contrast

enhanced

mammography, employs k-edge imaging to distinguish tumors from surrounding tissue
through differential attenuation of materials at different X-ray energies.4 The emergence
of DEM is a first step in the development toward multi-energy X-ray breast imaging.
Iodinated small molecules have been utilized as X-ray contrast agents since the
1950s. However, these agents have drawbacks including nonspecific biodistribution, short
blood half‐lives, and contra‐indication for use with renal insufficiency.5 Most importantly,
they are not optimized for many newly emerging multi-energy X-ray imaging technologies
such as DEM and photon-counting mammography.6 Given these limitations, researchers
have turned to nanotechnology for developing alternative X‐ray contrast agents, most of
which are iodinated nanostructures and inorganic nanoparticles with novel chemical
compositions.7-9 The use of nanoparticle contrast agents for mammographic techniques
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remains mostly unexplored, prompting the need to develop biocompatible nanoparticle
agents that are optimized for breast imaging with DEM.
In this chapter, I first describe the effect of breast density on breast cancer
detection. I then explain the principles behind X-ray contrast generation and detail the
development of mammographic techniques as well as other relevant X-ray imaging
technologies. In addition, I introduce examples of novel X-ray nanoparticle contrast agents
that are found in the literature. Lastly, as a preface to this dissertation work, I discuss
possible improvements to current nanoparticle agents for DEM and explore other utilities
for the proposed formulation.

1.2 Background
1.2.1 Breast cancer
1.2.1.1 Overview
Worldwide, breast cancer is the most common form of cancer to affect women,
accounting for 30% of all cancer diagnoses in women.10 In the United States, breast
cancer is the second most deadly cancer for women, exceeded only by lung cancer.11 In
2021, an estimated 281,550 new cases of breast cancer will be diagnosed and about
43,600 women will die in this year from this disease.12 Currently, the average lifetime risk
of a woman developing and dying from breast cancer is about 13% and 3%, respectively.
The incidence rates for breast cancer have generally declined since the year 2000 but
have been slowly increasing by 0.3% per year in recent years,13, 14 likely due to higher
body mass index and lower fertility rates. The overall mortality rate peaked in 1989, but
since has declined rapidly, for a total decrease of 40% through 2017. The large decline
2

has been attributed to both improvements in treatment and earlier detection through
population-wide mammography screening.15 Early detection is particularly important since
women diagnosed with early or local stage breast cancer have much higher five-year
relative survival rates (99%) compared to those diagnosed with metastatic disease
(27%).16

1.2.1.2 Breast density
Breasts are mainly comprised of fibrous, glandular and adipose tissues. Breast
tissue density reflects the amount of fibroglandular mammary tissue relative to adipose
tissue in the breasts measured during a mammogram.17 Following a mammogram, a
woman’s breast tissue is categorized as follows: 1) fatty, 2) scattered areas of
fibroglandular tissue, 3) heterogeneously dense, and 4) extremely dense.18 Women with
breasts that are either heterogeneously dense or extremely dense are said to have high
breast density. Dense breasts have relatively high amounts of fibroglandular tissue and
low amounts of adipose tissue.19 Breast density is influenced by genetics and generally
decreases with increasing age, body mass index and number of children.20 Some drugs
also affect breast density, such as tamoxifen (decreases density) and postmenopausal
hormone replacement therapy (increases density).21
Dense breasts are common. About 50% of the screening population are classed
as having mammographically dense breasts.22 Fibroglandular tissue is radiologically
denser and attenuates X-rays more strongly than adipose tissue. As shown in Figure 1-1,
high breast density reduces the accuracy of a mammogram as abnormal breast changes,
such as calcifications and tumors, are masked by the superimposing fibroglandular
tissues.2 It is known that the sensitivity of mammography for women with low density
3

breasts is 88%, whereas it is only 30-60% in women with dense breast tissues.3
Furthermore, the cancer risk for women with high breast density is higher by a factor of
3.25 than the risk of women with low density breasts.23 This increased risk is independent
of issues related to mammography screening. Therefore, women with high breast density
are a vulnerable population due to their higher inherent risk and the poor sensitivity of
mammographic screening for them.

Figure 1-1 Breast lesion on a mammogram in a fatty breast vs. a dense breast.
A comparison of a breast tumor (yellow arrows) found in a patient with mostly adipose
breast tissues (left) and in a patient with dense fibroglandular tissues (right). Breast lesions
can be easily detected in women with low breast density but are challenging to identify for
women with high breast density. Reproduced with permission from Wang et al (2014).2
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1.2.2 Imaging of breast cancer
1.2.2.1 Introduction
One of the keys to successful treatment of breast cancer and long-term survival is
early detection. Population wide mammography screening programs have been shown to
reduce mortality due to breast cancer by at least 15%.24 This approach allows cancerous
lesions to be detected early, allowing timely treatment and thereby preventing disease
progression and metastasis.25 However, in the case of high breast density, current
mammographic techniques are not effective at detecting tumors due to decreased
sensitivity, which leads to delayed diagnosis, more advanced stage and worse patient
outcomes.26
Women with dense breasts may benefit from supplemental screening, such as
ultrasound or contrast enhanced MRI, in addition to mammograms. Breast ultrasound
combined with mammography may offer increased diagnostic sensitivity, but it has a high
rate of false-positive results and is dependent on operator expertise.27 MRI provides good
soft tissue contrast and high specificity but suffers from long acquisition time and poor
accessibility.28 MRI is also not cost-effective to use routinely and is not applicable for many
patients due to claustrophobia or contraindications such as pacemakers and metal
implants.29, 30 In addition, recent publications on long term retention of gadolinium in the
brain after injections of gadolinium contrast agents raises another concern for MRI.31-33
With regards to other modalities such as nuclear imaging with sestamibi, the
current American College of Radiology appropriateness criteria state that there is
insufficient evidence to support their use.34 At present, no new imaging methods have
been recommended to replace mammography for breast cancer screening. As a result,
considerable efforts are being made to improve the sensitivity and specificity of
5

mammography. Mammographic techniques that are more effective for detecting tumors in
dense breasts would streamline screening and save many lives.

1.2.2.2 X-ray contrast generation principles
The design of X-ray tubes can vary among different clinical X-ray applications,
such as conventional radiography, mammography or CT, but the essential components
and contrast generation principles remain the same. X‐rays can be generated by directing
electrons at a heavy material (anode). In an X‐ray tube, electrons are accelerated from
the cathode to the anode in an electric field. Only 1–2% of the electrons come close
enough to the nucleus to cause an interaction.35 These electrons, whose velocity is
sufficiently high, are decelerated in the electric field of the atomic nuclei of the anode
material (e.g., molybdenum or tungsten). As a result of the deceleration process, part of
the kinetic energy of the electron is converted into X‐ray photons called Bremsstrahlung.
In contrast, for characteristic radiation, electrons are knocked out of their shell when an
accelerated electron comes in contact. During the collision, the kinetic energy is
transmitted by the incoming electron. The result is an ionization of the atom and a short‐
term vacant space in the K shell. An electron will immediately fill this vacant space from a
higher energy shell, and the energy is released as a characteristic X‐ray photon. The
emitted X‐ray spectrum is therefore composed of a continuous spectrum (Bremsstrahlung)
and a line spectrum (characteristic radiation). After leaving the tube, the X‐ray spectrum
is filtered to reduce low‐energy radiation components, which would only increase patient
dose without providing diagnostic information.
The filtered X‐ray beam is directed at the subject and some of its intensity is lost
(i.e., X‐ray attenuation) due to two separate interactions with matter: the photoelectric
6

effect and Compton scattering.36 In the case of the photoelectric effect (Figure 1-2A), a
photon collides with and releases all its energy to an electron. The electron leaves the
atomic network and thereby loses its atomic bond. The atom becomes ionized, and the
photon is absorbed. This interaction is also known as absorption. The photoelectric effect
typically scales with Z3 (Z = atomic number) for a given photon energy. Once the X-ray
energy is above the K‐edge of the element, a sudden increase in X‐ray absorption occurs
at a photon energy level that is just above the binding energy of the innermost electron
shell of an atom. Compton scattering (Figure 1-2B), in contrast, occurs when a photon
collides with and gives only part of its energy to an electron. The energy is high enough
so that the electron leaves the atom, and the atom becomes ionized. The X‐ray photon is
deflected, weakened, and scattered. This effect most likely occurs with electrons on the
outermost shells of neighboring atoms. When the density of a material or organ increases,
the probability of occurrence of one of these two X‐ray interactions also increases.
Therefore, brightness levels on the X‐ray image reflect the different densities of tissue.
More strongly attenuating, or dense, tissues are displayed brighter on the image, whereas
weakly attenuating tissues appear darker.
Finally, the detector records certain characteristics of the X‐ray photons leaving
the subject. Most detectors in medicine use a direct or indirect process. Indirect, solid‐
state detectors convert the incoming X‐ray radiation with a scintillator into visible light,
which is integrated with a photodiode. Instead of the scintillator and the photodiode, direct
detectors use only an X‐ray‐sensitive semiconductor that generates charges when
photons arrive,37 which are then detected by electrodes. The amount of charge of a pixel
is proportional to the incident X‐ray photon energy.

7

Figure 1-2 X-ray interactions with matter.
Incoming X-rays interact with materials mainly via the (a) photoelectric effect and (b)
Compton scattering. The photoelectric effect occurs when the energy of an incoming Xray photon is higher than the binding energy of the innermost electron shell, resulting in
the absorption of the photon, ejection of an electron and a significant spike in X-ray
attenuation. For Compton scattering, the incoming X-ray photon transfers part of its energy
to an electron in the outermost shell, which causes the photon to be deflected and
scattered in a different direction. Reproduced with permission from Hsu et al (2020).7

1.2.2.3 Conventional mammography
Mammography is the specific X‐ray examination of the breast. The linear X-ray
attenuation coefficients for the three breast tissue types, and their difference, decrease
with increasing X-ray energies, resulting in a significant reduction in subject contrast as
well as image contrast.38 Thus, mammography requires the use of particularly “soft,” low‐
energy X‐ray radiation spectra typically in the range of 25–40 kV.39 To ensure the highest
diagnostic quality and lowest radiation exposure, mammography has several unique
technical features, such as the use of molybdenum or rhodium anodes to generate soft X‐
ray spectra, utilization of the Heel effect to image the tissue‐tight chest wall for a higher
8

dose rate, and use of a small focal spot to ensure the necessary high spatial resolution.40
Some modern digital mammography machines are equipped with tungsten targets that
generate slightly broader energy spectra. An example of mammographic X-ray spectra
generated using molybdenum targets is shown in Figure 1-3.38 Molybdenum spectra are
well suited for imaging non-dense breasts, but slightly higher energy spectra are desirable
for imaging dense breasts. This can be achieved by using filters that are of higher atomic
number than molybdenum, such as rhodium. Furthermore, a firm compression of the
breast is essential for reducing scattered radiation, radiation dose and blurring from patient
motion, thus improving tissue conspicuity and contrast sensitivity.

Figure 1-3 Example of mammographic X-ray spectra with molybdenum targets.
In mammography, a molybdenum target is commonly employed with a molybdenum or
rhodium filter to generate soft, low-energy X-ray spectra suitable for imaging of the breast.
Reproduced with permission from Yaffe et al (2014).38
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1.2.2.4 Dual energy mammography
Dual energy mammography (DEM), or contrast enhanced mammography, has
recently become clinically available and is seemingly the best modality for dense breast
imaging.41 Dual energy X-ray breast imaging is based on k-edge imaging, which relies on
differential energy-dependent attenuation of materials for detecting the object of interest.42
DEM is performed by placing two distinct spectra (low- and high-energy) on either side of
the photoelectric k-shell absorption edge, or k-edge, of the contrast material.43 The
excitation of k‐shell electrons leads to a sudden spike in photon absorption and a sharp
discontinuity in energy dependent linear attenuation coefficient. The low-energy (26-32 kV
with rhodium or aluminum filtration) images provide soft tissue contrast while high-energy
(42-49 kV with copper filtration) images above the k-edge contain substantial information
from the imaging agent. Then, a logarithmically weighted image subtraction between the
low- and high-energy images is done to create a dual energy image. The weighting factor
is calculated to eliminate the signal variation that arises from attenuation difference
between adipose and fibroglandular tissues.44 As a result, the signal from anatomical
background is suppressed and that from the contrast agent is enhanced. A contrast agent
that is taken up by a tumor can therefore improve the conspicuity of lesions that would
otherwise be obscured by surrounding dense tissue in single energy images.
The current FDA-approved DEM systems (e.g., Hologic or GE) involve only minor
software and hardware upgrades to existing digital mammography equipment (installation
of extra beam filters). Several clinical trials have found that the sensitivity of DEM is
superior to conventional mammography and matches that of contrast enhanced breast
MRI.25, 26 DEM is also found to have fewer false positives, indicating a greater specificity
compared to MRI.45 Furthermore, a recent study comparing DEM and MRI found that
10

women preferred DEM due to the shorter procedure time, greater comfort, less noise and
less anxiety.46 The radiation dose of DE mammography is about 1.2x that of conventional
mammography and efforts are ongoing to further reduce the radiation dose.26

1.2.2.5 Developing mammography technologies
Mammography has extended in recent years to include a tomographic procedure
called digital breast tomosynthesis or three-dimensional mammography.47,

48

This

technique can effectively reduce or avoid the masking effects of tissue superposition
present in projection radiography. The X-ray energy spectra used in tomosynthesis are
generally higher than those used in digital mammography. Tomosynthesis can also be
done in a dual energy approach. Tomosynthesis images are acquired by continuously or
discretely moving the X-ray tube on a circular arch, while making a series of low-dose
projection images around a stationary, compressed breast. The X-ray tube (or
mammography detector) typically moves between 15° and 50°.38 The obtained projection
images are then reconstructed into 1 mm-thick planar cross-sectional images using an
iterative reconstruction algorithm or filtered back projection. Due to the limited range of
projection angles, tomosynthesis has an anisotropic spatial resolution, with the highest
resolution in plane and a lower resolution between planes. Therefore, the resulting slices
of the breast may allow for a sharper image of glandular tissue, while the areas above and
below appear out of focus.49
The development toward spectral X-ray imaging has seen attraction in
mammography over the past decade.50, 51 Spectral mammography uses energy-resolved
photon counting detectors to discriminate detected photons via two different energy
thresholds and extract information about material compositions, such as breast density.52,
11
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Images are acquired by varying several system parameters, such as tube voltage, tube

current and high bin fraction (HBF).54 HBF is defined as the ratio of the number of high
energy photons to the total number of photons. The system produces two spectral images
that include a sum image consisting of the complete spectrum and a high-energy image
that is formed based on the HBF. The low energy threshold is set to separate electronic
noise from the primary spectrum, and the high energy threshold is set to sort all remaining
photons into two energy bins. This technique provides the energy information using a
single exposure,55 which can lower the total radiation dose and eliminate misregistration
artifacts associated with DEM.56 In addition, radiologist performance with this technique
was found to be noninferior to that of conventional mammography when imaged at an
average 40% lower mean glandular dose.57,

58

However, there is room for further

investigations with this technology; with topics such as alternative energy binning methods
remaining unexplored.

1.2.2.6 Other relevant X-ray imaging technologies
CT offers the next level in information content as a full tomographic modality, which
is typically operated at an energy range of 80–140 kV. During the last four decades, CT
has experienced explosive growth, which can be attributed to its short acquisition time,
wide availability, and groundbreaking diagnostic benefits. The fast temporal resolution of
CT can overcome respiratory motion, thus providing the potential for breast imaging. A
great effort has been made to develop advanced reconstruction algorithms to improve
diagnostic

quality

and

reduce

radiation

exposure.59-61

Marked

technological

advancements have also been made in the design of the gantry – a rotating ring‐shaped
frame in which an X‐ray tube and detector are mounted on opposite sides. As the gantry
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rotates the X‐ray tube and detector around the patient, X‐rays are generated, attenuated
by the patient, and recorded. Several thousand sectional views of the patient's body are
acquired per rotation and cross‐sectional images are reconstructed. From the resulting
CT slices, 3D images and views can be generated from different angles. The resulting
gray levels are described in Hounsfield units (HU), which make CT a quantitative and
highly reproducible diagnostic modality. By definition, air has a value of −1,000 HU (black)
and water a value of 0 HU. The HU values for body tissues depend on the system
specifications and settings, but soft tissues are typically about 40–80 HU and bones about
1,000–1,500 HU (white).
The concept of breast CT was explored in the early years of CT technology
development.62-64 Several groups have since been evaluating breast CT equipped with a
flat panel area X-ray detector and a cone bream geometry. These systems are capable of
acquiring projection images 360° around the patient’s breast at a radiation dose similar to
that of conventional mammography.65 Owing to the large number of projections, a much
higher tube energy (50-80 kV) is used than for mammography.66 This technique does not
require the compression of the breast, which improves patient comfort during imaging.
Due to its 3D isotropic tomographic nature, cone-beam breast CT removes tissue overlap
and provide higher spatial and contrast resolution than mammography for the detection of
breast masses and microcalcifications in dense breasts.67, 68 Although breast CT may have
potential clinical applications, several technical challenges are to be addressed before its
widespread adoption, such as longer radiologist reading time and limited visualization of
the chest wall.
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1.2.3 Contrast agents for mammography
1.2.3.1 Introduction
Poor native contrast between different soft tissues has prompted the use of
exogenous contrast agents since the early development of X‐ray imaging technologies.
As previously mentioned, radiographic imaging agents play an important role in breast
cancer screening; the use of contrast agents can enhance the detection of breast tumors
and is critical for highlighting tumorigenic neovasculature. The clinically approved X‐ray
contrast agents are barium sulfate suspensions, which are mostly used for gastrointestinal
tract imaging, and iodinated small molecules, which are used in many oral and
intravascular applications. Iodine (Z = 53) is currently the only contrast agent that has
been used in clinical breast imaging with mammographic techniques. Clinical iodinated
contrast agents were initially developed as mono‐iodinated molecules, such as sodium
iodide, and have since evolved to tri‐iodinated derivatives of benzoic acid, such as
iohexol.69 These compounds can be in monomeric or dimeric forms and are further
categorized into ionic and non-ionic formulations. A subset of these compounds and their
structures are presented in Figure 1-4.70 The current formulations provide excellent water
solubility, improved biological tolerance, and low osmolality.
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Figure 1-4 Chemical structure of commonly used iodinated contrast agents.
Tri-iodobenzene compounds that are used in clinical studies with X-ray breast imaging.
Formulations include (a) ionic monomers, (b) ionic dimers, (c) non-ionic monomers and
(d) non-ionic dimers. Reproduced with permission from Pasternak et al (2012).70

Despite the efforts made to optimize the physicochemical properties of iodinated
small molecules, further improvement is still needed. These agents are cleared from the
blood stream via kidney filtration within minutes, requiring swift post injection imaging.71 In
fact, all the clinical studies with DEM were performed within 3 to 4 minutes after injection.4,
25, 26, 72

These agents are also nonspecific, which leads to random vascular permeation

and very low tumor accumulation. Due to their low contrast payloads and rapid clearance,
large amounts of contrast agent are often used to ensure sufficient and prolonged
contrast. However, injecting large volumes of iodine can lead to contrast-media induced
nephropathy in those with pre-existing renal complications,5 such as diabetes mellitus.
Iodinated agents are also known to cause adverse reactions,73 such as nausea, allergies
and anaphylaxis, in some patients. Lastly, the contrast produced by iodinated agents in
DEM is sub-optimal.6, 74 The relatively high k-edge of iodine (33.2 keV), while ideal for
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higher energy X-ray imaging modality such as CT (80-140 kV), is not suited for the lower
energy range (26-49 kV) used in DEM. In the following sections, I further describe the
efforts made to improve the properties of iodinated agents using nanotechnology, identify
new, candidate contrast materials for DEM, and explore nanoparticle formulations for Xray breast imaging.

1.2.3.2 Iodinated nanoparticle contrast agents
Iodine is currently the standard in contrast enhanced mammography as well as
other X-ray imaging techniques, such as CT. To overcome the shortcomings of iodinated
molecular agents, researchers have made efforts to improve their physicochemical
properties and contrast payloads by incorporating them into different nanocarrier types.
The earliest reports were based on emulsions, micelles or liposomes containing iodinated
lipids or oils, or iodinated small molecules.75-77 Figure 1-5 shows a summary of lipid-based
nanoparticles and their structures.78 Many of these formulations are much larger in size (>
5 nm) and utilize polyethylene glycol (PEG)-lipids to bypass kidney filtration and prolong
blood retention time. They also carry higher iodine payloads per entity compared to small
molecules. Nanoparticles that circulate for a long time have advantages over rapidly
cleared agents since they provide longer lasting contrast and have a greater opportunity
to enter disease sites. Long circulating agents are especially useful for imaging changes
in vascularity such as sustained angiogenesis and permeable vasculature, which are
known hallmarks of cancer. The leaky nature of tumor neovessels allows agents to
passively accumulate in the diseased tissues through the enhanced permeability and
retention (EPR) effect, enhancing contrast for better tumor detection.79 Hence, an agent
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designed for breast cancer screening should also be effective as a vascular contrast
agent.

Figure 1-5 Lipid-based nanoparticles used for contrast agent development.
Schematic depiction of some of the most widely used nanotechnology platforms for
improving the delivery, biocompatibility and functional properties of iodinated agents and
inorganic nanocrystals. Reproduced with permission from Mulder et al (2006).78

An emulsion is formed when an amphiphilic surfactant encapsulates a small
droplet of an iodinated oil in the core. Radiopaque emulsions are often loaded with
Lipiodol, an iodinated derivative of poppy seed oil that is clinically used as an intravascular
embolizing agent.80, 81 Lim et al. used Tween lipids to encapsulate Lipiodol into an iodized
oil nanoemulsion for imaging hepatic metastatic lesions in rats.82 These nanoparticles
were 117 nm in diameter and provided longer lasting CT contrast in both the liver and
blood pool compared to iopamidol (a clinically-approved iodinated molecular agent).
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PEGylated amphiphilic surfactants are widely used to prolong the blood circulation
of iodinated nanoemulsions, improving their utility as X-ray contrast agents for blood pool
and tumor imaging.9, 83-86 For example, Kong et al. reported an emulsion of Lipiodol with
Pluronic F127 and PEG-diamine as the outer shell layers.87 The nanoemulsions were 150
nm in diameter and provided vascular CT contrast for up to 4 hours. To increase iodine
content in the formulations, de Vries et al. synthesized dense, tri-iodinated oils and
formulated into nanoemulsions using either PEGylated phospholipids or block
copolymers.88 These nanoparticles contained a high concentration of iodine (130 mg/ml)
and produced marked CT contrast in the heart and blood vessels. The nanoemulsion
circulation half-life was found to be approximately 3 hours. Attia et al. prepared PEGylated
nanoemulsions based on hexa-iodinated monoglycerides (65% wt. of iodine).89 This agent
showed strong CT contrast enhancement of the blood pool with a long circulation half-life
around 6.7 hours. The same group also demonstrated that the size of oil nanoemulsions
has no impact on the agent’s pharmacokinetic and biodistribution profiles.90
Micelles are formed when lipids arrange themselves into a spherical monolayer
with a hydrophilic polar surface and hydrophobic fatty acid core. Since micelles do not
contain an oil core, the hydrophobic tails of the amphiphiles are typically labeled with
iodinated molecules. Thus, radiopaque micelles are formulated with high concentrations
of iodinated moieties in the core.91, 92 Notably, the Torchilin group synthesized an iodinated
lipid by reacting triiodobenzoic acid to PEGylated polylysine polymer (MPEG-iodolysine).93
MPEG-iodolysine micelles were 80 nm in diameter and had an iodine content of 33.8%.94
This agent is effective for imaging the blood pool, liver and spleen as strong CT contrast
was observed in these organs for up to 3 hours.
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Unlike micelles and emulsions, liposomes are formed by assembling amphiphilic
lipids or polymers into a bilayer that encloses an aqueous core. Later formulations saw
the addition of PEG to amphiphilic lipids, which resulted in increased circulation half-lives
for longer lasting tumor and vascular contrast.95-98 Liposomes can carry hydrophilic agents
in the core as well as hydrophobic substances in the bilayer.99-101 However, the internal
hydrophilic payloads tend to diffuse through the lipid bilayer due to chemical gradients.
Thus, to prevent the leakage of payloads, cholesterol is often added to the liposomal
formulations to increase the rigidity and reduce the water permeability of the bilayer.102, 103
Karathanasis et al. co-encapsulated an iodine solution (iodixanol) and a
chemotherapeutic (doxorubicin) in liposomes made of PEGylated phospholipids and
cholesterol.104 The resulting liposomes, 102 nm in diameter, had a high concentration of
iodine (155 mg/ml) and low leakage of the encapsulated agents (less than 1% of initial
payload). These liposomal nanoparticles were injected in a rat breast tumor model and
their intratumoral distribution was quantified via imaging with digital mammography. An
inverse linear relationship was found between the tumor growth rate and contrast
enhancement in the tumors.105 This imaging nanoprobe can be used to predict
chemotherapeutic effectiveness and facilitate personalized therapy of breast cancer by
measuring the extent of tumor vascular permeability through mammography. Samei et al.
used the same liposomal formulation to encapsulate a water-soluble iodinated agent
(iopamidol), and the resulting liposomes were injected into breast tumor bearing mice.106
The liposomes prolonged the circulation half-life of the iodine molecules as strong CT
contrast in the tumor was observed for up to 4.2 hours after injection. Bhavane et al.
imaged atherosclerotic plaques with dual energy CT using a similar liposomal
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formulation.107 The signal from iodinated liposomes was separated from the surrounding
tissue via dual energy decomposition and was found to localize within the plaque.
Recent developments include liposomes that co-encapsulate iodinated molecules
with other imaging agents for multi-modal imaging, or with drugs for theranostic
applications.108, 109 Liposomes can also be loaded with different types of iodinated agents
in both the core and lipid bilayer for increased contrast payload delivery. For example,
Kweon et al. used a mixture of phospholipids and cholesterol to encapsulate iopamidol
and Lipiodol in the core and lipid bilayer, respectively.66 This dual loading method was
effective at producing liposomes with substantially higher iodine content. In vivo CT
imaging showed strong contrast in the aorta (for up to 2.5 hours) as well as the liver and
spleen due to the absence of PEG in the formulation.
Dendrimers are highly branched polymeric macromolecules that contain a central
core, internal branching layers and an exterior surface. The functional groups at the
surface provide multivalent sites for conjugation of drugs or imaging agents, and allow for
easy modifications to confer specific properties.110-112 The most widely used dendrimer
type is poly(amidoamine), or PAMAM, which has multiple amine groups at the termini,
providing many sites for functionalization.113 For example, a CT contrast agent with 33%
wt. of iodine was synthesized by conjugating a triiodobenzenepropanoic acid derivative
onto a PAMAM dendrimer.114 A recent study reported the use of tetraiodobenzene
derivates to further increase the iodine content (80% by weight) of PAMAM dendrimers.115
PEGylation of these branched molecules were found to improve the blood circulation
times.116
Other platforms for developing X-ray imaging agents include polymerized iodine
compounds and lipoproteins. A small, long circulating nanoparticle based on polymerized
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iodine compound was reported by Hainfeld et al.117 This agent was synthesized by
polymerizing iodinated molecules (iohexol) with carbohydrazide and then covalently
crosslinking with aminoPEG. The polymer iodine nanoparticle was small (20 nm) and had
a very long blood half-life of 40 hours, which greatly enhanced the contrast of murine
glioma tumors in CT imaging. A similar nanoparticle type was reported by Yin et al., where
iohexol was polymerized using hexamethylene diisocyanate and cross-linked with mPEGpolylactide.118 A 36-fold increase in CT contrast was observed in murine breast tumors
after the injection of this agent.

1.2.3.3 Candidate contrast materials for DEM
The contrast agents used in clinical studies with dual energy X-ray breast imaging
are iodinated small molecules such as iopamidol or iodixanol. As previously mentioned,
current agents are limited by short circulation times, poor tumor targeting ability, low
contrast generating payloads and contrast induced nephrotoxicity. Moreover, it has
recently been found that the contrast produced by iodine in DEM is sub-optimal. The high
k-edge of iodine (33.2 keV) is less suited for the lower energy range (26-49 kV) used in
DEM. More specifically, only 78% of the high-energy spectrum is above the k-edge of
iodine even at the maximum tube potential value (49 kV) or best possible imaging
conditions for iodine.74 The remaining 22% of the spectrum cannot contribute to the signal
difference-to-noise ratio (SDNR), thus reducing the overall contrast production. As a
result, alternative contrast materials, namely those with lower atomic numbers than iodine,
are sorely needed for tumor detection with dual energy X-ray breast imaging.
Recently, a list of candidate dual energy contrast materials has been identified
through theoretical modeling. Elements with Z ranging from 42 (molybdenum) to 52
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(tellurium) should provide the best contrast in DEM while still contributing a sufficient dose
fraction to low-energy anatomical images, as shown in Figure 1-6.6 The characteristics for
some of these elements as well as iodine, including atomic number, k-edge, maximum
contrast-to-noise ratio (CNR) and optimal dose fraction to low-energy images, are listed
in Table 1-1. Furthermore, the lower K‐edge energies allow for more achievable energy
pairs as well as greater flexibility in the positioning of the high‐energy spectrum, resulting
in optimal dual energy subtraction.

Figure 1-6 CNR and dose distribution to low-energy images for Z between 1 and 80.
Contrast materials with Z ranging from 42 to 52 (highlighted in yellow) were identified to
provide superior CNR values and dose fractions to that of iodine for breast imaging with
DEM. Reproduced with permission from Karunamuni et al (2014).6
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Table 1-1 Characteristics of candidate contrast materials and iodine for DEM.
Element

Atomic
number

K-edge
(keV)

Maximum
CNR

Optimal dose
fraction

Molybdenum (Mo)

42

20.0

40.3

0.46

Rhodium (Rh)

45

23.2

39.0

0.40

Palladium (Pd)

46

24.4

40.4

0.40

Silver (Ag)

47

25.5

42.6

0.40

Tin (Sn)

50

29.2

44.1

0.33

Tellurium (Te)

52

31.8

41.9

0.34

Iodine (I)

53

33.2

42.6

0.32

From these materials, silver (Z = 47) with a k-edge energy of 25.5 keV is of
particular interest. First, the lower k-edge of silver allows 99% of the high-energy spectrum
to be placed above the k-edge, thus contributing to the dual energy SDNR.74 The SDNR
for silver was determined to be on average 40% higher than that for iodine when imaged
with protocols optimized for current iodinated agents. This means that silver provides
higher levels of contrast than iodine, and minimal equipment modifications, if any, are
needed for imaging a silver agent. Additionally, the frequent use of silver filters in DEM
allows energies above the k-edge of silver to be removed in the low-energy spectrum,
providing a mean photon energy closer to silver’s k-edge for optimal contrast production.
Second, silver is relatively low in material cost, currently at $0.89 per gram. Lastly, silver
is the most advertised component and most frequently used material (435 products, or
24%) in nanotechnology-based products.119 Due to their bactericidal effect and optical
scattering properties, silver nanoparticles are popular additives in a large portion of
consumer applications, such as catheters, toothpaste, antiseptic sprays and optical
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sensors.120-122 Therefore, an agent based on silver should provide benefit over iodine and
have potential as a novel contrast material for contrast enhanced DEM.

1.2.3.4 Inorganic nanoparticle contrast agents
Considering the limitations of current iodinated agents, significant effort has been
devoted to developing new, candidate radiographic contrast materials. A few alternatives
to iodine have been identified, most of which are inorganic nanoparticle-based
formulations composed of high Z elements. Nanoparticles based on these elements are
well‐suited as CT contrast agents as their k‐edges fall within the diagnostic energy range
employed by many clinical CT imaging scanners. Nanoparticles are particularly
advantageous for use as contrast agents since synthetic control over their composition,
size, shape and surface chemistry can greatly influence their physical and functional
properties. They can be finely tuned to yield the desired circulation times, clearance
profiles, solubility, biocompatibility, targeting ability and therapeutic effects for various
biomedical

applications.

Figure

1-7

shows

the

various

shapes,

surface

coating/functionalization and biomedical applications of inorganic nanoparticles.123
Furthermore, inorganic nanoparticles typically contain a dense metal core loaded with
hundreds to millions of contrast generating atoms, which may compensate for the poor
sensitivity of X-ray imaging techniques.124 Compared to small molecules, nanoparticles
have higher payloads per entity, thus may prove more compatible with patients whose
kidney function is impaired, as fewer excretion events would be needed. Therefore, the
use of inorganic nanocrystals as X-ray imaging agents may alleviate biocompatibility and
contrast generation issues associated with iodine as outlined above.
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Figure 1-7 Characteristics and biomedical applications of inorganic nanoparticles.
Inorganic nanoparticles can be synthesized in different shapes and sizes. Synthetic
control over their physical parameters and functional properties allows them to be tailored
to certain biomedical applications. Reproduced with permission from Her et al (2017).123

Some of the first inorganic nanocrystals proposed as radiographic contrast agents
were based on gold, such as gold nanorods and dendrimer entrapped gold
nanoparticles.111, 125 Numerous groups have worked on developing gold nanoparticles
(AuNP) as CT contrast agents. Gold (Z = 79) has a high k‐edge energy of 80.7 keV, is
very dense (19.3 g/cm3) and is generally regarded as biocompatible and bioinert.126 The
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higher k-edge means that gold is more suited than iodine for the higher energy range used
in CT. Higher energies allow for better separation between tissue background and contrast
media, which in turn reduces patient dose. In addition, AuNP are well developed in terms
of synthetic control over their size, shape, and surface chemistry,8, 127 and have been
demonstrated for use in a myriad of biomedical applications,128 such as drug delivery,
photoacoustic imaging, radiotherapy and photothermal ablation.129, 130
Hainfeld et al. were the first to develop surface stabilized, spherical AuNP as X-ray
imaging agents.131 AuNP were 1.9 nm in diameter and strongly opacified the major blood
vessels of the rats when imaged using a conventional mammography unit. Due to the
small size, these nanoparticles were swiftly cleared through the renal system as evidenced
by high contrast enhancement in the kidneys and bladder in post-injection X‐ray images.
This was the initial report to demonstrate the renal excretion of X-ray nanoparticle contrast
agents. Notably, sufficient (if not complete) clearance from the body is required for
eventual clinical translation of nanoparticle contrast agents due to the inability of the
human body to metabolize or transport heavy elements. Subsequent studies have found
that renal clearance efficiency of nanoparticles generally decreased with increasing size,
while those much larger in size (> 10 nm) were mainly taken up in the liver and spleen. On
the other hand, AuNP surfaces can be modified with PEG molecules to increase the
overall size and prolong the circulation time for blood pool and tumor imaging applications.
Moreover, Hainfeld et al. conjugated HER2 antibody fragments to the surface of
AuNP to allow targeted CT imaging of breast cancer. This study aimed at demonstrating
the feasibility of using targeted AuNP to determine breast tumor types in vivo. The mice
were inoculated with either HER2 positive or negative breast cancer cells and were
imaged using a micro-CT after the injection of HER2-targeted AuNP. They found that the
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enhancement of HER2 positive tumors was greater compared to HER2 negative tumors.
This technology may have potential clinical applications in tumor phenotyping and
delineation of surgical margin. In combination with breast CT, this imaging agent may also
have use in screening of certain cancer types in dense breasts.
While AuNP have shown to be effective for X-ray imaging, the high cost of gold
may be an issue for mass production or widespread use. Other high Z elements have also
been explored as an alternative to iodine for X-ray imaging. Bismuth (Z = 83) has a higher
k-edge (90.5 keV) than gold, is much cheaper than gold and is regarded as being one of
the most biocompatible of the heavy elements. However, bismuth is less dense than gold,
so bismuth nanoparticles generally have a lower payload than comparable AuNP. Rabin
et al. were the first to propose the use of bismuth nanoparticles as CT contrast agents for
blood pool and lymph node imaging.132 More recently, Naha et al. reported the synthesis
of dextran coated bismuth-iron oxide nanoparticles as biocompatible CT and T2-weighted
MR contrast agents.133 Interestingly, bismuth can degrade into molecular Bi3+ species in
vivo as a result of oxidative instability, thus allowing several bismuth nanoparticle
formulations with sizes above the glomerular filtration cutoff (> 5.5 nm) to undergo rapid
urinary clearance.134, 135
Tantalum (Z = 73) is another electron-dense element that has been extensively
studied for use in CT contrast agents. Tantalum has a k-edge of 67.4 keV, is biocompatible
due to low toxicity of its oxide and is low in cost. The recent publications on tantalum
nanoparticles have indicated a substantial investment from industry and great interest for
commercial use. A group from General Electric developed several tantalum oxide
formulations with an overall size below 5 nm.136-138 They found that more than 98% of the
injected dose (ID) was excreted from the body within 48 hours after injection, which is
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among the best clearance of all nanoparticle agents reported to date. In another study,
tantalum oxide nanoparticle surface was functionalized with PEG for long blood circulation
and a fluorophore for bimodal imaging.139 These nanoparticles provided strong CT
contrast enhancement of the blood pool for up to 3 hours after injection.
Although high Z elements, such as gold, bismuth and tantalum, are promising
contrast materials for high energy X-ray imaging, their application in DEM is limited. These
elements have a k-edge that lies beyond the mammographic energy range and thus
cannot be used as contrast agents for DEM. As previously mentioned, silver is an excellent
choice as an element upon which to base DEM specific contrast agents and is relatively
low-cost. Karunamuni et al. were the first to develop a contrast agent specifically for DEM
and the first to use silver as an X-ray contrast agent.140 To avoid the release of toxic silver
cations, they encapsulated a polyvinylpyrrolidone (PVP)-coated elemental silver
nanoparticle core within a larger silica shell to prevent the oxidation of silver atoms. The
silica-silver nanoparticles, 102 nm in diameter, were then stabilized by PEG molecules to
improve hydrophilicity and biocompatibility. The nanoparticles were injected into mice and
imaged using a 26 kV molybdenum target with molybdenum filter and a 49 kV rhodium
target with rhodium filter. The contrast in dual energy images was increased by a factor of
9, compared with single energy imaging. No adverse effects were observed. This study
represents a first step in developing a safe and stable DEM contrast agent.
Furthermore, Naha et al. developed an array of thiol‐PEG capped gold silver alloy
nanoparticles (GSAN) with an overall size of 16 nm.141 The inclusion of gold increased the
oxidation potential of silver,142 thereby improving the biocompatibility of GSAN. The
combination of silver and gold also made GSAN a dual‐modality X‐ray contrast agent.
Following the administration of GSAN to a murine model of breast cancer, CT imaging
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revealed significant contrast in the blood pool and at the tumor site, indicating the passive
tumor targeting capability of GSAN via the EPR effect. DEM imaging studies showed that
GSAN could provide higher contrast in breast tumors compared to iopamidol. This study
presents a unique strategy to prevent the leaching of silver ions, thus ensuring the safety
of the agent, while providing functionality for two separate X-ray imaging modalities.
Several reports have indicated that silver has potential as a CT contrast agent in
addition to a contrast agent for DEM. Silver’s k-edge is situated at the lower end of the
energy spectra used in CT, and should therefore strongly attenuate lower energy X-rays,
resulting in some (but not optimal) contrast enhancement. A study synthesized PAMAM
dendrimer-entrapped silver nanoparticles and showed that their CT contrast is comparable
to that of iodine.143 Another study synthesized hyaluronic acid-coated elemental silver
nanoparticles and then labeled them with a radioisotope.144 This agent could serve as both
a CT contrast agent and a radiotracer for tumor imaging. Recently, Zou et al. synthesized
PVP-coated silver nanoparticles and used micro-CT to detect their distribution in the
middle and inner ear following transtympanic injection.145 Owing to their strong antimicrobial effects, silver nanoparticles were previously shown to treat chronic otitis
media,146 an inflammatory disease of the middle ear that usually presents with ear pain.
Since these nanoparticles have potential use in ear therapy, it is necessary to track their
kinetics in the ear and provide information relevant to the future design of this novel
treatment regime.

29

1.3 Preface to dissertation
As mentioned above, the primary form of contrast agent for X-ray based imaging
is iodinated small molecules such as iodixanol. Only these agents have been used in
clinical studies with DEM. However, iodinated molecular agents have drawbacks including
rapid clearance, potential adverse reactions, non-specific localization, and suboptimal
contrast production. Silver has recently been identified as an element that produces higher
levels of contrast than iodine in dual energy X-ray breast imaging. Elemental silver
nanoparticles have been incorporated into consumer and medical products, such as
catheters and bandages, as a broad-spectrum antimicrobial agent.147, 148 However, the
antimicrobial activity has been attributed to the oxidation of zero-valent metallic particles
in biological media, resulting in the release of silver cations.149-151 Silver cations are known
thiol toxicants that can disrupt mitochondrial respiratory chain and elevate intracellular
reactive oxygen species (ROS) levels, causing oxidative stress and cell damage.152, 153
Subsequently, the first report of a novel contrast agent specialized for DEM was based on
the encapsulation of a solid silver core in a larger silica shell.140 The nanoparticle core
provided dual energy contrast and the shell layer prevented the release of silver ions.
Moreover, an alternative strategy was devised, whereby a small quantity of gold was
added in the formulation to raise the oxidation potential of silver.141 The bimetallic goldsilver alloy structure significantly decreased the toxicity compared to silver nanoparticles.
To the best of our knowledge, these are the only studies that have developed a
nanoparticle contrast agent specialized for dual energy X-ray breast imaging.
From these initial results, I have identified several improvements that could be
made to current formulations in terms of material cost, biocompatibility, clearance and
utility in other biomedical applications. Herein, I propose silver sulfide nanoparticles for
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further investigation as a novel X-ray contrast agent. First, the current prices for silver and
sulfur are $0.89/g and $0.05/kg, respectively, so the material costs for a dose of silver
sulfide nanoparticles for a woman of average weight would be $6.48. This is much cheaper
than gold-silver alloy nanoparticles, which would cost about $227 for the same dose.
Second, the highly insoluble nature of silver sulfide should preclude the formation of silver
cations, providing robust biocompatibility and stability in biological media. Third, current
agent formulations could be retained within the body, potentially for years, due to their
large size (> 5 nm). The long-term retention of contrast agents would be a concern that
would likely prevent their eventual clinical application. I seek to develop sub-5 nm, renally
clearable silver sulfide nanoparticles, improving the likelihood of translation. Lastly, silver
sulfide nanoparticles are also known for their exceptional optical properties, including
tunable near-infrared fluorescence emissions and photothermal conversion activities.
Therefore, their applicability may extend beyond X-ray imaging applications.
This dissertation describes the design and synthesis of silver sulfide nanoparticles
and investigates their utility as a diagnostic agent for X-ray and optical imaging and also
a therapeutic agent for cancer treatment via phototherapy. The subsequent chapters are
ordered as follows:
Chapter 2: Develop an “all-in-one” nanoprobe based on hydrophobic silver sulfide
nanoparticles for safe and flexible screening of breast cancer.
Chapter 3: Synthesize size-tunable, hydrophilic silver sulfide nanoparticles with
efficient renal clearance for increased translational potential.
Chapter 4: Investigate the effect of synthetic conditions on silver sulfide
nanoparticle coating integrity and subsequent clearance and hepatic cell
interactions.
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Chapter 5: Design, synthesis and in vitro testing of a biodegradable, polymeric
silver sulfide nanoparticle for multimodality detection, image-guided surgery and
photothermal therapy of breast cancer.
Chapter 6: Summarize the major discussion points and address the limitations,
alternatives, and future directions for this dissertation work.
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Chapter 2 : An all-in-one nanoparticle
multimodality breast cancer screening

contrast agent for

2.1 Abstract
Conventional X-ray mammography has low diagnostic sensitivity for women with
dense breasts. As a result, alternative contrast-enhanced screening tools such as dual
energy mammography (DEM), computed tomography (CT), magnetic resonance imaging
(MRI), and near-infrared fluorescence (NIRF) imaging are being used or investigated for
these women. However, currently available contrast agents are non-ideal, have safety
issues, and each imaging technique requires a different contrast agent. We therefore
sought to develop a multimodal contrast agent that is functional for each breast imaging
modality to simplify the diagnosis process and address the issues of existing contrast
agents. Herein, we present a novel “all-in-one” nanoparticle (AION) multimodal imaging
probe that has potent DEM, CT, MRI, and NIRF contrast properties and improved
biocompatibility. AION were formed by co-encapsulation of a near-infrared fluorophore
(DiR), silver sulfide nanoparticles (Ag2S-NP), and iron oxide nanoparticles (IO-NP) in
PEGylated micelles. AION showed negligible cytotoxicity, which was in agreement with its
minimal silver ion release profiles. AION generated strong contrast with all imaging
modalities as demonstrated in phantom imaging. AION allowed in vivo tumor imaging as
evidenced by the increase in contrast after injection. This study indicates the potential of
AION as an effective multimodal contrast agent for breast cancer diagnosis with a range
of imaging methods.
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2.2 Introduction
The key to good prognosis of breast cancer is early detection. Currently, X-ray
mammography is the gold standard for breast cancer screening and has been shown to
reduce mortality from breast cancer.1 Nevertheless, it is well established that diagnostic
sensitivity of mammography is greatly reduced in women with dense breasts, who are
about 50% of the screening population.2 The sensitivity decreases from a level of 87% in
women with less dense breasts to only 30–62% in women with dense breasts.3, 4 When
mammography is used alone as a screening tool, decreased sensitivity may lead to
delayed diagnosis, more advanced stage and reduced survival. Moreover, women with
dense breasts have a three-fold higher risk of developing breast cancer, independent of
issues related to screening.5 Therefore, alternative screening tools are being developed
for this population.
Contrast-enhanced imaging techniques such as magnetic resonance imaging
(MRI), dual-energy mammography (DEM), computed tomography (CT), and near-infrared
fluorescence (NIRF) imaging have emerged to improve breast cancer detection for women
with dense breasts. These imaging modalities each use contrast agents to highlight breast
abnormalities and overcome the masking effect from increased breast density. Screening
breast MRI requires gadolinium-based contrast agents; however, free gadolinium ions can
cause nephrotoxicity in patients with renal disease6, 7 and gadolinium deposits in the brain,
with unknown effects.8-11 Similarly, contrast-mediated nephropathy as well as patient
allergic reactions are risks posed by iodinated contrast agents, such as iopamidol, which
are commonly used in CT and DEM.12-14 Moreover, iodinated agents produce suboptimal
contrast especially in the case of DEM.15 Improved contrast agents are needed for tumor
detection and characterization with these imaging modalities.
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Nanoparticles have potential as safe and effective contrast agents for numerous
breast imaging modalities.15-21 For example, iron oxide nanoparticles (IO-NP) provide
contrast in T2- or T2*-weighted MRI that can be used for distinguishing lesions from normal
tissues.22 Silver nanoparticles have recently been identified to produce stronger contrast
than iodinated agents in DEM.15, 21 In addition, silver nanoparticles should provide CT
contrast that is comparable to iodine as silver’s k-edge at 25.5 keV allows for strong
attenuation of lower energy X-rays.20 However, to form stable and safe silver-based
nanoparticles, a high percentage of gold inclusion was required,20 resulting in a significant
material cost. To overcome this cost issue, we herein propose silver sulfide nanoparticles
(Ag2S-NP) whose ultralow solubility constant (Ksp = 6.3 × 10−50),23 we hypothesized, would
limit the release of silver ions, providing good biocompatibility, but with low material costs
(the cost of sulfur is about $0.09/kg).24 Combining Ag2S-NP, IO-NP and a NIRF
fluorophore creates a multimodality agent for multiple imaging techniques. This will allow
a safe and flexible screening option for intermediate and high risk patients, including
women with dense breasts who need additional screening for improved sensitivity over
conventional mammography. To our knowledge, the development of a multimodal contrast
agent specific for breast cancer screening has rarely been explored. The integration of
Ag2S-NP, IO-NP and NIRF fluorophores into one platform has not previously been
reported and provides functionalities for four different breast imaging modalities. This
probe is uniquely designed to address issues related to current contrast agents. Moreover,
the use of Ag2S-NP as contrast agents for X-ray imaging has not previously been reported
and there is only a handful of examples of novel contrast materials developed specifically
for mammography.
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In this study, we report a novel “all-in-one” nanoparticle (AION) multimodal contrast
agent designed for noninvasive breast cancer detection using DEM, CT, MRI, and NIRF
imaging modalities. AION were synthesized by encapsulating hydrophobic Ag2S-NP, IONP, and DiR in mixed micelles formed with polyethylene glycol (PEG) modified
phospholipids via a one-pot ultrasonic emulsification procedure. The straightforward
design of AION and their facile synthesis would be advantageous for clinical translation.
Next, AION were characterized using various analytical tools such as transmission
electron microscopy (TEM), dynamic light scattering (DLS), scanning electron microscopy
(SEM) and energy dispersive X-ray spectroscopy (EDX). After characterization, AION
were investigated for their contrast generating potential with phantom imaging. In vitro
cytotoxicity effects and silver ion leaching from AION were assessed. Lastly, in vivo
imaging and biodistribution studies were performed in a murine model of breast cancer to
evaluate the utility of AION as a multimodal contrast agent for breast cancer detection.

2.3 Materials and methods
2.3.1 Materials
Silver diethyldithiocarbamate ((C2H5)2NCS2Ag, 99%), 1-dodecanethiol (DT, 98%),
and silver nitrate (AgNO3, 99%) were purchased from Sigma-Aldrich (St. Louis, MO).
Oleic-acid

coated

10

nm

IO-NP

in

chloroform

and

1,1’-dioctadecyl-3,3,3’,3’-

tetramethylindotricarbocyanine iodide (DiR) powder were purchased from Ocean
NanoTech (San Diego, CA) and Thermo Fisher Scientific (Eugene, OR), respectively.
Both 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-mPEG2000) were
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purchased from Avanti Polar Lipids (Alabaster, AL). All chemicals were used without
further modifications and Milli-Q deionized (DI) water (18.2 MΩ.cm) was used throughout
the entire study.

2.3.2 Synthesis of hydrophobic Ag2S-NP and AION
Hydrophobic Ag2S-NP with an average core size of 4.7 nm were synthesized using
methods based on previous reports.25, 26 In brief, 26 mg of (C2H5)2NCS2Ag was added to
10 g of DT in a 100 ml three-neck round-bottom flask at room temperature. The reaction
mixture was placed under reduced pressure using house vacuum for 10 minutes with
constant stirring. Then, N2 was introduced to create an inert atmosphere for the reaction
mixture, while being heated to 210 °C at a heating rate of 15 °C/min using a temperature
controlled heating mantle. The reaction was kept at 210 °C for 1 hour. After the reaction
was completed, the mixture was allowed to cool to room temperature. The product was
precipitated via addition of 50 ml of absolute ethanol and isolated by centrifugation at 7000
rcf for 20 minutes. The supernatant was discarded and the pellet was resuspended in 50
ml of ethanol and isolated again by centrifugation using the same parameters. After
repeating this process three times, the as-prepared DT-coated Ag2S-NP were dried for
subsequent use in formation of AION.
A combined solution (1 ml) of Ag2S-NP (20 mg), IO-NP (2 mg), DiR (100 μg), DSPC
(1.1 mg) and DSPE-mPEG2000 (3.9 mg) suspended in chloroform and methanol was
added to a glass vial containing 10 ml of DI water. The mixture was emulsified for
approximately 10 seconds using a bath sonicator and was allowed to gently stir uncovered
overnight in order to allow chloroform evaporation. The resulting solution was centrifuged
at 2630 rcf for 10 minutes and was then filtered through a 0.22 μm filter (EMD Millipore,
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Billerica, MA) to remove aggregates. Using 10 kDa MWCO ultrafiltration tubes (Sartorius
Stedim Biotech, Germany), the nanoparticles were concentrated and washed three times
with DI water. Finally, all empty micelles and smaller sized particles were
removed via potassium bromide (KBr) density gradient centrifugation. This was done by
gently adding 200 μl of the concentrated AION sample on top of the 1.3 g/ml KBr solution
(1 ml) in a 1.5 ml Eppendorf tube. Then, the tubes were spun at 14,500 rpm for 1 hour.
After centrifugation, 300 μl at the top of the solution was carefully removed and discarded.
20 ml of DPBS was added to the remaining solution containing AION, then AION was
washed thrice with DPBS and concentrated using 10kDa MWCO ultrafiltration tubes, and
stored at 4°C for future use.

2.3.3 Characterization
Both Ag2S-NP and AION samples were examined using an FEI Tecnai T12
electron microscope with an acceleration voltage of 120 kV. Formvar carbon-coated
copper grids with 200 mesh (Electron Microscopy Sciences, Hatfield, PA) were used to
prepare the TEM samples. Briefly, 10 μl of diluted Ag2S-NP or AION samples (5 μl from
concentrated stock diluted with 495 μl DI water) were dropped onto the grids and allowed
to dry before imaging. The core diameter of AION was measured using ImageJ (National
Institutes of Health, Bethesda, MD).
To prepare for analysis, AION samples were drop casted onto an aluminum
substrate and dried completely in a vacuum. An FEI Quanta 600 FEG scanning electron
microscope operated at 20 kV and equipped with EDX spectrometry (EDAX, Inc.) was
used to acquire SEM images and EDX spectra and line scan measurements of AION.
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The hydrodynamic diameter and zeta potential of AION were measured using a
Nano ZS-90 Zetasizer (Malvern instrument, UK). In brief, 10 μl of AION from the stock
were diluted with 2 ml of DI water. 1.5 ml and 1 ml of nanoparticle suspension were used
for the measurement of hydrodynamic diameter and zeta potential, respectively. The
number mean was reported for the hydrodynamic diameter. All measurements were
performed at 25 °C.
The UV/visible absorption spectrum of AION was measured by an UV/visible
spectrophotometer (Thermo Fisher Scientific, USA). In brief, 100 μl from AION stock (DiR
concentration: 4.4 μg/ml) were diluated with 2900 μl of DI water. The diluted samples were
used to record UV-visible spectra and fluorescence spectrum. The absorbance spectrum
was normalized to a maximum absorbance of 1. The NIR fluorescence spectrum was
obtained using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA)
with an excitation wavelength of 748 nm.
The silver and iron concentrations of AION were determined using ICP-OES
(Spectro Genesis ICP). The samples were prepared by dissolving 10 μl of AION stock
solution in 1 ml of concentrated nitric acid and making the final volume to 10 ml with DI
water.

2.3.4 Silver ion leaching
The silver ion release experiments were done as per a previously published
procedure.20 Briefly, 50 μl of AION (from 100 mg Ag per ml stock) were added to 4950 μl
of DI water or simulated lysosomal fluid (citrate buffer at pH 5.5) and incubated at 37 °C.
Samples were collected from the larger volume using 10 kDa MWCO ultrafiltration tubes
at the following time intervals: 1, 2, 6, 24, 48, 72, 96, 120, 144, and 168 hours. Three
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independent experiments were done for each time point. The cumulative silver ion
released (%) was calculated and presented as mean ± SD for each time point.

2.3.5 Cell viability assay
HepG2

(human

hepatocellular

liver

carcinoma)

and

J774A.1

(murine

macrophages) cell lines were purchased from ATCC (Manassas, VA) and cultured
according to the supplier’s instructions. In vitro cytotoxicity of AION was evaluated using
the LIVE/DEAD assay (Invitrogen Life Technologies, Grand Island, NY). In brief, 80,000
cells were seeded in 20 mm diameter glass bottom dishes with the appropriate cell culture
media supplemented with 10% fetal bovine serum and 1% streptomycin/penicillin and
incubated at 37 °C under 5% CO2. After 24 hours of incubation, cells were treated with
AION or AgNP dispersed in cell culture media at either 0.2 or 0.5 mg Ag/ml. Once the
treatment period of 24 hours was complete, the cells were washed once with sterile DPBS
and incubated with 400 μl of LIVE/DEAD cocktail (2 ml DPBS, 0.5 μl stock calcein-AM, 1
μl stock ethidium-1 homodimer and 2 μl 3.2 mM Hoechst 33342) for 20 minutes. The cells
were then imaged using Nikon Eclipse Ti-U fluorescence microscope with DAPI (ex: 359,
em: 461 nm), FITC (ex: 495, em: 519 nm), and Texas Red (ex: 595, em: 613 nm) filters.
Four images were taken per plate for each channel. The number of cells for the calceinAM, ethidium-1 homodimer and Hoeschst stain for each sample was counted using a
custom MATLAB (MathWorks, Natick, MA) program. The viability percentage was
determined by taking the ratio of living cells to total number of cells. The relative cell
viability (% control) is presented as mean ± SD for each concentration and cell line. Three
independent experiments were performed.
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2.3.6 Phantom imaging
The DEM contrast properties of AION were investigated using a step phantom.15
This step phantom was fabricated using materials that attenuate X-rays similarly to
glandular and adipose tissues i.e., the major X-ray attenuating components of breast
tissues. These background materials are arranged so that the composition of the phantom
varies from 100% glandular to 100% adipose tissues. A Tygon plastic tube containing
AION (17 mg Ag/ml) was inserted into a channel through the center of the longitudinal
direction of the step phantom. Then, a Hologic Selenia Dimensions prototype DEM system
(Bedford, MA) was used to image the phantom containing AION by acquiring two
mammograms with two distinct X-ray tube voltages and beam filters. The high energy (HE)
images were acquired at 45 kV and 40 mAs, while the low energy (LE) images were
acquired at 26 kV and 100 mAs. Copper and silver filters were used for the HE and LE Xrays, respectively. Finally, a logarithmically weighted subtraction between the LE and HE
images was performed to create a dual energy (DE) image as described in previous
studies.15, 20, 21 A total of three scans was performed. The mean DEM signal intensities
generated from AION, DPBS and empty tube (background without contrast) were
measured using ImageJ by placing a rectangular ROI on the target in each image. The
SDNR (Equation 1) was calculated and presented as mean ± SD.

𝑆𝐷𝑁𝑅 =

|𝐷𝐸𝑀 𝑠𝑖𝑔𝑛𝑎𝑙 (𝐴𝐼𝑂𝑁 𝑜𝑟 𝐷𝑃𝐵𝑆)−𝐷𝐸𝑀 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)|
𝑛𝑜𝑖𝑠𝑒 𝑜𝑓 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑

(1)

The CT phantom was constructed according to a previously reported method.27 In
brief, different concentrations (0.5 to 10 mg/ml, diluted with DI water) of iopamidol, AgNO3,
and AION were placed into PCR tubes that were later secured in a plastic rack. Negative
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controls were prepared using DI water and PBS. The phantom included three replicates
for each concentration and each agent. The rack was immersed in water (21 cm in height)
and scanned with a Siemens SOMATOM Force clinical CT scanner at 80, 100, 120, and
140 kV. The images were acquired using the following parameters: tube current = 360
mA, matrix size = 512 × 512, slice thickness = 0.5 cm, field of view (FOV) = 37 × 37 cm.
Osirix 64 bit was used to determine the attenuation values in Hounsfield units (HU) for
each sample tube using the ROI analysis tool. CT attenuation rates (HU·ml/mg and
HU/mM) were calculated for each agent at each voltage and presented as mean ± SD.
The MRI phantom was prepared by placing AION samples of different
concentrations (0.01 to 0.32 mM based on iron, diluted with DI water) in a 2% agar gel
doped with 0.35 mM manganese chloride. The phantom was scanned using a Siemens
Magnetom Trio with a 3 T magnet. T1-weighted spin-echo and inversion recovery pulse
sequences were used to obtain T1 relaxation times and T1-weighted MR images. The MR
imaging parameters were: echo time (TE) = 5.8 ms, repetition time (TR) = 10000 ms, slice
thickness = 3 mm, flip angle (FA) = 180 degrees, imaging matrix = 256 × 256, field of view
(FOV) = 180 × 180 mm and number of averages (NA) = 2. Multiple inversion time (TI)
values were chosen and shown as follows: 50, 100, 150, 200, 300, 400, 600, 700, 800,
900, 1000, 1400, 1800, 2200, 3000, 4000, 5000 and 6000 ms. The T2 relaxation times and
T2-weighted MR images were determined using a spin-echo sequence with the following
parameters: TR = 10000 ms, slice thickness = 3 mm, NA = 1, FA = 90 degrees, imaging
matrix = 256 × 256 and FOV = 180 × 180 mm. Multiple TE values were chosen and shown
as follows: 6.6, 8.8, 11, 13, 15, 20, 25, 30 and 40 ms. The resulting images were processed
using ImageJ. An oval ROI was placed on the tubes at each TE and TI for the
determination of T2 and T1 relaxation times, respectively. Both r1 and r2 relaxivities were
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calculated through curve fitting of 1/T1 or 1/T2 (ms−1) as a function of AION (or iron)
concentration (mM).
The phantom was constructed by placing different concentrations of AION (ranging
from 0.02 to 0.5 mM of DiR) suspended in DI water into a black bottom 96 well plate (n =
3). The plate was imaged using an IVIS Spectrum (PerkinElmer, Waltham, MA) with
excitation and emission wavelengths at 710 nm and 780 nm, respectively. Finally, the
images were processed using the Living Image 4.5.4 Software designed for IVIS imaging
systems.

2.3.7 Animal tumor model
All in vivo experimental protocols were conducted in accordance with PHS policy
on humane care and use of laboratory animals (Public Law 99–158) and with approval
from the Institutional Animal Care and Use Committee of the University of Pennsylvania
under protocol number 805593. Imaging experiments were performed using mice with
breast tumors (n = 5 per group). The breast cancer model was created by inoculating nude
female mice (Taconic Biosciences, Hudson, NY) with MDA-MB-231 cells in their
mammary glands (4 × 106 cells in 50 μL HBSS). Tumors were grown to an approximate
size of 100 mm3 at 5 weeks post-inoculation and pre-contrast tumor images were acquired
at this time. Immediately following the scans, a dose of 250 mg Ag/kg (or 25 mg Fe/kg)
was administered via the tail vein. Mice were anesthetized with isoflurane during all
imaging experiments.
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2.3.8 In vivo tumor imaging
Tumor-bearing mice were imaged using the afore-mentioned Hologic Selenia
Dimensions DEM prototype at several time points: pre-injection, 5, 30, 60, and 120
minutes. Images were acquired using the same conditions used for the DEM phantom
imaging as described above i.e., HE (45 kV) and LE (26 kV) with a tungsten target. After
DE subtraction, the DEM signals in the tumors and muscle near the hind leg were
calculated using ImageJ by placing an oval ROI on the target in each image at each time
point. The CNR (Equation 2) in the tumors of each mouse was calculated and presented
as mean ± SEM.

𝐶𝑁𝑅 =

|𝐷𝐸𝑀 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 (𝑡𝑢𝑚𝑜𝑟)−𝐷𝐸𝑀 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 (𝑚𝑢𝑠𝑐𝑙𝑒)|
𝑛𝑜𝑖𝑠𝑒

(2)

CT imaging experiments were performed using a MicroCAT II scanner (Imtek, Inc.,
Knoxville, TN) with the afore-mentioned tumor-bearing mice to investigate the CT contrast
production from the AION. Mice were scanned prior to injection and at 2 and 24 hours post
injection. CT images were acquired using the following parameters: slice thickness = 100
μm, FOV = 51.2 × 76.8 mm, tube voltage = 80 kV, tube current = 500 μA. A Feldkamp
cone beam correction and a Shepp-Logan filter were used as the reconstruction kernel.
The CT images were analyzed using Osirix 64-bit and the attenuation values in Hounsfield
units (HU) for the tumors were measured from three different slices at each time point.
Data are presented as mean ± SEM.
MRI was performed using a 4.7 T 50 cm horizontal bore MR Spectrometer
equipped with a 30 cm ID gauss/cm and a 12 cm ID gauss/cm gradient tube and interfaced
to a Varian DirectDrive console. T2*-weighted MR images were acquired using a multi65

gradient echo multi-slice sequence with a 35 mm coil under the following parameters: TR
= 1000 ms, TI = 60 ms, NA = 3, FA = 90 degrees, number of echoes = 8, slice thickness
= 1 mm, imaging matrix = 128 × 128 and FOV = 30 × 30 mm. TE values were chosen
between 3.3 and 26.4 ms (with an interval of 3.3 ms). Post-contrast images of the tumorbearing mice were acquired 24 hours after injection using the same imaging parameters
as the pre-contrast images. Throughout the experiment, the respiratory rate of the mice
was monitored and their body temperature was maintained at 37°C. Color coded R2 maps
were generated from the MR images acquired with the above sequence using a custom
written MATLAB program for pixel-wise curve fitting of the T2 relaxation times. The first
four echo times from 3.3 ms to 13.2 ms were chosen to construct the maps. Mean
R2 values were computed by averaging pixels within the tumor ROI for each mouse (three
tumor slices per mouse). Squared correlation coefficient was also calculated to examine
the quality of curve fitting for each pixel across the tumor regions. Results at each time
point are presented as mean ± SD.
Fluorescence imaging experiments were performed using an IVIS Spectrum
system (PerkinElmer, Waltham, MA). Tumor-bearing mice were imaged before injection
and 2 and 24 hours after injection using the DiR channel (745 nm excitation, 800 nm
emission) with an exposure time of 1 second. All images had the same illumination settings
and were analyzed using the Living Image 4.5.4 Software designed for IVIS imaging
systems. The average radiant efficiency of each tumor image was recorded using the ROI
tool. The tumor-to-background ratio was calculated at each time point and presented as
mean ± SEM.

66

2.3.9 Biodistribution
Tumor-bearing mice were sacrificed at 24 hours after injection and their blood
samples were then collected. After the left ventricle was perfused with PBS, the liver,
lungs, heart, spleen, kidneys, tumors and feces were collected. The organs and tumors
were first weighed and minced into small pieces that were then digested in 2 ml of
concentrated nitric acid at 75 °C for 16 hours. The digested samples were made to 10 ml
with DI water for subsequent measurement of silver concentration via ICP-OES. Data are
presented as mean ± SEM.

2.3.10 Pathology analysis
Non tumor-bearing mice (n = 4 per group) were sacrificed at 24 hours after injection
of PBS (vehicle control) or AION at a dose 250 mg Ag/kg (the same volume was used in
each case). After the left ventricles were perfused with PBS, the livers and spleens were
collected. The organs were briefly washed with cold PBS and cut into small pieces with
thickness of 5 to 6 mm. The organ pieces were then fixed in 10% neutral buffered formalin
and dehydrated with ethanol. Subsequently, tissues were embedded in paraffin, sectioned
and stained with hematoxylin and eosin (H&E) for histological examination. The stained
slices were analyzed with a light microscope (Nikon).

2.3.11 Statistics
All experiments were carried out in triplicate at the least, or in three independent
experiments. Statistical analyses were performed via two-tailed Student’s t-tests using
GraphPad Prism 6 software.
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2.4 Results
2.4.1 AION synthesis and characterization
To

synthesize

AION

(Figure

2-1A),

hydrophobic

Ag2S-NP

were

first

synthesized via a thermal decomposition single-source precursor approach adapted from
previous reports.25,

26

This reaction resulted in dodecanethiol-coated Ag2S-NP with an

average core diameter of 4.7 ± 1.2 nm (Figure 2-1B). The as-prepared Ag2S-NP, along
with oleic-acid coated 10 nm IO-NP (Figure 2-1C) and the lipophilic DiR fluorophore were
encapsulated in the hydrophobic core of micelles composed of DSPC and DSPEmPEG2000 phospholipids (1:1 molar ratio) using a one-pot ultrasonic emulsification
method. The 200:50:20:1 mass ratio of Ag2S-NP/phospholipids/IO-NP/DiR was chosen to
prepare AION with a high payload of Ag2S-NP in order to achieve desirable DEM and CT
contrast enhancement, while maintaining appropriate concentrations of IO-NP and DiR for
sufficient MRI and NIRF contrast, respectively. Of note, PEGylated phospholipids were
included as the carrier material due to their high stability and biocompatibility, as well as
to deter opsonization and thus facilitate accumulation within the tumor via the enhanced
permeability and retention (EPR) effect.28-30 As a result, we did not observe significant
changes in particle diameter (< 5%) as determined by DLS when incubated in PBS
containing 10% fetal bovine serum at 37 °C for 24 hours, proving its robust stability in
physiological conditions.
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Figure 2-1 Schematic representations of AION formulation.
(a) Schematic depiction of AION structure and composition. TEM images of (b) asprepared 4.7 nm Ag2S-NP, (c) oleic acid coated 10 nm IO-NP, (d) AION particles and (e)
an individual AION particle at a higher magnification showing the inclusion of Ag2S-NP
(red circles) and IO-NP (yellow circles). All scale bars are 10 nm.

The average core size and hydrodynamic diameter of AION were 88 ± 22 nm and
114 ± 2.7 nm as determined by TEM (Figure 2-1D, E) and DLS, respectively. A
polydispersity index of 0.161 was measured by DLS. The zeta potential of AION was found
to be −42.5 ± 0.8 mV, indicating good stability towards coagulation or flocculation. The
EDX spectrum (Figure 2-2) showed that AION have the expected 2:1 Ag:S stoichiometry
and contain more silver than iron, which is consistent with the mass ratio used in the
synthesis. A representative EDX line scan across a single AION particle is provided
in Figure 2-3, which confirms the inclusion of both iron and silver within the same
nanoparticle. AION have a broad UV-visible absorption band that is typical of Ag2S-NP
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with an absorption peak at 748 nm, which corresponds to the excitation wavelength of DiR
(Figure 2-4).26 Under excitation at 748 nm, a sharp fluorescence emission peak at 780 nm
was observed that is again typical of DiR (Figure 2-4). Both absorption and emission peaks
of AION lie within the NIR region (650–900 nm), where tissue is more transparent to light.31

Figure 2-2 EDX spectrum of AION.

Figure 2-3 EDX line scan across a single AION particle.
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Figure 2-4 Absorption and fluorescence emission spectra of AION.

2.4.2 In vitro evaluation of AION
Although silver nanoparticles have been widely used in many consumer products,
release of silver ions from these nanoparticles could pose a safety risk. We therefore
evaluated the silver ion leaching potential of AION and a control silver nanoparticle (AgNP)
by incubating them in two different media (DI water and citrate buffer at pH 5.5) at 37°C.
AgNP were synthesized using a protocol consistent with AION preparation except for the
incorporation of DT-coated elemental silver nanoparticles (5 nm in core diameter) instead
of Ag2S-NP.32 A TEM image of AgNP is shown in Figure 2-5. Citrate buffer with a slightly
acidic pH was used to simulate lysosomal fluid and the tumor microenvironment for the
following reasons: 1) most silver nanoparticles are found in lysosomes after phagocytosis
and 2) greater release of silver ions occurs at lower pH.33-35 The results showed both AION
and AgNP have similar silver ion release profiles with minimal release (~ 0.1%) over 7
days per the case of DI water (Figure 2-6A). No statistical significance was found between
the release profiles. However, a substantial amount of silver ions was released from AgNP
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(~ 0.4%) compared to AION (~ 0.1%) under slightly acidic conditions (Figure 2-6B).
Notably, no statistical difference was found between the release profiles of AION in neutral
and acidic conditions, indicating the robust stability of these nanoparticles. These results
are consistent with other reports in that elemental silver-based nanoparticles leach more
silver ions at lower pH, and the ultralow solubility of Ag2S-NP prevents the release of silver
ions.33, 36

Figure 2-5 TEM image of AgNP.
The inset shows a TEM image of as-prepared 5 nm pure silver nanoparticles (same scale
bar).
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Figure 2-6 Silver ion release from AION and AgNP and their impact on cell viability.
Silver ion release from AION and AgNP when incubated in (a) DI water and (b) citrate
buffer (pH 5.5) at 37 °C over a period of 7 days. Viability of (c) HepG2 and (d) J774A.1
cells when incubated with AgNP and AION for 24 hours. Error bars are one standard
deviation. Some error bars are hidden by the data point marker. * indicates P < 0.05
(unpaired Student’s t-test).

To assess the effects of silver ion release, we examined the impact of AION on the
viability of HepG2 (Figure 2-6C) and J774A.1 (Figure 2-6D) cells. These cells were
incubated with AgNP and AION at two different concentrations (0.2 and 0.5 mg/ml of Ag)
for 24 hours. The AION formulation was found to be biocompatible with both cell lines.
However, when these cells were incubated with AgNP, their viability was significantly
reduced compared to that of AION at each concentration. This result is in agreement with
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the observed silver ion release as more silver ions were released from AgNP compared
to AION. AgNP is a pure silver nanoparticle that is unstable towards oxidation and can
release silver ions in biological conditions, which have previously been shown to cause
cytotoxicity issues.37 Overall, our hypothesis that use of Ag2S-NP would reduce silver ion
release and improve biocompatibility of AION compared with pure silver nanoparticles was
deemed correct.

2.4.3 Multimodal contrast properties via phantom imaging
We performed phantom imaging to evaluate the contrast generating properties of
AION with the various breast imaging modalities. The DEM contrast properties of AION
(at a concentration of 17 mg Ag/ml) were investigated using a step phantom.38, 39 From
Figure 2-7A, it is evident that the background signal variations are removed and the
contrast from AION is enhanced after DE subtraction. The signal difference-to-noise ratios
(SDNR) calculated from the DE images indicate a significant increase in signal from
background breast tissues when AION is present (Figure 2-7B).15,

20

Therefore, DEM

imaging results indicated that AION is a suitable DEM contrast agent and that DEM
subtraction can suppress the signal from the superimposing breast tissues and allow
AION-containing breast tumors to be detected.
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Figure 2-7 Phantom imaging of AION with X-ray based imaging modalities.
(a) DEM phantom images (HE = high energy, LE = low energy, and DE Sub = dual energy
subtraction) and (b) signal difference-to-noise ratios derived from (a). (c) CT phantom
image and (d) CT attenuation of AION as a function of concentration at 80 kV. (e) CT
attenuation rates of different agents for each tube voltage. Error bars are one standard
deviation in all cases. * indicates P < 0.05 (unpaired Student’s t-test).

Since silver nanoparticles were previously shown to have CT attenuation
properties, we expected similar results from AION.20, 40 We evaluated the CT contrast
properties of AION using a clinical CT imaging system. A CT phantom image of the
different agents is presented in Figure 2-7C. AION produce contrast that is linearly
correlated with concentration, as is typical in CT (Figure 2-7D).27 Examination of the CT
attenuation rates revealed that AION attenuate X-rays slightly less than iopamidol and
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nearly identically to silver nitrate as expected (Figure 2-7E). A statistical significance was
found between the CT attenuation rates of AION and iopamidol at each tube voltage as
expected. Notably, the CT attenuation rates of AION and iopamidol follow the same trend
where the rates steadily decrease as the X-ray tube voltages increase from 80 to 140 kV.
This is consistent with the fact that silver and iodine have k-edges (26 keV and 33 keV,
respectively) that attenuate lower energy X-rays more strongly than higher energy X-rays.
From these experiments, we conclude that AION produce CT contrast close to that of an
iodinated agent and could serve as a CT contrast agent.
An agar phantom containing different concentrations of AION was scanned with a
clinical MRI scanner (Figure 2-8A). It is evident that the signal is reduced with increasing
concentrations of AION, as is expected from an iron oxide nanomaterial containing agent.
The T2 values of these solutions decreased from 200 to 7.45 ms as AION concentrations
increased from 0.01 to 0.32 mM. The transverse relaxivity (r2) was 429.4 mM−1s−1 and the
longitudinal relaxivity (r1) was 8.3 mM−1s−1 resulting in a high relaxivity ratio (r2/r1) of 51.7
at 3 T, demonstrating the potential of this agent for T2-weighted MR imaging. Lastly, the
NIRF contrast properties of AION were determined using an IVIS Spectrum imaging
system and the default filter set for DiR (Figure 2-8B). The fluorescence intensity observed
becomes greater with increasing AION concentrations. Furthermore, we examined
whether the metallic nanoparticles might have reduced the of the DiR fluorophore
molecules. We first synthesized a control micellar DiR nanoparticle (mDiR) using a
protocol consistent with AION preparation, but without the incorporation of Ag2S-NP and
IO-NP. We then compared the NIRF peak intensities of AION and mDiR at a fixed DiR
concentration and found AION to in fact have higher NIRF signal. This indicates that the
metallic nanoparticles within AION do not induce drastic quenching of the DiR
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fluorophores. In summary, phantom imaging studies have demonstrated that AION
produce strong contrast in vitro and should be an effective contrast agent for in vivo breast
tumor imaging.

Figure 2-8 MRI and NIRF phantom images of AION.
(a) MRI phantom image (the highest concentration corresponds to 90 μg Ag/ml) and (b)
NIRF phantom image of AION (the highest concentration corresponds to 500 μg Ag/ml).
Scale bar in units of radiant efficiency (x109 (p/s/cm2/sr)/μW/cm2).

2.4.4 In vivo breast tumor detection
The promising results from in vitro biocompatibility analyses and phantom imaging
encouraged us to investigate the applicability of AION as a safe and effective contrast
agent for in vivo breast cancer imaging. The in vivo imaging experiments were performed
using mice inoculated with human breast cancer cells. After pre-injection scans were
done, the mice were injected with AION at a concentration of 250 mg Ag/kg (or 25 mg
Fe/kg for MRI) and imaged with DEM, CT, MRI, and NIRF systems at various time points.
77

Of note, shorter post-injection time points (i.e., 5–120 minutes) were chosen for DEM to
align with the current clinical imaging procedure with this modality. The representative
DEM images shown in Figure 2-9A indicated that the DEM contrast at the tumor site (in
red dashed circles) is increased when compared to the pre-injection scan. The CNR in the
tumors (Figure 2-9B) was significantly higher after injections of AION, at all time points.
No significant differences in signal were found among the post-injection time points
imaged with DEM. Similar results were obtained from in vivo CT breast tumor imaging
experiments as presented in Figure 2-9C. Significantly higher CT attenuation and contrast
were found in the tumors at both post-injection time points compared to the pre-injection
scan (Figure 2-9D). There is no significant difference in the CT attenuation between the
two post-injection time points. These increases in tumor contrast post-injection are
consistent with the in vivo DEM imaging results and indicate that AION have potential as
contrast agents for breast cancer screening with CT, which could have use with future
clinical breast CT scanners.41, 42

78

Figure 2-9 In vivo tumor imaging with AION using X-ray based imaging modalities.
(a) DEM images of representative tumor-bearing mice at pre-injection and 120 minutes
post-injection with AION. (b) DEM image-derived contrast-to-noise ratios in the tumor
regions at the time points imaged. (d) CT images of a representative tumor-bearing mouse
pre-injection and at 24 hours post-injection. Scale bar in units of CT attenuation (HU). (d)
Average CT attenuation at pre-injection and 2 and 24 hours post-injection. Error bars are
standard error of mean. Red dashed ovals indicate tumors. Pre-injection is noted as 0
hours for both graphs. * indicates P < 0.05 compared to pre-injection scans (paired
Student’s t-test).

For in vivo MR imaging, we scanned the tumor-bearing mice using a 4.7 T small
animal MR system. Representative T2-weighted MR images and the corresponding
transverse relaxation rate (R2) maps at the level of tumor of a mouse before and after
injection of AION are shown in Figure 2-10A. The mean R2 values over the tumor ROI
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significantly increased from 51 ± 5 Hz to 75 ± 17 Hz with the injection of AION. Pixel-wise
squared correlation coefficient was used to examine the quality of the curve fitting and a
mean value of 0.93 ± 0.04 was found across the tumor regions, indicating a reliable
R2 measurement. Notably, the inherent heterogeneity of the tumor tissues causes
localized deposition of AION within the tumors which led to large variations in tumor signal
intensity as observed by MRI. Lastly, we evaluated the in vivo NIRF contrast properties of
AION using the aforementioned fluorescence imaging system (Figure 2-10B). The
average NIRF tumor-to-background ratio (TBR) significantly increased after injections of
AION (Figure 2-10C). The TBRs at the 2- and 24-hour post-injection time points were not
found to be significantly different. Overall, this result is in good agreement with the other
contrast-enhanced imaging modalities as AION can readily improve breast tumor
conspicuity in vivo.

Figure 2-10 In vivo MRI and NIRF optical imaging with AION.
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(a) Top: MR images of representative tumor-bearing mice pre-injection and at 24 hours
post-injection with AION. Images are shown with TE of 13.2 ms. Red dashed circles
indicate tumors. Bottom: representative R2 maps of the same mouse tumor before and
after injection of AION. Scale bar in units of Hz (1/s). (b) NIRF images of representative
tumor-bearing mice with AION at different time points. Black dashed circles indicate
tumors. Scale bar in units of radiant efficiency (x109 (p/s/cm2/sr)/μW/cm2). (C) Tumor-tobackground ratio calculated from the NIRF images with AION. Error bars are standard
error of mean. * P < 0.05 compared to pre-injection scan (paired Student’s t-test).

2.4.5 Biodistribution and pathology analyses
At 24 hours post-injection, animals were sacrificed and their organs and tumor
tissues were collected for biodistribution analysis. The silver content in the tissues was
determined using ICP-OES as shown in Figure 2-11. The results indicated that higher
amounts of AION are taken up by the liver and spleen, which are the organs responsible
for opsonization and reticuloendothelial phagocytosis. This finding is not atypical as other
studies have reported similar results with comparable nanoparticle designs.43,
44

Additionally, the animals did not show any adverse effects after injection with AION.

Moreover, some degree of tumor accumulation is observed (more than 1% injected dose
per gram of tissue), suggesting that the combination of surface PEGylation and particle
size of AION facilitated their accumulation at the tumor site via the EPR effect. It is
interesting to note that this level of tumor accumulation is sufficient to readily improve
tumor conspicuity, at the dose used. Nevertheless, the design of AION could be modified
to include higher molecular weight PEG ligands in order to provide more substantial stealth
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characteristics for evading the reticuloendothelial system (RES), thereby increasing the
accumulation level of AION to further enhance contrast in tumors.45, 46

Figure 2-11 Biodistribution of AION at 24 hours post-injection.
Silver content in tumor tissues and major organs was analyzed by ICP-OES.

To assess the in vivo safety of AION, we performed histopathological examination
of organs (i.e., liver and spleen). Necropsy was performed at 24 hours after injection of
AION at a dose of 250 mg Ag/kg and organs were fixed and stained with H&E for pathology
analysis. As shown in Figure 2-12, no evident histopathological abnormalities or lesions
were observed from the treated mice in comparison with the control. These preliminary
findings support the in vivo safety of the AION contrast agent.
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Figure 2-12 Representative H&E stained micrographs of major organs.
The liver and spleen samples were collected from control mice and AION treated mice at
24 hours after injection. The dose of AION was 250 mg Ag/kg. No apparent organ damage
of lesion was observed from the treated mice in comparison with the control. AION in these
organs are indicated by black circles. Scale bar = 100 µm.

2.5 Discussion
The sensitivity of conventional mammography is poor in women with dense
breasts, primarily due to the masking effect from superimposing fibroglandular tissues. 2
Women with high breast density also have an increased chance of developing breast
cancer, which is an inherent risk apart from issues related to screening.5 These women
are a vulnerable population and often require alternative screening methods for more
accurate diagnosis of breast cancer. Other imaging techniques such as contrastenhanced DEM, CT, MRI, and NIRF imaging are being used or explored. These
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techniques are less affected by breast density and can highlight tumors via use of contrast
agents. Several studies indicate that DEM and MRI have improved specificity and low
false positive rates compared with conventional mammography, where the specificity is
often limited, leading to unnecessary workups and benign biopsies. Furthermore, DEM
has potentially better specificity than MRI due to linearity of contrast with agent
concentration in X-ray imaging.47-49
Some of these techniques are already being used clinically; however, they can
vary widely in terms of cost, availability, and patient comfort. For instance, MRI is
expensive, is not readily available, and is not applicable to patients with claustrophobia or
contraindications such as pacemakers and metal implants.50-52 More recently, gadolinium
based contrast agents for MRI were found to accumulate in neural tissues even in subjects
with normal renal function and remain there for a long time.8-11 The health effects from
long-term retention of gadolinium in the brain are currently unknown. This finding provides
incentive to develop alternative and improved contrast agents especially for women with
elevated breast cancer risks as they commence screening in their 20s and continue for
many years. Moreover, each of the imaging methods requires a different contrast agent,
which can be problematic if supplemental screening is needed. The administration of
multiple doses of agents can pose a safety concern as additional stress is being put on
the body’s clearance mechanisms. Therefore, it is highly advantageous to create a single
probe that avoids the use of gadolinium or iodine based contrast agents to ensure safety
and is functional for a variety of breast imaging modalities to provide flexibility in the
diagnosis process. With the integration of several imaging modality agents, this
multimodal nanoprobe could combine information from each individual imaging modality
to provide complementary data, enhancing diagnostic specificity.53
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In this study, we developed AION as a multimodal contrast agent that improves
tumor conspicuity with the aforementioned breast cancer imaging methods. AION are
composed of two metal nanoparticles (i.e., IO-NP and Ag2S-NP) and a NIRF fluorophore
(i.e., DiR). In particular, IO-NP generate T2 contrast and are generally regarded to be safer
and more biocompatible than gadolinium based nanoparticles due concern over the
consequences of long-term gadolinium retention.54 We chose Ag2S-NP as the material for
DEM and CT contrast generation owing to their excellent biocompatibility that resulted
from their very low solubility product. Ag2S-NP are also much lower in cost than gold-silver
alloys (GSAN), a comparable DEM and CT agent. With the current metal prices (i.e.,
$0.55/g and $41.01/g for silver and gold, respectively),55, 56 the cost of a dose of 250 mg
Ag/kg for a woman of average weight would be $10 for AION versus $330 for GSAN. The
price would therefore be reduced by at least 30-fold with the use of silver sulfide-based
agent (compared to GSAN with inclusion of 20% gold). Furthermore, Ag2S-NP were
previously shown to emit in the second NIR window (950–1350 nm), which is more
desirable than the first NIR window due to lower photon absorption/scattering and tissue
autofluorescence.26,

57

This allows for imaging of deeper tissues and organs with

enhanced signal-to-noise ratio. Therefore, it is possible to exclude DiR from the
formulation and instead use Ag2S-NP to provide NIRF signal when NIR-II imaging systems
become more widely available.
AION were shown to release a minimal amount of silver ions when incubated in
both neutral and slightly acidic conditions. Of note, this study was performed without the
use of any media that contains chloride ions, especially physiological buffers such as PBS
or PBS with 10% serum. This is because the released silver ions can react with the
chloride ions in the media to form silver chloride precipitates that are difficult to separate
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from the silver nanoparticles and be collected in the filtrate. The results for silver ion
release may therefore be rendered inaccurate in such experiments. Interestingly, the
overall cumulative silver ion release (%) in both conditions is substantially (at least fivefold) lower than that of PEG-thiol-coated silver nanoparticles (i.e., 0.7% in DI water and
2.5% in citrate buffer over 7 days).20 This could be explained by the lipid coating of the
nanoparticles preventing access to the silver nanoparticle surfaces.28 Thus, we attributed
the minimal silver ion release of AION to both the phospholipid coating and the low
solubility of Ag2S-NP.
Our study has limitations, there was some level of elemental silver (or AION)
accumulation in the liver and spleen after injection. Although this finding is not atypical,
the surface PEGylation and particle size could be modified to slow their clearance by the
RES and further increase their accumulation at the tumor site. As mentioned earlier, the
inclusion of higher molecular weight PEG (e.g., 5k) on the particle surface could better
deter opsonization and evade the RES. Moreover, decreasing the nanoparticle size from
115 nm might also improve tumor accumulation.30
Notably, the contrast in the tumors was elevated over a range of time points. This
could be beneficial for future clinical applications as AION can provide contrast for many
hours after administration which eliminates the need for swift post-injection imaging as
seen with current contrast agents, allowing for flexible scheduling and planning. Future
directions for this platform might include the synthesis of ultra-small (< 5 nm) aqueousphase silver based nanoparticles that can be swiftly excreted renally. This is
advantageous as excretion from the body is an important criterion for FDA approval of a
nanoparticle based contrast agent. Furthermore, these particles can be encapsulated in
biodegradable polymeric nanoparticles for increased circulation time and enhanced tumor
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accumulation.58 Lastly, AION are a promising contrast agent for DEM and may have use
in the emerging technique of photon-counting spectral mammography.59, 60

2.6 Conclusion
In this study, we developed an “all-in-one” multimodal nanoparticle contrast agent
for use by multiple breast cancer imaging techniques. AION were synthesized by
incorporating Ag2S-NP, IO-NP, and DiR in the hydrophobic core of phospholipid micelles.
We included Ag2S-NP in the formulation to provide DEM contrast and minimize the release
of silver ions that can cause safety concerns. This was confirmed by the in vitro silver ion
leaching and cell viability studies where minimal silver ion release and negligible
cytotoxicity were found. AION produced strong DEM, CT, MR, and NIRF contrast in
phantoms and in vivo. Accumulation of AION in tumors allowed in vivo imaging at multiple
times points after the administration of AION. Therefore, AION have potential as a safe
and effective multimodal contrast agent for a range of breast cancer imaging techniques.
To increase the translational potential of Ag2S-NP contrast agents, we develop sub-5 nm,
hydrophilic Ag2S-NP with efficient renal excretion in the next chapter.
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Chapter 3 : Size-tunable silver sulfide nanoparticles for efficient
renal excretion
3.1 Abstract
Significant effort has been focused on developing renally-clearable nanoparticle
agents since efficient renal clearance is important for eventual clinical translation. Silver
sulfide nanoparticles (Ag2S-NP) have recently been identified as contrast agents for dual
energy mammography, computed tomography (CT) and fluorescence imaging and probes
for drug delivery and photothermal therapy with good biocompatibility. However, most
Ag2S-NP reported to date are not renally excretable and are observed in vivo to
accumulate and remain in the reticuloendothelial system (RES) organs, i.e., liver and
spleen, for a long time, which could negatively impact their likelihood for translation.
Herein, we present renally-clearable, 3.1 nm Ag2S-NP with 85% of the injected dose (ID)
being excreted within 24 hours of intravenous injection, which is amongst the best
clearance of similarly sized nanoparticles reported thus far (mostly between 20-75% of
ID). The urinary excretion and low RES accumulation of these nanoparticles in mice were
indicated by in vivo CT imaging and biodistribution analysis. In summary, these ultrasmall
Ag2S-NP can be effectively eliminated via urine and have high translational potential for
various biomedical applications.
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3.2 Introduction
The key for potential clinical translation for intravenous contrast agents that include
heavy metals is efficient renal clearance.1 Rapid renal excretion of the agents should avoid
safety concerns from long-term retention in the reticuloendothelial system (RES) organs
(i.e., liver and spleen) and minimize interference with diagnostic results from subsequent
screening or monitoring.2, 3 Efficient clearance is especially important for patients who will
receive multiple injections of agent. For example, women with dense breasts, who belong
to the very population that is at high risk for breast cancer, are recommended to receive
supplemental screening with techniques such as dual energy mammography (DEM), for
which iodinated contrast agents are currently used.4, 5 These women may receive ten or
more screenings in their lives, underscoring the importance of the agent being eliminated
quickly.
Over the past decade, much effort has been made in developing renally-clearable
metal nanoparticles for use in bioimaging applications. Reports have focused on
modulating the size, shape, surface charge and composition of quantum dots and gold
nanoparticles.6 Various studies demonstrated that nanoparticles with zwitterionic coating
ligands (i.e., glutathione and cysteine) and sizes between 1-6 nm have high renal
clearance efficiencies.1,

7, 8

In addition, some studies indicated that renal clearance of

nanoparticles is core density-dependent, where greater clearance was observed with
lower density particles such as those based on silver.9, 10
Recently,

silver

sulfide

nanoparticles

(Ag2S-NP)

were

reported

to

be

biocompatible, likely due to their very low solubility constant (Ksp = 6.3 × 10−50), and have
been studied as fluorescence imaging probes and photothermal therapeutic agents as a
result of their near-infrared (NIR) optical properties.11, 12 Furthermore, we have found that
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silver produces stronger contrast than iodine in DEM and also provides computed
tomography (CT) contrast.13-16 Such nanoparticles would perform well as DEM specific
contrast agents when screening for breast cancer. Therefore, the development of renallyclearable Ag2S-NP would improve the likelihood of translation and support their use as
cancer imaging agents with DEM and CT.
In this study, we report the successful renal clearance of 3.1 nm Ag2S-NP as
evidenced by CT imaging. These nanoparticles were obtained by modulating the reaction
time of a viscosity-mediated synthesis that can finely tune the average core sizes between
2 to 10 nm. From biodistribution analysis, we found that 85% of the injected dose (ID) was
excreted from the body within 24 hours of intravenous injection, one of the highest
clearance efficiencies of similarly sized metal nanoparticles or quantum dots reported to
date. A renal clearance efficiency of 20-75% of ID was reported in most previous studies
for nanoparticle imaging agents.6 We also found that these small aqueous Ag2S-NP have
good biocompatibility as observed from in vitro cell viability and histopathological
assessments. Consequently, these nanoparticles with efficient renal clearance and high
translational potential might find applications in imaging with DEM and CT.

3.3 Materials and methods
3.3.1 Materials
Silver nitrate (AgNO3, 99%), sodium citrate dihydrate, sodium borohydride and Lglutathione (GSH, 98%) were purchased from Sigma-Aldrich (St Louis, MO). Ethylene
glycol was purchased from Fisher Scientific (Fair Lawn, NJ). All chemicals were used as
received.
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3.3.2 Synthesis of aqueous Ag2S-NP and AgNP
The method to synthesize water-soluble Ag2S-NP with tunable core sizes was
adapted from previous reports.17, 18 In brief, a flask containing 40 ml of ethylene glycol was
heated to 120 °C. Then, 100 mg AgNO3 and 140 mg GSH (a molar ratio of 4:3) were
added to the flask under nitrogen flow. The reaction mixture was kept at this temperature
for one minute to form a colorless transparent mixture. A heating mantle coupled with a
temperature controller was used to heat the mixture to 165 °C at a heating rate of 20 °C
per minute. The mixture gradually turned from colorless to dark brown after 10 minutes of
heating. The mixture was quenched by cooling in an ice water bath at different time points
(11, 13, 15, 16, 22 and 28 minutes) to obtain Ag2S-NP with core sizes between 2 and 10
nm. The products were isolated by adding absolute ethanol and centrifuging at 7000 rcf
for 10 minutes. Then, the pellet was collected and redispersed in 20 ml of DI water. The
nanoparticles were washed three times in DI water using 3 kDa MWCO filtration tubes
(Sartorius Stedim Biotech, Germany). The tubes were spun at 4000 rpm for 30 minutes.
After the last wash, the buffer was changed to DPBS and the nanoparticles suspension
was concentrated to a final volume of 1 ml. Finally, the nanoparticles suspended in DPBS
were filtered through a 20 nm membrane to remove any aggregates and stored at 4 °C for
use in subsequent experiments.
The method to synthesize water-soluble AgNP was adapted from a previous
study.15 Briefly, 1.25 ml of 0.1 M sodium citrate dihydrate solution and 1.25 ml of 0.1 M
silver nitrate were added to 500 ml DI water while stirring. Then, 5 ml of 0.1 M sodium
borohydride in DI water was added to the reaction mixture under vigorous stirring for 1
minute. Subsequently, 30 mg GSH dissolved in 5 ml of DI water was added to the mixture,
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which was gently stirred overnight. The product was washed thrice with DI water and
concentrated using 10 kDa MWCO filtration tubes, which were spun at 4000 rpm for 20
minutes. The nanoparticles were suspended in DI water and filtered through a 20 nm
membrane to remove aggregates prior to storing at 4 °C for use in subsequent
experiments.

3.3.3 Nanoparticle characterization
TEM samples were prepared by dropping 10 μl of diluted Ag2S-NP samples (2 μl
from concentrated stock added to 498 μl DI water) onto Formvar-coated, carbon filmstabilized copper grids (Electron Microscopy Sciences, Hatfield, PA). The grids were dried
in air before imaging. All Ag2S-NP samples were examined using the T12 cryo-electron
microscope (FEI Technai) operated at 120 kV. High-resolution TEM imaging was
performed using JEM-F200 (JEOL USA, Inc.) operated at 200 kV. ImageJ (National
Institutes of Health, Bethesda, MD) was used to measure the core diameter of Ag 2S-NP
(from 1000 nanoparticles per sample).
A Rigaku GiegerFlex D/Max-B X-ray diffractometer operated at 45 kV and 30 mA
with a monochromatized Cu Kα radiation wavelength of 1.5406 Å and a scan rate of 2°
per minute was used to record the XRD patterns of dried Ag2S-NP in the range of 20°-60°.
Ag2S-NP samples were completely dried onto an aluminum substrate under
vacuum. Their EDX spectra were recorded using a Quanta 600 field emission gun
scanning electron microscope (FEI, USA) operated at 15 kV and equipped with EDX
detectors (EDAX, Inc.).
A Malvern Nano ZS-90 Zetasizer was used to measure the hydrodynamic diameter
(HD) and surface charge of Ag2S-NP samples containing 1 ml of diluted nanoparticle
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suspension. HD was reported from the number mean. HD and zeta potential
measurements were performed at 25 °C.
A Thermo Scientific Genesys UV/visible spectrophotometer was used to record
the UV-visible absorption spectrum of diluted Ag2S-NP samples. The absorption intensity
was normalized to a maximum of 1 across all samples.
A Spectro Genesis ICP-OES was used to determine the concentrations of silver
presented in Ag2S-NP samples. The samples were prepared as follows: 10 μl of Ag2S-NP
stock solution was first dissolved in 1 ml of nitric acid and then DI water was added to
make the final volume to 10 ml. Three replicates per sample were used.
A JASCO FT/IR-480 Plus spectrophotometer was used to collect the infrared
spectra of Ag2S-NP and glutathione. The samples were prepared by grinding 2 μL from
concentrated Ag2S-NP stock (40 mg Ag per ml) or glutathione (15 mg) with 100 mg of
dried potassium bromide powder and pressing them into compact pellets.

3.3.4 Silver ion leaching assessment
The silver ion release profiles of different sized Ag2S-NP were determined
according to a previously published procedure.15, 16 Briefly, Ag2S-NP or AgNP suspended
in DI water (50 μl from a 100 mg Ag per ml stock) were added to a glass vial and the final
volume was made to 5 ml with DI water or citrate buffer at pH 5. The vials were incubated
at 37 °C. Then, silver ions released from the larger volume were collected using 3 kDa
MWCO ultrafiltration tubes over a 7 day period. The silver content was measured using
ICP-OES and cumulative release of silver ions (%) for each time point was presented
(mean ± SD).
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3.3.5 In vitro cytotoxicity
TCMK-1 and AML12 cell lines were used to evaluate the in vitro cytotoxicity of
Ag2S-NP. They were cultured according to the instructions from ATCC. The viability was
assessed according to a previously published method.15 In brief, 20000 cells from each
cell line were seeded in each well of a 96 well plate. The seeded cells were allowed to
stabilize for 24 hours. The cells were then treated with Ag2S-NP at concentrations of 0
(control), 0.5 and 1 mg Ag per ml for 4 hours. Once the treatment was done, the cells were
washed with PBS to remove the nanoparticles and incubated with the MTS assay
(Promega, Madison, WI, USA). Then, the absorbance at 490 nm was recorded using a
microplate reader. The cell viability relative to control (%) for each concentration and cell
line was determined and presented as mean ± SD.

3.3.6 CT and DEM phantom imaging
The method for constructing a CT phantom was reported in a previous
study.19 Iopamidol, AgNO3, and Ag2S-NP of varying concentrations (0.5 to 10 mg per ml)
were loaded into small tubes (0.2 ml volume) and secured in a plastic rack with parafilm.
Three replicates were included for each concentration and each agent. The phantom was
placed into a plastic bucket that contained water of 21 cm in height. Then, a clinical CT
scanner (Siemens SOMATOM Force) was used to scan the phantom and images were
acquired with the following settings: field of view (FOV) = 37 × 37 cm, tube current = 360
mA, tube voltage = 80 to 140 kV, slice thickness = 0.5 mm and matrix size = 512 × 512.
Image analysis was done using Osirix 64-bit. CT attenuation for each sample tube at each
concentration was determined from three different slices and the attenuation rates
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(HU·ml/mg) were calculated based on this result. The attenuation rates (mean ± SD) of all
agents at each voltage are presented.
Ag2S-NP were evaluated for their DEM contrast properties using a contrastembedded gradient ramp phantom that varies continuously from 100% glandular to 100%
adipose tissue. In addition, adipose layers were added to the top and bottom of the ramp
section to simulate the skin layer of the breast. In brief, samples prepared at a
concentration of 15 mg per ml of silver or iodine were loaded into polyethylene tubes and
inserted into the holes of the phantom in the direction of varying glandularity. Three tubes
were prepared for each sample (Ag2S-NP of 2.3 nm, Ag2S-NP of 3.1 nm, Ag2S-NP of 5.1
nm, AgNO3, iopamidol, and PBS). Then, images of the phantom were acquired using a
Hologic 3Dimensions mammography system, which has a tungsten anode and 70 μm
detector. The system is capable of dual-energy (DE) imaging, in which a high-energy (HE)
and a low-energy (LE) image are acquired in a single study. DE images of the phantoms
were obtained by a weighted logarithmic subtraction of the HE and LE image pairs. 15,
16

The HE images in our study were acquired at 45 kV using a copper filter and 90 mAs.

The LE images were acquired at 26 kV using a silver filter and 100 mAs. The technique
parameters were chosen based on our previous work imaging silver nanoparticles.13,
14

Each tube was scanned a total of three times. Analysis of the phantom images was

performed using MATLAB. The signal intensity and noise values were measured by
selecting rectangular regions of interest for each tube and signal difference-to-noise ratios
were calculated according to a previous study.14 Data are presented as mean ± SD.
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3.3.7 Animal experiments
In vivo imaging experiments were conducted using 8 weeks old female nude mice
(n=4 per group) purchased from Taconic Biosciences (Hudson, NY). After pre-contrast
imaging was done, a dose of 250 mg Ag per kg of body weight was administered through
the tail vein. As control, iopamidol was injected at the same dose. Isoflurane was used to
anesthetize the mice during the imaging experiments.

3.3.8 In vivo CT imaging
A MicroCAT II small animal CT scanner (Imtek, Inc., Knoxville, TN) was used to
image the mice. The mice were scanned at the following time points: 0 (pre-injection), 5,
30, 60 and 120 minutes post injection. The following parameters were used to acquire the
images: tube current = 500 μA, tube voltage = 80 kV, voxel size = 100 μm3, FOV = 51.2 ×
76.8 mm and slice thickness = 100 μm. Image reconstruction was done by applying a
Shepp-Logan filter and a Feldkamp cone beam correction. Image analysis was done using
Osirix 64-bit. CT attenuations for the various organs were measured and averaged from
three slices. The change in attenuation from pre-injection scan is presented as mean ±
SEM in Hounsfield units.

3.3.9 Pharmacokinetics
Blood samples were collected via retro-orbital bleeding with heparinized capillary
tubes at the following time points after injection: 5, 10, 20, 30, 60, 90, 120 and 240 minutes.
Each sample was weighed prior to overnight digestion in nitric acid at 75 °C. DI water was
then added to the digested samples before measuring the silver content with ICP-OES.

105

Data are presented as mean ± SD. A first-order exponential decay model was used to fit
the data and determine the circulation half-life.

3.3.10 Biodistribution of Ag2S-NP
At 24 hours p.i., mice were sacrificed and blood samples were collected from them.
20 ml of PBS was perfused via the left ventricle and major organs including the heart,
lungs, liver, kidneys, spleen and fecal matter were collected. The weights of the organs
and remaining carcasses were recorded. Next, the organs and carcasses were cut into
small pieces and immersed in 3 ml of nitric acid for overnight digestion at 75 °C. Then, 7
ml of DI water was added to the digested samples. The samples were filtered before
measuring the concentration of silver with ICP-OES. Data are presented as mean ± SEM.

3.3.11 Pathology analysis
Mice were injected with PBS solution or Ag2S-NP at a dose of 250 mg Ag per kg
and were sacrificed after 24 hours. Their major organs were collected, rinsed with chilled
PBS and were cut into 5 to 6 mm thick pieces. Tissue fixation was done by placing the
organ pieces in 10% neutral buffered formalin overnight at 4 °C. The tissues were
dehydrated with ethanol prior to embedding in paraffin and staining with hematoxylin and
eosin (H&E). A digital microscope (Nikon) was used to examine the stained slices.

3.3.12 Statistical analysis
At least three replicates or three independent experiments were carried in all
studies. GraphPad Prism 6 software was used to perform all statistical analyses. The
specific statistical tests that were done are written in the figure caption when applicable.
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3.4 Results
3.4.1 Size-tunable Ag2S-NP synthesis and characterization
Hydrophilic, size-tunable Ag2S-NP were synthesized using a viscosity-mediated,
thermal decomposition method, as depicted in Figure 3-1.17 A highly viscous reaction
medium was employed to sufficiently reduce the nucleation rate and finely control the
growth of the nanoparticles.18 The reaction was quenched at various time points between
10 and 20 minutes to obtain an array of low dispersity, glutathione-coated silver sulfide
nanoparticles with core sizes ranging between 2 to 5 nm, as determined by transmission
electron microscopy (TEM) in Figure 3-2. An electron micrograph of a 3 nm Ag2S-NP taken
by high-resolution TEM is shown in Figure 3-3, which indicates lattice fringes (d = 2.60 Å)
similar to that with monoclinic Ag2S phase. Powder X-ray diffraction was used to
investigate the crystalline structures of the resultant nanoparticles (Figure 3-4). The
diffraction peaks become less distinctive and more broad with decreasing nanoparticle
size, which is consistent with the results found by others.20 The characteristic diffraction
peaks become apparent with increasing nanoparticle size, and the patterns match well
with the monoclinic crystalline structure of Ag2S and differ from that of pure silver. These
nanoparticles have a 2:1 Ag:S stoichiometry as expected and possess a broad absorption
band that is attributed to the electronic properties of Ag2S-NP. The hydrodynamic diameter
(HD) and zeta potential of the differently sized Ag2S-NP are shown in Table 3-1. The
infrared absorption peak at 2500 cm−1 in the Fourier transform infrared spectrum (Figure
3-5) which corresponds to free thiol group is absent, suggesting that the glutathione
molecules are bound to the nanoparticle surface through the Ag-thiol bond.21 Notably, no
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red shift in the absorption spectra, hence no increase in nanoparticle sizes was observed
after incubation in PBS or PBS with 10% fetal bovine serum at 37°C for 24 hours as
determined by UV/visible spectroscopy (Figure 3-6), indicating the stability of these
nanoparticles. This can be attributed to the zwitterionic nature of glutathione that provides
high stability in biological media and prevents serum protein adsorption, thereby
maintaining a small overall size for efficient renal excretion.8 For subsequent experiments
we used a subset of the synthesized Ag2S-NP, i.e., the 2.3, 3.1 and 5.1 nm nanoparticles.

Figure 3-1 Synthesis of Ag2S-NP with tunable sizes.

Figure 3-2 Representative TEM images and core size distributions of Ag2S-NP.
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Figure 3-3 Electron micrograph of a 3 nm Ag2S-NP via HR-TEM.

Figure 3-4 X-ray diffraction patterns of Ag2S-NP of different sizes.

Table 3-1 Characterization of Ag2S-NP formed at differing reaction times.
Reaction time
(minutes)

TEM diameter
(nm)

16

DLS

Surface charge
(mV)

HD (nm)

PDI

5.1 ± 0.8

7.4 ± 1.0

0.20

−18 ± 3

15

4.1 ± 0.5

6.8 ± 2.2

0.37

−15 ± 3

13

3.1 ± 0.5

4.9 ± 1.0

0.46

−11 ± 2

11

2.3 ± 0.4

3.9 ± 1.0

0.60

−7 ± 1
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Figure 3-5 FT-IR spectra of Ag2S-NP and GSH.

Figure 3-6 Stability assessment of differently sized Ag2S-NP.

3.4.2 Silver ion leaching and in vitro cytocompatibility
As previously reported, elemental silver nanoparticles are not stable towards
oxidation, which can result in the release of silver ions.22 There is a safety concern over
this aspect. We therefore investigated the leaching potential of differently sized Ag2S-NP
when incubated in DI water and citrate buffer at pH 5.23 Citrate buffer with a low pH was
used to mimic the acidic conditions found in lysosomal fluid, the tumor microenvironment
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and urine.24 It is particularly important to probe stability at lower pH since silver
nanoparticles are often internalized into lysosomes after phagocytosis and are found to
release more silver ions under acidic conditions.25, 26 Of note, chloride-containing media
were not used in this study because chloride ions can react with released silver ions to
form silver chloride aggregates, preventing the detection of silver ions. A pure silver
nanoparticle (AgNP) with the same coating and of comparable size to the Ag2S-NP (Figure
3-7) was used as control.15 We found that the release of silver ions from AgNP was at
least ten-fold higher than Ag2S-NP of all sizes in both media over 7 days (Figure 3-8A, B).
The release profiles of the differently sized Ag2S-NP were not statistically significantly
different for either condition. In addition, no significant difference was observed in the
release profiles between neutral and acidic pH, demonstrating the stability of these
nanoparticles. Overall, our results indicated that Ag2S-NP (regardless of core size) have
minimal silver ion release compared to elemental silver-based nanoparticles due to the
ultralow solubility of Ag2S-NP, which effectively prevents the release of silver ions.

Figure 3-7 Electron micrograph of AgNP.
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Figure 3-8 Silver ion release and impact on viability from differently sized Ag2S-NP.
Silver ion release from Ag2S-NP of different core diameters and AgNP when incubated in
(a) DI water and (b) citrate buffer of pH 5 at 37 °C over a 7-day period. Viability of (c)
TCMK-1 and (d) AML12 cells when incubated with Ag2S-NP for 4 hours. * indicates P <
0.05 compared to control (two-way ANOVA with Bonferroni’s multiple comparisons test).
Error bars are one standard deviation. Some error bars are smaller than the data point
marker and are thus not visible.

We then assessed the impact of differently sized Ag2S-NP on the viability of normal
kidney (TCMK-1) and liver (AML12) cells (Figure 3-8C, D) to probe the effects of silver ion
leaching. These cell types were chosen for the study since they should have the greatest
exposure to Ag2S-NP upon injection. Each cell type was incubated with the nanoparticles
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at the following concentrations for 4 hours: 0.5 and 1.0 mg per ml of Ag. Ag2S-NP of all
sizes were found to be biocompatible with both cell lines at each concentration with no
statistically significant differences compared to control. This result is expected since less
than 0.1% of the dose was taken up by each cell type at each concentration, and thus, the
particles most likely are not significantly endocytosed, which avoids further intracellular
interactions and possible cytotoxicity. Furthermore, Ag2S-NP have minimal silver release
and should not have an impact on cell viability regardless of particle size. Nevertheless,
since most Ag2S-NP are expected to be excreted via urine within the first few hours after
administration, cellular exposure to these nanoparticles and potential cytotoxicity would
be minimized. Overall, our results indicated that Ag2S-NP have good biocompatibility as a
result of minimal silver ion release.

3.4.3 Phantom imaging with CT and DEM
Next, we performed phantom imaging to examine the CT and DEM contrast
properties of differently sized Ag2S-NP. A clinical CT imaging system was used to evaluate
the CT attenuation properties of Ag2S-NP (Figure 3-9A), as silver nanoparticles were
previously shown to produce CT contrast.15, 16 The CT attenuation rates of all agents were
calculated and presented in Figure 3-9B. As expected, the CT attenuation rates of Ag2SNP are lower and significantly different than iopamidol at each tube voltage since silver
has lower atomic number and hence K-edge energy than iodine. However, no statistical
significance was found between the CT attenuation rates of Ag2S-NP and silver nitrate at
each tube voltage. Moreover, the CT attenuation rates among the differently sized Ag2SNP were not found to be significantly different, which is consistent with the fact that X-ray
absorption is generally related to the material density and atomic number. For all agents,
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the highest CT attenuation rate occurred at the lowest tube voltage (80 kV) and the rates
steadily decreased as the tube voltage increased to 140 kV. The K-edge energies of silver
(26 keV) and iodine (33 keV) are at the lower end of each CT energy spectra used, but
nearer to the mean photon energy of the low kVp spectrum than high kVp spectrum. This
allows for stronger attenuation of lower energy X-rays and results in approximately twofold higher contrast production when using 80 kVp in comparison with 140 kVp.

Figure 3-9 Phantom imaging of different agents with DEM and CT.
(a) CT phantom image at 80 kV and (b) CT attenuation rates for each tube voltage. (c)
DEM phantom images and (d) signal difference-to-noise ratios calculated from DE
subtraction images in (c). Error bars are one standard deviation in all cases. * indicates P <
0.05 (two-way ANOVA and one-way ANOVA for panels b and d, respectively, with Tukey’s
multiple comparisons tests).
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A clinical DEM system was used to perform imaging on a gradient ramp phantom.
A dual energy (DE) image was created from a logarithmically weighted subtraction of two
X-ray images that are acquired at low and high energy.14 It is evident that the contrast from
Ag2S-NP is greatly enhanced while the variation in background signal is reduced (Figure
3-9C). The signal difference-to-noise ratios (SDNR) for PBS, silver salts and three sizes
of Ag2S-NP were calculated from DE images and are presented in Figure 3-9D. The
results indicate that the signal produced from Ag2S-NP is significant higher than
background breast tissues or PBS, which is consistent with previously published
data.16 Moreover, there is no significant difference in the SDNR produced among all three
sizes and silver salts, which is expected since the concentration of silver was held constant
in all cases. From these experiments, we conclude that the signal produced in CT and
DEM is not affected by the sizes of Ag2S-NP and these nanoparticles could serve as a CT
and DEM contrast agent.

3.4.4 In vivo imaging with CT
To non-invasively monitor the distribution profile and clearance potential of Ag2SNP, we injected female nude mice with iodine (control) and 3.1 nm Ag2S-NP at a dose of
250 mg Ag per kg via tail vein and imaged them using a small animal CT scanner at
various time points. This core size was chosen for the clearance study since Ag2S-NP with
this size have a HD below 5.5 nm, which is required for renal clearance. 1 The dose used
is comparable to that used clinically for iodinated contrast agents.27,

28

Typically, the

minimal dose for CT contrast agents is 100 mg per kg body weight, and the agents are
often used at substantially higher doses.29 In comparison to the Ag2S-NP treated group,
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mice injected with iodinated agents had less contrast in the blood (or heart) as more agent
was cleared through the kidneys into the bladder immediately after injection (Figure 310A). On the other hand, vascular contrast and filtration of Ag2S-NP from the blood via the
kidneys were evident in segmented data (Figure 3-10B). This indicates that Ag2S-NP have
a much longer blood circulation time than iodine (Figure 3-10C). Moreover, the successful
renal excretion of these nanoparticles was observed when contrast in the bladder became
significantly higher after injection and remained high throughout the time course (Figure
3-11A). The quantification of CT contrast in different organs revealed the contrast in the
bladder was highest of all the organs at all time points after injection (Figure 3-11B). The
contrast in the blood and kidneys gradually decreased over the two-hour period whereas
the contrast in the liver and spleen remained at a more constant, higher level than preinjection. However, the small increase in CT attenuation (< 60 HU) at 2 hours post-injection
(p.i.) suggests that a small amount of Ag2S-NP remained in the RES organs. In addition,
a urine sample was collected at 2 hours p.i. and was examined under TEM, which revealed
the presence of these nanoparticles (Figure 3-12). The nanoparticles found in urine were
measured to have an average core diameter of 3.1 ± 0.4 nm, which matched the average
core size of injected Ag2S-NP. Furthermore, we compared the CT attenuation values in
the liver and spleen of mice injected with Ag2S-NP of larger size (90 nm) to confirm the
swift excretion of the small Ag2S-NP.16 Significantly higher accumulation in the RES
organs was evident with 90 nm Ag2S-NP since their large size prevented kidney filtration
and subsequent urinary excretion. It seems that the uptake in the RES was greatly
reduced with the ultrasmall Ag2S-NP as a result of kidney filtration and urinary excretion.
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Figure 3-10 In vivo CT data of mice injected with iopamidol or Ag2S-NP.
(a) In vivo CT images of the heart, kidneys and bladder of mice injected with iodinated
agents or 3.1 nm Ag2S-NP. Images taken at 5 minutes post-injection are indicated by white
boxes. Red and yellow dashed circles indicate the kidney and bladder, respectively. (b)
3D region growing segmentation to visualize vascular contrast and clearance via kidney
filtration of a mouse injected with Ag2S-NP. White arrowheads mark the blood vessels.
Heart and kidneys are labeled H and K, respectively. (c) The change in CT attenuation in
the blood (or heart) of mice at different time points compared to pre-injection. Error bars
are one standard deviation.
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Figure 3-11 In vivo CT imaging and biodistribution of mice injected with Ag2S-NP.
(a) Representative 3D volume rendered CT images of a mouse injected with Ag2S-NP that
have an average core diameter of 3.1 nm. The images are shown with a window level of
500 HU and window width of 200 HU. Green arrowheads mark the blood vessels and
green circles indicate the bladder. Hearts and kidneys are labeled H and K, respectively.
Some attenuation from food minerals were observed in the abdomen before injection. (b)
The change in CT attenuation in different organs of mice at different time points compared
to pre-injection. (c) Biodistribution of Ag2S-NP with an average core size of 3.1 nm in major
organs and remaining carcasses at 24 hours p.i. as determined by ICP-OES. The values
are given in units of %ID per gram and %ID as indicated by the blue (left y-axis) and red
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(right y-axis) bars, respectively. Error bars are standard error of mean. Some error bars
are smaller than the data point marker and are thus not visible.

Figure 3-12 TEM image of a urine sample collected at 2 hours post-injection.

3.4.5 Pharmacokinetic and biodistribution profiles
To study the pharmacokinetics of Ag2S-NP, we collected blood samples at various
time points after injection and measured the silver concentrations using inductively
coupled plasma optical emission spectroscopy (ICP-OES). We determined the circulation
half-life to be 86.6 minutes, which is longer than most clinical iodinated agents (they have
an average half-life of 13 minutes).30 In addition, we found that less than 0.2% of ID was
detected in the feces collected over 24 hours, indicating that the clearance of Ag2S-NP
through the biliary pathway or GI tract is highly unlikely. This finding suggests that renal
excretion is the main elimination route for Ag2S-NP.
To determine the clearance efficiency of these small Ag2S-NP, we used ICP-OES
to analyze the silver content in the tissues collected at 24 hours after injection. More silver
(8-12% of ID per gram of tissue) was found in the RES organs than in other tissues (Figure
3-11C), which is consistent with the CT imaging results (although there is a difference in
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time point). Notably, the level of uptake was significantly lower in comparison with other
studies, which an average uptake of more than 30% of ID per gram was observed for nonrenally clearable nanoparticles whose sizes are above the kidney filtration threshold.16, 3134

The remaining carcasses was measured to have less than 0.2% of ID per gram (or 3%

of ID) with most retention in the tail (or the site of injection). The tails were analyzed
separately from the rest of the carcasses since some agents might remain there for a
prolonged period of time due to possible injection errors.35 From these results, we
determined that 85 ± 2% of ID was excreted from the body via urine and feces within 24
hours of intravenous injection. This finding indicates that efficient renal clearance and low
body retention can be achieved with these small Ag2S-NP.

3.4.6 Histopathology
The in vivo safety of Ag2S-NP was assessed by histopathological examination of
organs (i.e., heart, lungs, liver, spleen, kidneys and urinary bladder) that were fixed and
stained with H&E at 24 hours after injection. As shown in Figure 3-13, the treated mice did
not show any evident histological abnormalities in those organs in comparison with the
control population. Interestingly, some nanoparticles are observed in the glomeruli of the
kidneys where particles undergo glomerular filtration for elimination via urinary excretion.
The in vivo safety of ultrasmall, renally-excretable Ag2S-NP is supported by these
preliminary results.
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Figure 3-13 Representative H&E stained micrographs of major organs.
H&E stained micrographs of organs including heart, lung, liver, spleen, kidney and bladder
from mice injected with PBS (control) or Ag2S-NP (treated). The dose of Ag2S-NP was 250
mg Ag per kg. The treated mice did not show any apparent organ damages or lesions as
compared to the control. Scale bar = 50 μm.

3.5 Discussion
Contrast-enhanced DEM has improved sensitivity for women with intermediate
and high risk compared with conventional mammography. This technique has recently
been approved for clinical use and can be made available with only minor upgrades to
existing digital mammography imaging equipment.4 Currently, X-ray breast imaging is
performed with iodinated small molecules. However, due to their small size, these agents
have very short half-lives as they are rapidly cleared from the blood through extravasation
and kidney filtration, which can be seen from the CT imaging results.30 The rapid contrast
washout requires immediate post-injection imaging and high doses. In addition, these
agents are nonspecific which leads to systemic vascular permeation and low tumor
accumulation. Furthermore, their swift renal filtration can result in contrast-induced
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nephropathy in patients with kidney disease.36, 37 Lastly, the contrast produced by these
agents in DEM is non-ideal.14
Given these limitations, considerable effort in the past decade has been devoted
to developing alternative X-ray imaging agents, most of which are novel nanoparticlebased formulations. Nanoparticle contrast agents are more advantageous for cancer
screening as they have prolonged circulation times and are known to generate better
target to background ratios.38, 39 They can be conjugated with targeting ligands to increase
the amount of contrast material at diseased sites.40 In particular, silver nanoparticles are
an emerging X-ray contrast agent that produces stronger DEM contrast than iodine and
provides CT contrast.13 Only a few contrast materials developed specifically for DEM have
been reported to date.13, 15, 16 However, most of them are not renally excretable due to
large size and are observed in vivo to remain in the RES organs for a long time, which can
prevent their eventual clinical translation and FDA approval.3, 41
In this study, we developed sub-5 nm Ag2S-NP as a DEM and CT contrast agent
that have improved biocompatibility and can be excreted renally. Since pure silver
nanoparticles are easily oxidized in biological media, we chose silver sulfide as the
material due to their very low solubility constant that effectively prevents the release of
silver ions, resulting in high stability and biocompatibility. Renal excretion is preferred
because this pathway allows nanoparticle contrast agents to be swiftly eliminated from the
body, whereas hepatic excretion is a very inefficient and slow elimination process. Urinary
clearance of intravascular agents relies mainly on glomerular filtration in the kidneys,
which is highly dependent on particle size. Several studies reported that nanoparticles
with a HD of 5.5 nm or less, which is below the filtration-size threshold of 6-8 nm, can be
rapidly cleared via the urine, thus effectively minimizing uptake by the RES organs and
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long-term body retention.1,

8, 42

From in vivo CT imaging, we observed significant CT

contrast in the bladder and a small increase in CT attenuation in liver and spleen of mice
injected with 3.1 nm Ag2S-NP. Biodistribution analysis revealed that 15% ID of 3.1 nm
Ag2S-NP remained in the entire body at 24 hours post-injection, and thus we determined
that 85% ID was excreted from the body. Other groups have reported a renal clearance
efficiency of 50% ID for 2 nm glutathione coated gold nanoparticles, 70% ID for 3 nm silica
nanoparticles and 75% ID for 4 nm cysteine coated quantum dots at 24 hours, 48 hours
and 4 hours post-injection, respectively.1, 8, 43 It should be recognized that these reported
values were determined using various quantification methods with different levels of
accuracy. Some groups obtained their data using fluorescent or radiolabeled
nanoparticles, which is often considered semi-quantitative. Our results were obtained
using ICP-OES, which provides the highest level of data accuracy by directly measuring
the concentrations of the element of interest. Notably, some of the reported clearance
values were determined solely from urine samples collected over a period of time and
without the analysis of the remaining carcasses. This approach could result in an
underestimation or inaccurate representation of the clearance profile. Therefore, the total
retention and excretion values reported from our biodistribution study are reliable and
indicate that the ultrasmall Ag2S-NP are indeed renally clearable with low body retention.
Ag2S-NP were previously reported for use in several biomedical applications
including targeted imaging, biosensing, drug delivery and photothermal therapy. They
were mostly used as optical imaging probes for having good stability and biocompatibility
and size-tunable NIR fluorescence properties. Many studies utilized their fluorescence
emission in the second NIR window (950-1350 nm) for imaging of deep tissues and organs
without significant effects from tissue absorption and autofluorescence.44 In addition, they
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were found to possess photothermal conversion capabilities, which allowed them to serve
as a theranostic agent.45 Moreover, they could be conjugated with targeting peptides or
drugs for in vivo targeted tumor imaging or disease treatment.18 Most importantly, most
studies found them to be biocompatible as a result of their low solubility product constant.
Our study, where we have reported a Ag2S-NP formulation with high renal clearance
efficiency, may have a broader impact due to the above-mentioned biomedical
applications.
Our study has limitations, for example we performed the in vivo experiments using
mice as the initial animal model to study toxicity and excretion of the lead candidate
nanoparticle formulation. Further toxicity assessments should be performed in larger
species such as dogs or swine in order to gather data for submission to the Investigational
New Drug program prior to human clinical studies. While our clearance results are
positive, longer biodistribution timepoints (i.e., 1 week, 1 month and 6 months) should be
assessed to probe any further toxicity or excretion. In addition, serum could be collected
from the blood samples and subjected to a clinical chemistry panel to determine the serum
biochemistry for any potential toxic effects on organ functions. Lastly, it is important to
note that certain degree of polydispersity is always present in the nanoparticle size, which
is contrary to small molecule probes that usually have well-defined size or molecular
weight. Therefore, any observed renal clearance should be considered as a combined
effect that is integrated from a population of slightly differently sized nanoparticles.
In the future, we could study the excretion characteristics of these nanoparticles in
a mouse model of chronic kidney dysfunction to confirm their safety and excretion in the
presence of a renal disease. Moreover, we could evaluate the excretion and DEM contrast
of these nanoparticles in a murine model of dense mammary tissues as reported by
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others.46 We could also synthesize Ag2S-NP with lower molecular weight zwitterionic
ligands to ensure the smallest possible HD for more efficient renal clearance and lower
retention. Furthermore, longer circulation times and enhanced tumor accumulation could
be achieved by encapsulating these nanoparticles in larger biodegradable polymeric
particles.47 Lastly, Ag2S-NP may be an ideal contrast agent for the emerging technique of
photon-counting digital mammography and future clinical breast CT scanners.48-50

3.6 Conclusion
In this study, we developed an array of biocompatible, sub-5 nm Ag2S-NP. In
vivo CT imaging indicated the successful excretion of 3.1 nm Ag2S-NP via urine with low
accumulation in the RES organs. We found that 85% of the injected dose was excreted
within 24 hours of intravenous injection, which is one of the highest clearance values of
similarly sized nanoparticle imaging agents reported to date. Therefore, these ultrasmall
silver sulfide nanoparticles with efficient renal excretion have potential as safe DEM and
CT contrast agents and are highly promising for future clinical translation. In the next
chapter, we examine factors that can affect subsequent nano-bio interactions and develop
methods to further improve the clearance efficiency of Ag2S-NP.
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Chapter 4 : Effect of nanoparticle synthetic conditions on ligand
coating integrity and subsequent nano-bio interactions
4.1 Abstract
Numerous nanoparticles composed of heavy metals are being investigated for
their use in various biomedical applications, such as contrast agents for medical imaging,
delivery vehicles for drugs or other therapeutic applications. The key for potential clinical
translation for these types of agents is efficient renal clearance. However, a recent review
of the topic revealed that only 20-75% of the injected dose of nanoparticles designed for
renal clearance was excreted within 24 hours for most of these formulations. Moreover,
clearance does not greatly improve at longer time points. We hypothesized that in the
case of silver sulfide nanoparticles (Ag2S-NP) the high temperature synthetic conditions
may compromise the integrity of surface ligands, hampering clearance of the agents. We
therefore sought to compare the clearance and cellular distribution between sub-5 nm
silver sulfide nanoparticles (Ag2S-NP) synthesized via high temperature and microfluidic,
room temperature approaches. In this study, we found that the thermolysis approach led
to significant ligand degradation. On the other hand, the surface coating shell was
unaffected by the microfluidic synthesis. We demonstrated that the clearance was
improved for Ag2S-NP with intact ligands, with less uptake in the liver. Moreover,
differential distribution in hepatic cells was observed, where Ag2S-NP with degraded
coatings tend to accumulate in Kupffer cells and those with intact coatings are more
frequently found in hepatocytes. Therefore, understanding the impact of synthetic
processes on ligand integrity and subsequent nano-bio interactions will provide the
knowledge necessary to design nanoparticle syntheses and select appropriate ligands
that will result in formulations with enhanced clearance.
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4.2 Introduction
There now is an extensive array of nanoparticles developed for a broad range of
biomedical uses, such as disease detection with imaging,1-3 cancer treatment with
phototherapy,4-6 and delivery vehicles for drugs or nucleic acids.7-9 Synthetic control over
a nanoparticle’s physical and chemical properties, such as composition, size, shape, and
surface chemistry, can determine its solubility, biodistribution, pharmacokinetics and
suitability for various applications.10 For example, nanoparticles are often modified with
long hydrophilic polymer ligands, such as polyethylene glycol (PEG), for imaging the
vasculature, atherosclerotic plaques, and tumors due to increased blood circulation
times.11-13 However, most nanoparticles are eventually cleared from the circulatory system
by phagocytic cells in the reticuloendothelial system (RES) organs, namely the liver and
spleen.14 Accumulation in the RES organs can lead to possible long-term toxicity,
especially for formulations that contain heavy metal elements, due to the body’s lack of
ability to metabolize these components. Concerns over the retention of such agents
remain a major challenge for their final FDA approval.
Much effort has been devoted to improving the clearance of nanoparticle agents.
Reports have mainly focused on the development of renally clearable nanoparticles that
can be rapidly eliminated via the urine, thus reducing uptake by the RES organs. Glomeruli
in the renal cortex are responsible for the urinary excretion of intravenous agents. The
glomerular filtration barrier is consisted of multiple cell layers, each with a distinct pore
size and charged surface.15 This highly selective sieve governs the renal clearance of
nanoparticles based on their size and surface charge among other factors. 16 In general,
nanoparticles smaller than 6 nm and capped with neutral surface ligands, such as
glutathione, have been found to undergo rapid and efficient renal excretion.17-19 Therefore,
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sufficient (if not complete) clearance from the body through the renal system should avoid
safety issues from long-term body retention, thus increasing the likelihood for eventual
clinical translation.
We have recently reported the successful clearance of sub-5 nm silver sulfide
nanoparticles (Ag2S-NP) via urine with low RES accumulation. These nanoparticles were
synthesized by thermally decomposing silver salts and glutathione (which served as both
capping ligand and sulfur donor) in a viscous medium.20 Most importantly, we found that
85% of the injected dose (ID) was excreted within 24 hours of intravenous injection,
whereas only 20-75% of ID was cleared within 24 hours for most nanoparticle
formulations.21 In addition, the clearance did not greatly improve at longer time points for
these prior formulations.22 Despite the relatively extensive clearance that we observed for
Ag2S-NP, better excretion is needed for clinical translation. We hypothesized that the
ligands used as surface coatings might be degraded or altered during the nanoparticle
formation process, especially in the case of thermolysis of molecular precursors as in the
previously used synthesis. For more efficient renal clearance, the coating ligands should
remain intact in order to carry out their functions of providing stability in biological media,
deterring protein adsorption and avoiding sequestration from phagocytic cells.23 We
therefore sought to understand the effects of synthetic conditions on the integrity of
surface coating ligands and subsequent clearance and nano-bio interactions of Ag2S-NP.
In this study, we developed a novel microfluidics approach to synthesize sub-5 nm,
low dispersity Ag2S-NP and preserve the glutathione ligands during the process. This
synthesis prevents the decomposition of organic coatings by introducing a primary sulfur
source (i.e., sodium sulfide) and allowing nanoparticle formation to proceed at room
temperature. As a result, the structure of the surface coating shell of as synthesized Ag2S-
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NP was not degraded, as determined by nuclear magnetic resonance (NMR)
spectroscopy and thermogravimetric analysis (TGA). In vivo CT imaging showed higher
contrast in the kidneys and bladder after injection, indicating the successful renal excretion
of these nanoparticles. The clearance of nanoparticles was improved mostly by reducing
the level of uptake in the liver. Moreover, we found that the distribution in hepatic cells is
greatly influenced by the integrity of surface ligands. Interestingly, more nanoparticles with
intact coatings were found in hepatocytes, indicating the ability to evade Kupffer cells and
access the hepatobiliary clearance pathway. Consequently, the findings from this study
should advance our knowledge on methods for improving the clearance efficiency and
cellular interactions of nanoparticle platforms.

4.3 Materials and methods
4.3.1 Materials
Silver nitrate (AgNO3, 99%), L-glutathione (GSH, 98%), calcium chloride dihydrate,
sodium hydroxide solution (NaOH, 1 N), collagenase from Clostridium histolyticum (type
IV) and deuterium oxide (D2O, 99.9%) were purchased from Sigma-Aldrich (St. Louis,
MO). Anhydrous sodium sulfide (Na2S) was purchased from Alfa Aesar (Tewksbury, MA).
HBSS buffer (1X) without calcium, magnesium and phenol red was purchased from
Invitrogen (Waltham, MA).

EGTA buffer (0.5 M, pH 8) was purchased from Fisher

Scientific (Pittsburgh, PA). OptiPrep™ density gradient medium (60% iodixanol in water)
was purchased from BioVision Inc. (Milpitas, CA). Insyte™ Autoguard™ shielded IV
catheter (24G x 0.75”) and ethylene glycol were purchased from Becton, Dickinson and
Company (Franklin Lakes, NJ). PE-conjugated monoclonal anti-F4/80 antibody was
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purchased from Miltenyi Biotec (Bergisch Gladbach, North Rhine-Westphalia, Germany).
Herringbone microfluidic chip mixers and male luer fluid connectors were purchased from
Microfluidic ChipShop (Jena, Germany).

4.3.2 Synthesis of Ag2S-NP via thermal decomposition of single-source precursors
We synthesized hydrophilic Ag2S-NP with size tunability according to our previous
report.20 Briefly, AgNO3 (100 mg) and GSH (140 mg) were added to ethylene glycol (40
ml), which was preheated to 120 °C. The mixture was purged with nitrogen gas and heated
at a rate of 20 °C per minute up to 165 °C. Different nanoparticle core sizes were obtained
by quenching the reaction in ice water at various time points. The products were isolated
by centrifuging (7000 rcf for 10 minutes) with absolute ethanol. The collected pellet was
resuspended in DI water and washed thrice (centrifuging at 4000 rpm for 30 minutes)
using 3000 Dalton MWCO filtration tubes (Sartorius Stedim Biotech, Germany). The buffer
was changed to PBS after the last wash, and the nanoparticles were filtered through a
0.02 µm membrane (GE Healthcare Life Sciences, UK) and stored at 4 °C for subsequent
experiments.

4.3.3 Synthesis of Ag2S-NP via a novel microfluidics approach
We developed a novel microfluidics method to synthesize water-soluble, low
dispersity Ag2S-NP with tunable core sizes using glutathione as the surface coating ligand.
First, 767 mg GSH (2.5 mmol) was added to a flask containing 75 ml DI water while stirring
and the pH of the mixture was adjusted to 7.5 using NaOH. 42.5 mg AgNO 3 (0.25 mmol)
was then added to the same mixture and the pH was again adjusted to 7.5 using NaOH.
The resulting solution, which was clear and colorless, was loaded in a 10 ml syringe. In a
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separate flask, 10 mg Na2S (0.13 mmol) was dissolved in 25 ml DI water while stirring and
the

solution

was

loaded

in

a

10

ml

syringe.

The

final

molar

ratios

of

GSH(ligand):AgNO3(silver precursor) and AgNO3(silver precursor):Na2S(sulfur source)
were 10:1 and 2:1, respectively. Next, the syringes were mounted onto syringe pumps,
and both solutions were injected into a herringbone microfluidic chip mixer. To synthesize
nanoparticles with different core sizes, the flow rate for the Na2S solution was fixed at 0.5
ml/min and the flow rate for the GSH/AgNO3 solution was varied between 0.5 and 2.5
ml/min. The resultant mixture was collected in a flask, covered in aluminum foil, and
subjected to constant stirring for 24 hours under ambient conditions. The nanoparticle
suspension, which was dark brown in color, was washed three times in DI water and
concentrated to a final volume of 1 mL using 3000 Dalton MWCO filtration tubes. The
tubes were spun for 20 minutes at 4000 rpm. Any aggregates in the suspension were
removed by a 0.02 µm membrane. The final product was stored at 4 °C.

4.3.4 Nanoparticle characterization
The core sizes and morphologies of Ag2S-NP were examined using a Tecnai T12
transmission electron microscope (TEM, FEI, Hillsboro, OR) operating at 100 kV. The
elemental content of Ag2S-NP was assessed using an FEI Quanta 600 scanning electron
microscope (FEI, Hillsboro, OR) equipped with EDAX EDS detectors (Ametek, Mahwah,
NJ). The elemental silver concentrations were measured by ICP-OES (Spectro Genesis,
Germany) following digestion in nitric acid and dilution with DI water. The hydrodynamic
diameter and surface zeta potential of Ag2S-NP (concentration of 0.1 mg Ag per ml) were
assessed by using a Nano-ZS-90 Zetasizer (Malvern Instruments, UK). 1H NMR spectra
of Ag2S-NP samples suspended in D2O were recorded on a Bruker 300 MHz spectrometer
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using the residual solvent peak as a reference. The thermal behavior of Ag2S-NP samples
was examined by thermogravimetric analysis (TGA) using a SDT Q600 TGA instrument
(TA Instruments, New Castle, DE) with a weight sensitivity of 0.1 µg. The instrument was
purged with nitrogen gas at a flow rate of 100 ml/min and was heated up to 500 °C at a
rate of 20 °C/min. An average of 10 mg of solid sample was used for the TGA experiment.
Data are presented as mean ± SD.

4.3.5 Animals
All animal experiments were performed using female nude mice (8 weeks old, n =
4 per group) purchased from Jackson Laboratory (Bar Harbor, Maine). Isoflurane was
used to induce anesthesia in mice. All experimental protocols were approved by the
Institutional Animal Care and Use Committee at University of Pennsylvania.

4.3.6 Biodistribution
In brief, mice were sacrificed at 24 hours after injection. Blood samples were
collected before perfusion with PBS. Major tissues including the bladder, feces, lungs,
liver, heart, spleen, and kidneys were collected and their weights were recorded. Next,
they were finely minced and subjected to overnight digestion with nitric acid (3 ml) at 75
°C. Then, each sample was added with 7 ml of DI water and filtered with a 0.22 µm
membrane prior to ICP-OES analyses. Data are presented as mean ± standard error of
mean (SEM).
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4.3.7 In vivo CT imaging
In vivo CT images were acquired with a MILabs µCT scanner (Utrecht, The
Netherlands) using the following parameters: peak voltage = 50 kV, current = 240 µA, step
angle = 0.75°, and exposure time = 75 ms. Mice were injected via the tail vein with Ag2SNP suspended in PBS at a dose of 250 mg Ag/kg. The mice were scanned before injection
and at 5, 30, 60, and 120 minutes post injection. The acquired images were subsequently
analyzed with Osirix. The change in CT attenuation from pre-injection scan of each tissue
type is presented as mean ± SEM in Hounsfield units.

4.3.8 Examination of liver tissue via TEM
Treated liver tissue samples were fixed in 2.5% glutaraldehyde and 2%
paraformaldehyde and then stained and embedded. Samples in 60 nm thick sections were
mounted onto copper grids and viewed using a Tecnai T12 electron microscope operated
at 100 kV.

4.3.9 Isolation of hepatocytes and Kupffer cells
Hepatocytes and Kupffer cells were isolated from livers of treated mice following a
literature method with some modifications.24, 25 First, solutions for liver perfusion and cell
isolation were prepared using DI water and stored at 4 °C unless otherwise specified.
HBSS-EGTA buffer (0.5 mM) was prepared by mixing 500 µl EGTA with 500 ml HBSS.
HBSS-CaCl2 buffer (1 mM) was prepared by mixing 500 µl of 1 M CaCl2 with 500 ml HBSS.
Concentrated collagenase solution was prepared by adding 1.6 g of collagenase to 50 ml
HBSS-CaCl2 buffer. This solution was filtered through a 0.45 µm membrane and stored at
-20 °C as 1 ml aliquots. 1 ml of concentrated collagenase solution was thawed just before
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use and added to 49 ml HBSS-CaCl2 buffer. All reagents were heated to 37 °C in a water
bath prior to the procedure. A silicone tubing was passed through a FH100M multichannel
peristaltic pump (Fisher Scientific, Hampton, NH) that was set at a volumetric flow rate of
4 ml/min. One end of the tubing was connected to a catheter needle and the other end
was immersed in warm HBSS-EGTA buffer.
Next, mice were anaesthetized with isoflurane and placed on their back on a
dissection board. Their limbs were secured to the board and the abdomen was sanitized
with ethanol wipes. Then, an incision was made on the ventral midline and the skin was
dissected away. The peritoneal cavity was exposed, and the intestines were pushed to
the side using a cotton tip. The catheter needle was inserted into the hepatic portal vein,
and the pump was immediately activated. The inferior vena cava was cut when the liver
became swollen and discolored. The liver was perfused with the buffer for 5 minutes, after
which the tubing was transferred to the collagenase solution. The liver was then digested
with collagenase for 5 minutes. Cell release and lobe breakdown were observed during
this time. After the digestion process was complete, the entire liver was dissected and
placed in a petri dish with cold HBSS-CaCl2 buffer. The hepatic cells were released by
gently mincing the liver lobes until no clumps were visible and were filtered through a 100
µm cell strainer with additional cold HBSS-CaCl2 buffer.
The filtered cells were collected in a 50 ml centrifuge tube and spun at 50 rcf for 3
minutes at 4 °C. The pellet, which contained only hepatocytes, was washed and purified
three times with HBSS-CaCl2 buffer using the same centrifugation condition. The
supernatant, which consisted of nonparenchymal cells (i.e., Kupffer cells, endothelial cells
and stellate cells), were spun at 500 rcf for 8 minutes at 4 °C. After the centrifugation spin
was complete, the pellet was collected and resuspended in 3 ml of 24% OptiPrep solution
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(i.e., 10 ml of Optiprep stock was diluted with 15 ml of DMEM culture medium). The cell
fraction was placed at the bottom of a 15 ml centrifuge tube, while 3 ml of 17.6% OptiPrep
solution (i.e., 10 ml of Optiprep stock diluted with 24 ml of DMEM) was loaded on top of
the cell suspension. Another layer was created by loading 3 ml of 11.2% of OptiPrep
solution (i.e., 10 ml of Optiprep stock was diluted with 43.5 ml of DMEM) on top of the
17.6% OptiPrep layer. Then, 3 ml of DMEM culture medium was loaded on top of all three
layers. Extra care should be taken when creating the density gradient layers to avoid
mixing at the interphases. The mixture was spun at 1400 rcf for 18 minutes without brakes,
after which the cell fraction between the 11.2% and 17.6% Optiprep layers was collected.
This cell suspension, enriched with Kupffer cells and liver sinusoidal endothelial cells, was
washed and purified three times with PBS by centrifuging at 500 rcf for 10 minutes. Purified
hepatocytes and Kupffer cells were fixed with 4% paraformaldehyde for 15 minutes at
room temperature and then washed with PBS. The cell fractions were suspended in PBS
and stored at 4 °C for further analyses.

4.3.10 Analysis of silver content in hepatic cells
Hepatocytes and Kupffer cells were manually counted with a hemocytometer and
spun down to form a pellet. Cell pellets were subjected to overnight digestion in 1 ml of
nitric acid at 75 °C. Each digested sample was diluted with 3 ml of DI water and filtered
through a 0.45 µm membrane to remove cell debris. Finally, the silver content in each
sample was analyzed via ICP-OES. Data are presented as mean ± SEM.
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4.3.11 Flow cytometry
The purity of the suspension containing Kupffer cells and liver sinusoidal
endothelial cells was analyzed using flow cytometry. 108 cells in 95 µl of PBS were
incubated with 5 µl of PE-conjugated recombinant human-anti-mouse F4/80 monoclonal
antibodies (i.e., a major macrophage marker) for 20 minutes at 4 °C in the dark. Cells were
then washed three times with PBS to remove excess antibody-dye conjugates. Flow
cytometry was performed using a FACSCanto System (BD Sciences, San Jose, CA). The
results were analyzed using the FlowJo version 9 software.

4.3.12 Statistics
All studies included at least three replicates or three independent experiments. All
statistical analyses were performed using GraphPad Prism 8 software. The figure caption
recorded the specific statistical tests that were done, when applicable.

4.4 Results
4.4.1 Novel microfluidics synthesis maintains the ligand structure
Ag2S-NP were synthesized either via a one-pot, high temperature (Synthesis A) or
a microfluidic, room temperature (Synthesis B) approach. As reported in our previous
study,20 Synthesis A involves the heating of silver nitrate and glutathione in ethylene glycol
and quenching the reaction at different time points. Silver nitrate served as the Ag+ source
and glutathione functioned as both the capping ligand and sulfur donor.26 Glutathione
consists of many functional groups, such as -SH, -COOH and -NH2, that strongly
coordinate with transition metal ions,27-29 forming high affinity metal-ligand clusters. Upon
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mixing of silver nitrate and glutathione, Ag+ would chelate with glutathione to form initial
Ag-thiolate precursor complexes.30 Then, a hydrothermal treatment was applied by
heating the reaction mixture to a high temperature (165 °C). During this process, the
carbon-sulfide (C-S) bonds were cleaved as Ag-thiolate complexes decompose due to
high temperature.31-33 As a result, Ag2S nuclei began to form and continued to grow until
the sulfur source was depleted or the reaction was quenched. The nanoparticle growth
was controlled by modulating the reaction time. For example, the reaction was quenched
between 10 and 20 minutes to obtain an array of Ag2S-NP with core sizes ranging between
2 to 7 nm (Figure 4-1A), as determined by TEM. For Ag2S-NP with a core diameter of 3.1
nm, the hydrodynamic diameter (HD) and surface zeta potential were found to be 4.8 ±
1.1 nm (polydispersity index of 0.44) and -12 ± 1 mV, respectively.
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Figure 4-1 Electron micrographs and core size distributions of Ag2S-NP formulations.
(a) Synthesis A involves heating of molecular precursors and quenching the reaction at (i)
17, (ii) 15, (iii) 13, and (iv) 11 minutes to obtain Ag2S-NP with the core sizes shown. (b)
Synthesis B involves mixing of precursors through a microfluidic chip at room temperature
and setting the combined flow rate at (i) 1, (ii) 1.5, (iii) 2 and (iv) 3 ml/min to obtain Ag2SNP with the core sizes shown. The scale is indicated in the bottom left corner on the
rightmost image for each row of images. Scale bar = 20 nm.

A novel microfluidics approach (Synthesis B) was developed to synthesize Ag2SNP under ambient conditions, while introducing a separate sulfur source. In this synthesis,
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we mixed glutathione with silver nitrate in water and raised the pH of the solution to near
neutrality, thus allowing glutathione molecules to coordinate with silver ions with high
selectivity.34 This mixture, which contains initial Ag-glutathione complexes, was injected
into a herringbone microfluidic chip mixer along with a solution of sodium sulfide. In this
case, silver nitrate and glutathione served as the sources of silver ions and capping
ligands, respectively. Sodium sulfide functioned as the primary donor of sulfide ions. The
microfluidic chip has a staggered herringbone pattern that creates repeated rotational and
extensional flows to efficiently and homogenously mix the input streams.35 As described
in other reports, the nucleation of Ag2S nuclei was triggered by the addition of inorganic
sulfide to the preformed Ag-glutathione complexes.36-38 Then, the free thiol groups of
glutathione would bind to the surface of the nanoparticles as the Ag2S cores were formed.
The nanocrystal growth was controlled by varying the combined flow speeds (i.e., the flow
rate of sodium sulfide solution was fixed at 0.5 ml/min). For example, the combined speed
was varied between 1 and 3 ml/min to obtain an array of Ag2S-NP with core sizes ranging
between 2 to 7 nm (Figure 4-1B), as determined by TEM. For Ag2S-NP with a core
diameter of 3.2 nm, HD and surface zeta potential were found to be 4.8 ± 0.2 nm
(polydispersity index of 0.34) and -6.3 ± 1.7 mV, respectively. Thus, the microfluidics
method allows for a highly controllable and reproducible synthesis of Ag2S-NP.
Next, we analyzed the ligand structure on the surface of 3 nm Ag2S-NP obtained
from Synthesis A and Synthesis B using one-dimensional 1H NMR spectroscopy. The
NMR spectrum of Ag2S-NP obtained from Synthesis A is shown in Figure 4-2 (top). We
observed no obvious proton resonance peaks or chemical shifts that correspond to
glutathione molecules. Hence, it seems that there must be a variety of ligand species
(likely glutathione degradation products) on the nanoparticle surface. On the other hand,
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the NMR spectrum of Ag2S-NP obtained from Synthesis B is shown in Figure 4-2 (middle),
which is very similar to that of free glutathione molecules. Some protons, such as those
attached to C3 and C11, showed 1H chemical shift changes or resonance broadening.
Moreover, the protons attached to C8 (i.e., closest to the metal core) showed significant
resonance shift and 1H resonance peak splitting. This indicates that the methylene protons
experience multiple chemical environments due to diastereotopicity induced by the chiral
metal core.39, 40 The result confirms the binding of glutathione molecules to the Ag2S-NP
surface. It also demonstrates that the structure of the coating ligand was not impacted by
the synthetic conditions of the microfluidics approach.

Figure 4-2 1H NMR spectra of glutathione and as synthesized Ag2S-NP.
Synthesis A: one-pot, high temperature approach; Synthesis B: microfluidics, room
temperature approach; GSH: glutathione.

We also performed TGA to further confirm the presence and amount of surfacebound organic ligands. It important to note that silver sulfide has a high melting point of
825 °C, which is beyond the temperature range used for the analysis, and thus should not
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contribute to the weight change (%). The TGA spectra of Ag2S-NP from Synthesis A are
shown in Figure 4-3 (blue). We found a small change in the weight change (< 0.04%/°C),
indicating a small amount of organic material is present in the nanoparticle sample. On
the other hand, the TGA spectra of Ag2S-NP from Synthesis B are shown in Figure 4-3
(red). We found the change in the weight change of Ag2S-NP followed a similar trend as
glutathione (black) over the same temperature range. Several thermal degradation steps
in the TGA curve of Ag2S-NP can be found due to the decomposition of the organic
molecules.41 Ag2S-NP curves showed an onset of mass loss at 50 °C, indicating the
removal of water molecules in the sample. The largest weight change occurred around
200 °C, which corresponds to the melting point and decomposition of glutathione. At the
max temperature of 500 °C, the total mass loss in Ag2S-NP from Synthesis B amounts to
33 wt %, which is much higher than that of Ag2S-NP from Synthesis A (10.5 wt %). From
these results, we determined that the one-pot, high temperature synthesis (which uses
ligand as sulfur donor) can compromise the integrity of nanoparticle surface coating shell.
We also demonstrated that the microfluidics, room temperature approach (which uses a
separate sulfur donor) can preserve the structural integrity of glutathione ligands. In
subsequent experiments, we compared the clearance profiles and cellular interactions
between Ag2S-NP (core diameter of 3 nm, HD < 6 nm) synthesized via thermolysis and
microfluidics methods.
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Figure 4-3 TGA spectra of glutathione and as synthesized Ag2S-NP.
The change in (a) weight (%) and (b) weight change (%/°C) of various samples as the
temperature increases to 500 °C. Synthesis A: one-pot, high temperature approach;
Synthesis B: microfluidics, room temperature approach; GSH: glutathione.

4.4.2 CT imaging indicates fast renal clearance of Ag2S-NP with intact ligands
We have previously shown Ag2S-NP to provide CT contrast.1,

20

We herein

monitored the clearance potential of Ag2S-NP using a small animal µCT scanner. In our
previous study, we found that Ag2S-NP with degraded ligands (from Synthesis A) were
cleared through the kidneys into the bladder after injection to a significant degree. 20 A
similar effect was observed for Ag2S-NP with intact ligands (from Synthesis B). In Figure
4-4A, both the kidneys and bladder showed higher CT contrast after injection. The three
main internal regions of the kidneys, including the cortex, medulla, and pelvis, were well
distinguished at 5 minutes post injection. The cortex contains glomeruli that filter the
nanoparticles into the collecting ducts located in the pyramids of the medulla. The pyramid
tips point toward the renal pelvis, which drains the nanoparticles into the urinary bladder
via the ureters. Filtration and excretion of these nanoparticles were evident in the
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segmented data (using a 3D region growing method), where the cortex and ureter were
shown in detail (Figure 4-4B). The kidney contrast gradually decreased, whereas the
contrast in the RES organs remained at a higher level (< 65 HU) than pre-injection (Figure
4-4C). Interestingly, we observed a faster renal clearance rate with these nanoparticles,
given by the strong contrast in the kidneys and less contrast in the blood (Figure 4-4D).
This indicates a difference in the circulation half-lives between these two nanoparticle
formulations. Therefore, tracking nanoparticle clearance with CT imaging revealed the
integrity of surface coating ligands can greatly influence the excretion rate and
pharmacokinetics of inorganic nanoparticles.
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Figure 4-4 In vivo CT imaging data for Ag2S-NP synthesized using microfluidics.
(a) Representative CT images of a mouse after injection using 3D volume rendering. The
images are shown with a window level of 700 HU and window width of 1000 HU. Kidneys
are labeled K. Green circles indicate the bladder. (b) 3D region growing segmentation of
a kidney at 5 minutes post injection to visualize glomerular filtration and collection of Ag2SNP into the bladder via the ureter. (c) The change in CT attenuation in various organs of
mice compared to pre-injection. (d) The change in CT attenuation in the blood of mice
compared to pre-injection. Synthesis A: one-pot, high temperature approach; Synthesis
B: microfluidics, room temperature approach.
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4.4.3 Intact surface coating improves clearance by reducing liver uptake
We determined the impact of surface coating integrity on the biodistribution
profiles. At 24 hours after injection, we used ICP-OES to analyze the silver content in
major organs. As shown in Figure 4-5, more silver was found in the liver than in other
organs for both Ag2S-NP formulations. Notably, we found the retention of silver in the liver
to be statistically significantly different between the two formulations. The liver uptake of
Ag2S-NP with degraded coatings (9.53 ± 0.5% ID) was nearly 2-fold higher than Ag2S-NP
with intact coatings (4.96 ± 1.3% ID). We calculated a clearance efficiency of 87.9 ± 0.4%
ID and 92.5 ± 1.7% ID for 3 nm Ag2S-NP with degraded and intact surface ligands,
respectively. Silver uptake in other organs was not statistically significantly different
between the two Ag2S-NP formulations. Hence, the structural integrity of surface ligands
plays a role in the clearance of nanoparticles, where intact coating shell improves
clearance by reducing uptake in the liver.

Figure 4-5 Biodistribution of 3 nm Ag2S-NP with intact vs. degraded surface coating.
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Silver content in major organs at 24 hours after injection as determined by ICP-OES. Error
bars are SEM. Synthesis A: one-pot, high temperature approach; Synthesis B:
microfluidics, room temperature approach. * indicates P < 0.05 (two-way ANOVA with
Bonferroni’s multiple comparisons test).

4.4.4 Differential nanoparticle distribution in hepatic cells due to coating integrity
Based on the biodistribution results, we detailed the liver uptake between the two
Ag2S-NP formulations by qualitatively examining the liver tissues under TEM and
quantitatively analyzing for their silver content via ICP-OES. Portions of the livers were
excised at 24 hours after injections and fixed in 4% paraformaldehyde. In a qualitative
analysis, inspecting these liver sections under TEM revealed that Ag2S-NP from Synthesis
A (with degraded coating) were mostly located in Kupffer cells, while Ag2S-NP from
Synthesis B (with intact coating) were frequently found in the hepatocytes with some
distributed in the Kupffer cells (Figure 4-6). Hence, the upholding of surface coating shell
shifts the distribution of nanoparticles toward hepatocytes.
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Figure 4-6 Electron micrographs of liver sections.
The scale is indicated in the upper left corner on the rightmost image for each row of
images. Synthesis A: one-pot, high temperature approach; Synthesis B: microfluidics,
room temperature approach.

In a quantitative measure, we isolated primary hepatic cells and analyzed for their
silver content. Hepatocytes are denser than other liver cell types and thus can be easily
pelleted and separated from the rest of the cell suspension using low centrifugation
speed.42 Purified nonparenchymal cells, such as Kupffer cells and liver sinusoidal
endothelial cells (LSEC), were examined with flow cytometry (Figure 4-7A). Cells were
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incubated with PE-conjugated anti-F4/80 antibodies. After gating the flow cytometry data,
we found the ratio of F4/80+ (Kupffer cells) and F4/80- (LSEC) cells in the purified cell
fraction to be 1:2 (Figure 4-7B), which is consistent with that observed in vivo.43 We then
investigated the silver content in both the hepatocyte and Kupffer cell populations. In
Figure 4-7C, silver uptake in the hepatocytes was statistically significantly higher for Ag2SNP with intact coatings (1.55 ± 0.15 pg Ag per cell) compared to Ag2S-NP with degraded
coatings (0.76 ± 0.05 pg Ag per cell). However, the opposite trend was observed for the
Kupffer cell population. This finding is in alignment with the results observed from
qualitative measurements of liver sections with TEM. We determined that the structural
integrity of nanoparticle surface ligands has a profound effect on the cellular interactions
in vivo, thus resulting in differential hepatic cell distribution profiles. Ag2S-NP with an intact
coating shell were found more frequently in hepatocytes, whereas the other nanoparticle
formulation was preferentially located in Kupffer cells.
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Figure 4-7 Flow cytometry for Kupffer cells and cellular distribution of Ag2S-NP.
(a) Representative flow plot with gating to show (b) percentages of F4/80 positive and
negative cells in the total nonparenchymal cell population after purification. (c) Distribution
of different Ag2S-NP formulations in hepatocytes and Kupffer cells. SSC: side scatter;
FSC: forward scatter; Synthesis A: one-pot, high temperature approach; Synthesis B:
microfluidics, room temperature approach. * indicates P < 0.05 (two-way ANOVA with
Bonferroni’s multiple comparisons test).
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4.5 Discussion
In our previous report, we found that sub-5 nm Ag2S-NP can be swiftly excreted
via urine with 85% of ID being cleared from the body at 24 hours after injection.20 A review
of recent literature revealed that the finding represents one of the highest clearance values
of metal nanoparticles with a similar core size. To date, FitzGerald et al. reported the best
renal clearance efficiency (> 98% of ID at 48 hours after injection) of a nanoparticle agent
(HD of 3.1 nm) based on small tantalum oxide cores coated with zwitterionic ligands.44 For
other nanoparticle formulations, only 20-75% of ID was cleared within 24 hours.21
Surprisingly, the clearance was not higher and did not greatly improve at longer time
points.22 We hypothesized that the synthetic conditions may affect the integrity of ligands
and therefore impact subsequent clearance and biointeractions. We developed a novel
microfluidics approach to preserve the surface coating shell, thus improving the clearance
of nanoparticle agents.
In this study, we first compared the formation mechanisms between two Ag2S-NP
formulations and investigated the effect on coating ligand integrity via NMR and TGA. As
we described above, Synthesis A, which represents a thermolysis approach, resulted in
Ag2S-NP with highly degraded surface ligands. This is mainly due to the dissociation of
carbon-sulfide bonds of glutathione molecules at high temperature in order to supply S2for nanocrystal nucleation and growth. In this case, glutathione is used as both the ligand
and sulfur source to form and coat Ag2S cores. It may be possible to increase the
concentration of glutathione, where excess thiol groups may bind to the surface of Ag 2SNP. However, this can change the reaction process since a high glutathione concentration,
or rather a low Ag+ concentration, may lead to fewer nanocrystal seeds and thus larger
nanoparticle size, which is not ideal for achieving efficient renal clearance.32 On the other
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hand, Synthesis B, which represents a novel microfluidics method, resulted in Ag2S-NP
with intact coating ligands on the surface. We designed the synthesis to include a primary
sulfur donor (i.e., sodium sulfide), thus allowing the reaction to occur at room temperature.
In this case, the reagents are not subjected to heating, which may help to maintain the
structural integrity of glutathione ligands. Thus, synthetic processes can greatly alter the
ligand structures and the resulting nanoparticle surface chemistry and physicochemical
properties.
Next, we closely examined the impact on subsequent clearance and nano-bio
interactions due to the difference in ligand integrity. Renal excretion of nanoparticle agents
relies on kidney filtration through the glomerular capillaries, whereas hepatic excretion
involves transport through the hepatobiliary pathway. Both elimination routes are highly
dependent on nanoparticle size and ligand chemistry among other factors.45 For both
Ag2S-NP formulations, the CT contrast in the bladder was the highest of all organs after
injection. Interestingly, Ag2S-NP with intact ligands appeared to have a shorter circulation
time as less contrast was found in the blood immediately post injection. Perhaps, the
nanoparticle surface is sufficiently coated with zwitterionic functional groups (from intact
glutathione) that prevent aggregation and formation of protein corona, thus maintaining a
small overall size for optimal renal filterability. This nanoparticle type also reduced the
retention in the liver by nearly 5% of ID. By comparing the liver uptake profiles at the
cellular level, we determined that Ag2S-NP with intact ligands are frequently found in the
hepatocytes, whereas Ag2S-NP with degraded ligands are preferentially located in the
Kupffer cells. It should be noted that the silver content measured in Kupffer cell samples
also includes the uptake by LSEC. These two cell types were collected from the same cell
layer following density gradient centrifugation but were not further separated by flow

158

cytometry sorting. Although LSEC are more abundant than Kupffer cells in the liver,
nanoparticles are removed from the circulation more predominantly by the latter.46 Several
studies have suggested that the uptake of nanoparticles by hepatocytes is greatly
influenced by the ligand chemistry, such as the degree of PEGylation, peptide conjugation,
and surface charge,47-50 in addition to the nanoparticle size (liver sinusoidal endothelial
fenestrations up to 200 nm).51 Hepatocytes can further eliminate the nanoparticles through
enzymatic breakdown, collection in the bile and eventual excretion into the intestines and
feces.45 This process is rather slow and inefficient compared to swift renal clearance. It is
possible that more clearance of nanoparticles, particularly those located in hepatocytes,
would be seen at longer biodistribution time points. However, for nanoparticles to enter
hepatocytes, nanoparticles must first evade Kupffer cells (resident macrophages in the
liver) and penetrate the fenestrated endothelium into the space of Disse. Uptake by
Kupffer cells is also affected by the surface chemistry. Nanoparticles with negatively
charged ligands or low PEG density have been found to accumulate in Kupffer cells.52-54
Furthermore, nanoparticles may remain in these cells for months to years and may be
taken up again by other phagocytes in the liver, resulting in prolonged exposure and
potential safety concerns.55 Therefore, the integrity of coating ligands plays a large role in
the clearance of nanoparticles as well as the interactions with certain hepatic cell types.
In the future, we could investigate the exact nanoparticle distribution between
LSEC and Kupffer cells since transcytosis from LSEC to underlying hepatocytes may
contribute to more hepatobiliary clearance. We could study the route of uptake for
hepatocytes and Kupffer cells to obtain information about other factors that may affect the
interactions at the cellular level. We could also examine the excreted nanoparticles in the
urine via mass spectrometry or liquid chromatography to understand the degree of surface
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ligand displacement or substitution in vivo. It was reported that the enzymatic degradation
of glutathione within the kidneys and efflux of glutathione in the liver sinusoid can modify
the nanoparticle surface with endogenous molecules and thus change the overall
clearance and biodistribution profiles.56 Moreover, we could analyze for silver content in
the feces to track the hepatobiliary excretion of nanoparticles over several months. Lastly,
we could evaluate the uptake in other phagocytic cell types, such as hepatic B cells or
splenic macrophages, to probe how ligand integrity influences the distribution of
nanoparticles among different cellular phenotypes.

4.6 Conclusion
In this study, we developed a microfluidics method to synthesize size-tunable
Ag2S-NP under ambient conditions, while introducing a primary sulfur source. In
comparison to the thermolysis method, we found that this approach could maintain the
nanoparticle’s “synthetic identity” – mainly keeping the coating ligand structure unaltered
during the synthesis. We demonstrated that ligand integrity can influence the
physicochemical properties of nanoparticles in terms of their pharmacokinetics,
biodistribution and clearance profiles. The intact surface coating shell improved the
clearance of Ag2S-NP by allowing rapid kidney filtration and reducing liver uptake. We
showed that this nanoparticle formulation was found more frequently in the hepatocytes
compared to Kupffer cells, which could be beneficial for clearance via the hepatobiliary
pathway. Importantly, synthetic conditions can modify the physicochemical properties of
nanoparticles, thereby affecting subsequent nano-bio interactions and in vivo
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performance. In the next chapter, we explore other biomedical utilities of Ag2S-NP and
enhance their performance through polymer encapsulation.
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Chapter 5 : Design of polymeric silver sulfide nanoparticles as
enhanced theranostic agents
5.1 Abstract
Breast cancer screening by conventional mammography is not effective in women
with dense breasts. While breast conserving surgery has become the treatment standard,
patients often require additional surgical interventions due to positive tumor margins.
Adjuvant therapies have shown to reduce local recurrence risks from incomplete
resection, but they offer limited improvements to overall survival. We therefore sought to
develop a multifunctional theranostic agent that can improve cancer detection in dense
breasts, augment surgery with real-time image guidance and treat residual tumors via
localized thermal ablation. Herein, we synthesized sub-5 nm silver sulfide nanoparticles
(Ag2S-NP) and encapsulated them in biodegradable polymeric nanoparticles (AgPCPP).
We found that AgPCPP have potent contrast properties for alternative screening tools
such as dual energy mammography (DEM), computed tomography (CT), photoacoustic
(PA) and near-infrared fluorescence (NIRF) imaging. We also found that AgPCPP produce
strong contrast for an intraoperative NIRF image-guided surgery system (FLARE). In
addition, the viability of breast cancer cells was significantly reduced by AgPCPP via
photothermal heating. Therefore, AgPCPP can serve as a “one-for-all” contrast agent that
should degrade into small components for swift renal excretion once the diagnostic,
surgical and therapeutic tasks are fulfilled, thus providing good prospects for translation
to clinical use.
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5.2 Introduction
Mammography screening is an effective method to detect breast cancer early and
has been shown to decrease mortality from this disease.1 However, mammography is
notably poor for detecting breast cancer in women with high breast density (i.e., about
50% of the screening population), with sensitivity of 30-60%.2 For most early detected
breast tumors, breast conserving surgery (BCS) followed by post-operative radiotherapy
(RT) remains the standard-of-care regardless of patient characteristics (i.e., breast
density).3 BCS offers equivalent overall survival and local control rates to full mastectomy,4
but only when there is a complete removal of tumors.5 Complete resection of breast tumors
can be challenging because of field cancerization of ductal carcinoma in situ. Those with
incomplete resection or positive margins, which are about 20-55% of BCS patients, require
additional surgical interventions to minimize the risk of cancer recurrence.6 Although
adjuvant RT has proven to reduce local recurrence rates, its benefits cannot outweigh the
impact of inadequate surgical clearance, underscoring the importance of complete tumor
resection at the time of initial surgery.7, 8 Therefore, these limitations highlight the need for
alternative screening methods with improved sensitivity for women with dense breasts as
well as real-time, intraoperative assessment of tumor location and margin status.
Dual energy mammography (DEM) has become clinically available and is
seemingly the best modality for dense breast imaging.9, 10 In this technique, two different
X-ray energies are used to distinguish tumors from surrounding beast tissues, thus
improving the diagnostic sensitivity for dense breasts.11, 12 Computed tomography (CT)
and optical-based imaging modalities, such as photoacoustic (PA) and near-infrared
fluorescence (NIRF) imaging, are also highly attractive methods for breast imaging due to
fast image acquisition and increased detection sensitivity.13 These techniques can
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highlight tumors via the use of exogenous contrast agents, and thus offer an abundance
of information needed for earlier diagnosis and treatment planning. Furthermore,
considerable efforts are being made to improve the accuracy and clinical outcomes of
BCS, such as the development of the fluorescence-assisted resection and exploration
(FLARE) system.14 The FLARE system can simultaneously acquire color video (i.e.,
anatomical structures) and NIRF emission (i.e., functional information) of the surgical field
and display merged images in real-time, thus permitting intraoperative image-guidance
throughout the procedure.15-17 Since tissue is relatively transparent and absorbs less light
in the NIR range (i.e., 700-900 nm), any desired targets that contain NIR emitting agents
can be easily detected at greater depth with a high degree of sensitivity.18
Currently, iodinated small molecules and indocyanine green (ICG) fluorophores
are used in clinical studies with X-ray breast imaging and the FLARE imaging system,
respectively.19-21 Compared to small molecules, nanoparticle-based contrast agents are
more ideal for cancer screening and surgery, since they can be long-circulating and are
known to preferentially accumulate within tumors via angiogenesis.22 Silver sulfide
nanoparticles (Ag2S-NP), also known as quantum dots, have been extensively studied for
PA and NIRF imaging and photothermal therapy (PTT) applications due to their
exceptional biocompatibility and optical properties, such as high photostability, tunable
NIRF emissions and photoconversion activities.23-26 More recently, we have found that
Ag2S-NP produce stronger contrast than iodine in DEM and also provide CT contrast.27, 28
Herein, we synthesized sub-5 nm Ag2S-NP with a narrow NIRF emission peak at
820 nm. Ag2S-NP were then encapsulated in larger polymeric nanospheres made of a
mixture of biodegradable poly-di(carboxylatophenoxy)phosphazene (PCPP) and novel
poly(ethylene glycol)-PCPP copolymer (PEG-PCPP) to form AgPCPP nanoparticles.
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These polymers can degrade into harmless hydrophilic byproducts and have been studied
as drug delivery vehicles and adjuvants for immunization.29-36 The size of AgPCPP can be
modulated by the amount of PEG-PCPP used in the formulation. We found that AgPCPP
generate enhanced PA and NIRF signals and photothermal effects due to strong
absorption of NIR light. We demonstrated that AgPCPP are biocompatible and
biodegradable in vitro and are effective contrast agents for X-ray and optical-based
imaging. In addition, we showed that AgPCPP significantly reduce the viability of breast
cancer cells via photothermal heating. Therefore, this “one-for-all” contrast agent can be
used preoperatively for breast cancer detection, intraoperatively for image-guided surgery,
and postoperatively for photothermal cancer treatment, before gradually breaking down
and releasing Ag2S-NP for renal excretion,27 thus addressing concerns over long-term
retention (Figure 5-1).

Figure 5-1 Schematic depiction of structural and functional properties of AgPCPP.
(a) Small Ag2S-NP are incorporated into biodegradable PCPP polymers, resulting in
larger, silver-based polymeric nanoparticles (AgPCPP). (b) AgPCPP have both diagnostic
and therapeutic functionalities for preoperative cancer detection, intraoperative tumor
delineation and postoperative photothermal treatment. (c) Ag2S-NP are gradually released
for renal excretion upon AgPCPP degradation.
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5.3 Materials and methods
5.3.1 Materials
Silver nitrate (AgNO3, 99%), 2-mercaptopropionic acid (2MPA, 95%), poly(bis(4carboxyphenoxy)phosphazene)

disodium

salt

(PCPP,

1

MDa),

spermine

tetrahydrochloride, calcium chloride dihydrate (CaCl2) and sodium hydroxide solution
(NaOH, 1 N) were purchased from Sigma-Aldrich (St. Louis, MO). Anhydrous sodium
sulfide (Na2S) was purchased from Alfa Aesar (Tewksbury, MA). Herringbone microfluidic
chip mixers and male luer fluid connectors were purchased from Microfluidic ChipShop
(Jena,

Germany).

The

procedures

for

the

synthesis

of

PEGylated

anionic

polyphosphazenes (PEG-PCPP, 800 kDa) were detailed in a published report.30

5.3.2 NIR fluorescent Ag2S-NP synthesis
The method to synthesize ultrasmall, aqueous Ag2S-NP with fluorescence
emission in the NIR range was adapted from a previous report.37 Briefly, 218 µL of 2MPA
(2.5 mmol) was added to a 250 mL conical flask containing 75 mL of DI water. The pH of
the mixture was adjusted to 7.5 using NaOH. Then, 42.5 mg of AgNO 3 (0.25 mmol) was
added to the flask, and the pH of the resulting mixture was again adjusted to 7.5 using
NaOH. A solution containing 5 mg of Na2S (0.0625 mmol) in 25 mL of DI water was
prepared separately and was slowly added to the above mixture in a dropwise fashion.
The reaction mixture was covered in aluminum foil and was subjected to constant stirring
for 24 hours under ambient conditions. The nanoparticle suspension, which appeared to
be dark brown, was washed three times in DI water and concentrated to a final volume of
1 mL using 3 kDa MWCO ultrafiltration tubes (Sartorius Stedim Biotech, Germany). The
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tubes were spun at 4000 rpm for 40 minutes. Finally, the nanoparticles were filtered
through a 0.02 µm membrane to remove any aggregates and stored at 4°C.

5.3.3 PCPP formulations and AgPCPP nanoparticle synthesis
The procedure to synthesize PCPP nanoparticles formulated with PEG-PCPP
polymers was adapted from previous studies.38-40 A 2 mL solution containing PCPP (1.8
mg) and PEG-PCPP (0.2 mg) was prepared in PBS and loaded in a 10 mL syringe. A 2
mL solution containing spermine (1.96 mg) was also prepared in PBS and adjusted to pH
7.4 before loading in a separate 10 mL syringe. Both solutions were injected into a
herringbone microfluidic chip mixer at a flow rate of 6 mL/min. The resultant mixture was
quickly transferred to 100 mL of 8.8% (w/v) CaCl2 solution and stirred for 20 minutes. The
solution was purified by centrifugation at 800 rcf for 10 minutes in DI water three times.
Finally, the nanoparticle suspension was concentrated and stored at 4°C in DI water. To
form AgPCPP nanoparticles, the desired amount of Ag2S-NP was added to the PCPP and
PEG-PCPP solution while keeping the total volume fixed at 2 mL. The amounts of PEGPCPP added in the formulation were varied from 0 to 0.5 mg to synthesize AgPCPP of
varying sizes.

5.3.4 Nanoparticle characterization
The core sizes and morphologies of Ag2S-NP and AgPCPP nanoparticles were
examined using a Tecnai T12 transmission electron microscope (FEI, Hillsboro, OR)
operating at 100 kV. The absorption spectra of the nanoparticles were characterized using
a Genesys UV/visible spectrophotometer (Thermo Scientific, USA) after diluting with DI
water. The NIR fluorescence emission spectra were recorded using a SpectraMax M5
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microplate reader (Molecular Devices, San Jose, CA) with an excitation wavelength of 700
nm. The surface morphology and elemental content of AgPCPP nanoparticles were
assessed using an FEI Quanta 600 scanning electron microscope (FEI, Hillsboro, OR)
operated at 15 kV and equipped with EDAX EDS detectors (Ametek, Mahwah, NJ). The
elemental silver concentrations were measured by ICP-OES (Spectro Genesis, Germany)
following digestion in 1 mL of nitric acid and dilution with DI water. The hydrodynamic
diameter and surface zeta potential of Ag2S-NP (concentration of 0.1 mg Ag per ml) were
assessed by using a Nano-ZS-90 Zetasizer (Malvern Instruments, UK).

5.3.5 AgPCPP degradation and Ag2S-NP release
AgPCPP nanoparticles (0.1 mg Ag) formulated with 10% (0.2 mg) of PEG-PCPP
polymers were added to 1 mL of PBS with 10% FBS in micro-centrifuge tubes. The tubes
were incubated in a water bath at 37 °C over a period of 7 days. At the desired time points,
samples were centrifuged at 800 rcf for 10 minutes, and the supernatants and pellets were
collected and analyzed via ICP-OES to measure the release of small Ag2S-NP. Three
samples were prepared for each time point. The amount of released Ag2S-NP was
calculated by dividing the mass of silver measured in the supernatant by the total silver
mass measured in both the supernatant and the pellet. The pellet from a sample incubated
for 7 days was examined under TEM and SEM to confirm the degradation of AgPCPP
nanoparticles.

5.3.6 Photothermal effect and photostability
Samples (1 mL) of ultrasmall Ag2S-NP and AgPCPP nanoparticles (10% PEGPCPP) at a concentration of 0.5 mg Ag per mL were exposed to 808 nm laser irradiation
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(OEM Laser Systems, Midvale, UT) at a power density of 2 W per cm2 for 10 minutes in a
quartz cuvette. Then, the samples were allowed to cool for 10 minutes without irradiation.
The temperature was monitored throughout the entire experiment using an optical
thermometer probe (Qualitrol Corporation, Fairport, NY). The photostability of AgPCPP
nanoparticles was assessed by repeating four times using the same method. Additionally,
AgPCPP nanoparticles were subjected to laser irradiation at different silver concentrations
(0.125, 0.25 and 0.5 mg per mL) and laser power densities (0.5, 1.0, 1.5, 2 and 2.5 W per
cm2) for 10 minutes during which changes in temperature were recorded. DI water was
used as control.

5.3.7 In vitro biocompatibility and photothermal therapy
The MTS assay (Promega, Madison, WI) was used to assess the cytotoxicity of
Ag2S-NP and AgPCPP nanoparticles (10% PEG-PCPP) towards the MDA-MB-231 human
breast cancer cell line. The cells were cultured according to the supplier
recommendations. In accordance with a previously published method,41 the cells were
seeded in a 96 well plate at a cell density of 10,000 cells per well and were allowed to
stabilize for 24 hours. Then, the cells were treated with the nanoparticles at different
concentrations for 24 hours: 0 (control), 0.05, 0.1, 0.25 and 0.5 mg Ag per mL (n = 3 wells
per plate used). Once the treatment was completed, the cells were washed with PBS twice
and incubated with the assay, after which the absorbance at 490 nm was recorded. The
relative cell viability (%) for each concentration and cell type was presented as mean ±
SD. Experiments were done in triplicates.
To evaluate cytotoxicity from photothermal ablation, we followed a protocol from a
previous study.42 MDA-MB-231 cells were seeded in a 96 well plate at a cell density of
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10,000 cells per well with two empty wells between them. The following day, media was
replaced with fresh 37 °C media containing free Ag2S-NP or AgPCPP at various
concentrations (n = 3 wells per condition). The wells were immediately irradiated with an
808 nm laser at a power density of 1.5 W per cm2 for a total of 5 minutes. The plates were
then incubated for 24 hours, after which they were washed twice with PBS and analyzed
using the MTS assay. The absorbance at 490 nm was recorded to determine the cell
viability relative to control (%) at different conditions, which was presented as mean ± SD.
Experiments were performed in triplicates.

5.3.8 CT and optical-based phantom imaging
CT imaging was performed using a MILabs µCT scanner (Utrecht, The
Netherlands) with a tube voltage of 50 kV, tube current of 240 µA, step angle of 0.75°, and
exposure time of 75 ms. Ag2S-NP and AgPCPP nanoparticles (n = 3 per concentration)
as well as other control materials of varying concentrations (0 to 4 mg Ag per mL) were
suspended in 1% agar gel and were loaded in 0.2 mL PCR tubes. The samples were
secured in a plastic rack with parafilm. The identical samples were loaded in an
acrylonitrile butadiene styrene tube holder and placed in the borehole of an
anthropomorphic thorax phantom body (QRM GmbH, Mohrendorf, Germany) for imaging
with a SOMATOM Force clinical CT scanner (Siemens Heathineers, Erlangen, Germany).
The clinical CT images were acquired using an adult abdomen routine imaging protocol
at 80, 100, 120, and 140 kVp. The following parameters were used during image
acquisition: FOV = 37 × 37 cm, tube current = 360 mA, anode angle = 8°, exposure time
= 0.5 s, slice thickness = 0.5 mm and matrix size = 512 × 512. For both µCT and clinical
CT imaging, Osirix 64-bit software was used to measure the CT attenuation for each
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sample at each concentration and to calculate the attenuation rates. Data was presented
as mean ± SD.
Photoacoustic images were obtained using a Vevo LAZR system (VisualSonics
Inc., Toronto, Canada) with an excitation wavelength of 700 nm. Ag2S-NP and AgPCPP
nanoparticles (n = 3 per sample) were loaded into polyethylene tubing (40 µL) at a range
of concentrations (0 to 1 mg Ag per mL). The tubes were placed in a plastic holder, which
was immersed in DI water. The following parameters were used during image acquisition:
PA gain 24 dB, ultrasound gain +27 dB, distance 1 cm from the LZ550 transducer (44 µm
axial resolution; 32-55 MHz broadband frequency). The images were analyzed using
ImageJ and the ROI values were recorded and normalized with respect to DI water. Data
was presented as mean ± SD.
NIR fluorescence images were acquired using an IVIS Spectrum instrument
(PerkinElmer, Waltham, MA) with excitation and emission wavelengths at 710 nm and 820
nm, respectively. Ag2S-NP and AgPCPP nanoparticles (n = 3 per sample) suspended in
DI water at different concentrations (ranging from 0 to 5 mg Ag per mL) were placed in a
black bottom 96 well plate (100 µL per well). The images were analyzed using Living
Image 4.5.4 Software and the ROI values were recorded and presented as mean ± SD.

5.3.9 Intraoperative NIR fluorescence phantom imaging
Intraoperative NIR fluorescence images were acquired using a dual-NIR channel
Vet-FLARE imaging system (Curadel, Marlborough, MA). The system was equipped with
a Model VP1 laser source and a Model VC2 handheld imaging head. Ag2S-NP and
AgPCPP nanoparticles (n = 3 per sample) of varying concentrations (0 to 8 mg Ag per
mL) were suspended in DI water and were loaded in 0.2 mL PCR tubes. The tubes were
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then placed in the center of the FLARE LT-1 light-tight enclosure. The following
parameters were used during live mode image acquisition: power of 100%, exposure of
47 ms, camera gain of 1 v/v, mean brightness of -26, mean contrast of 20, mean gamma
of 1. The color images, 2 independent NIR fluorescence images (700 nm and 800 nm)
and merged images were acquired simultaneously. The 700 nm and 800 nm NIR
fluorescence images were pseudo-colored blue and green, respectively, in merged
images. ROI values were recorded using custom software and presented as mean ± SD.

5.3.10 Statistics
At least three replicates or three independent experiments were carried in all
studies. GraphPad Prism 8 software was used to perform all statistical analyses. The
specific statistical tests that were done are written in the figure caption when applicable.

5.4 Results
5.4.1 Synthesis and characterization of Ag2S-NP and AgPCPP
Small core nanoparticles, Ag2S-NP, were synthesized in water by slowly adding a
solution of sodium sulfide to a reaction mixture containing 2MPA and silver salt. The
addition of sodium sulfide triggers the nucleation and growth of silver cations into silver
sulfide nanocrystals. The reaction was carried out at room temperature under ambient
conditions. 2MPA was used as the capping ligand to stabilize the silver sulfide cores and
provide hydrophilicity and colloidal stability in biological media. Nanoparticles coated with
this thiol ligand have been shown to be biocompatible and to be cleared via the kidneys.23,
37, 43

The core diameter of Ag2S-NP was determined to be 1.7 ± 0.6 nm (Figure 5-2A),
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while the hydrodynamic diameter was slightly larger (3.6 ± 1.3 nm). The zeta potential of
Ag2S-NP was found to be -70 ± 20 mV, which is expected due to the negatively charged
carboxylate groups of 2MPA.

Figure 5-2 Characterization of Ag2S-NP and AgPCPP.
(a) Electron micrograph of small core metal nanoparticles. (b) Effect of PEG-PCPP on
AgPCPP nanoparticle size. Error bars are one standard deviation. (c) AgPCPP formulated
with varying amounts of PEG-PCPP (presented as mg PEG-PCPP per mg of total PCPP
polymers, i.e., PCPP and PEG-PCPP). Images were taken by TEM (top) and SEM
(bottom). Scale bar = 200 nm.
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The aforementioned Ag2S-NP formulation was encapsulated in biodegradable
PCPP and PEG-PCPP polymers to form AgPCPP nanoparticles. The elemental peaks for
calcium, phosphorous, silver and sulfur were shown in EDX analysis of a single AgPCPP
nanoparticle, confirming the successful incorporation of Ag2S-NP into the polymer matrix.
We assessed the loading capacity of AgPCPP that were synthesized with addition of 0.1
mg PEG-PCPP per mg total PCPP polymers (which resulted in non-loaded PCPP
nanoparticles with a mean core diameter of 80 ± 14 nm). It was determined that up to 2.5
mg of silver payload could be loaded per mg of total PCPP content without resulting in
largely non-spherical or deformed AgPCPP nanoparticles. At the maximum loading
capacity, the average core diameter of AgPCPP increased by 57.5% when compared to
that of unloaded PCPP nanoparticles. Thus, the encapsulation of higher silver payloads
increased AgPCPP nanoparticle size.
We used a microfluidic device and incorporated a novel PEGylated PCPP
copolymer for the very first time to create low dispersity polymeric nanoparticles of tunable
size. The size of AgPCPP (0.5 mg Ag/mg total PCPP) could be controlled by varying the
amount of PEG-PCPP used in the synthesis. Addition of 0 to 0.5 mg PEG-PCPP per mg
of total PCPP polymers in the formulation resulted in AgPCPP in the size range of 40 to
350 nm (Figure 5-2B).39,
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The average core diameter of AgPCPP decreased with

increasing amounts of PEG-PCPP in a nonlinear fashion (Figure 5-2C). The result in this
study is consistent with previous reports, whereby the inclusion of a block co-polymer
limits and controls the growth of PCPP nanoparticles.30, 32 For subsequent experiments,
we used AgPCPP nanoparticles that were synthesized with 10% PEG-PCPP in the
formulation, or 0.1 mg PEG-PCPP per mg of total PCPP polymers.
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5.4.2 AgPCPP nanoparticle biodegradation
We evaluated the release of Ag2S-NP from their polymeric components by
incubating AgPCPP in 10% serum in PBS at 37°C for 1, 2, 4 and 7 days and sampling the
solution at different time points. We found that approximately 88% of Ag2S-NP were
released from AgPCPP in 7 days (Figure 5-3A), indicating the biodegradability of AgPCPP
and effective release of the payloads. TEM (Figure 5-3B) and SEM (Figure 5-3C) images
of the pellet collected at the end of the incubation period showed the breakdown and
morphological deformation of AgPCPP as well as the release of small core metal
nanoparticles.

Figure 5-3 In vitro biodegradability of AgPCPP.
(a) Payload release from AgPCPP nanoparticles. Error bars are one standard deviation.
(b) TEM and (c) SEM images of partially degraded AgPCPP nanoparticles after 7 days of
incubation. Scale bar = 100 nm.

5.4.3 Optical properties of Ag2S-NP and AgPCPP nanoparticles
The optical properties of Ag2S-NP and AgPCPP nanoparticles were determined to
assess their potential as agents for optical imaging and PTT. UV-visible measurements
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(Figure 5-4A) revealed a broad absorption band that is typical of semiconducting quantum
dots based on silver sulfide.44 The broadband absorbances in the NIR region suggest that
these nanoparticles could achieve photothermal conversion under NIR laser irradiation.45
Interestingly, we observed an aggregation induced red shift in the absorbance of AgPCPP.
At the same silver concentration, the absorbance of AgPCPP in the NIR range is at least
five-fold higher than that of free Ag2S-NP. Non-loaded PCPP nanoparticles at the same
polymer concentration as AgPCPP have minimal absorbance in the 400-900 nm range.
Furthermore, under excitation at 700 nm, we found that both Ag2S-NP and AgPCPP
nanoparticles have a fluorescence emission peak at 820 nm with a narrow full width at
half-maximum of 30 nm (Figure 5-4B). The emission peak of Ag2S-NP did not change after
being incorporated into polymeric nanoparticles. Notably, AgPCPP nanoparticles have
much stronger NIR fluorescence intensity than free Ag2S-NP at the same silver
concentration. Therefore, encapsulation of small nanoparticles (Ag2S-NP) into larger
polymeric nanoparticles (AgPCPP) can effectively enhance the optical properties of the
small metal cores.

Figure 5-4 Optical properties of Ag2S-NP and AgPCPP.
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(a) When Ag2S-NP are aggregated into AgPCPP nanoparticles, there is a red shift and an
increase in their absorbance. (b) Under excitation at 700 nm, stronger fluorescence
emission intensity is produced when Ag2S-NP are encapsulated in polymeric
nanoparticles.

5.4.4 Photothermal effect and photostability of AgPCPP
To evaluate the photothermal conversion activities, we measured the temperature
elevation by Ag2S-NP and AgPCPP when irradiated under 808 nm laser. As shown in
Figure 5-5A, AgPCPP increased the temperature of the solution by 40 °C within 10
minutes of irradiation at a power density of 2 W per cm2 and a silver concentration of 0.5
mg/ml. However, Ag2S-NP raised the solution temperature by only 10 °C under the same
conditions. The photothermal conversion efficiency of AgPCPP was calculated to be
25.2%,46 which is high compared to other reported structures.26, 47 We then evaluated the
photostability of AgPCPP under four irradiation/cooling cycles (Figure 5-5B). We found
that AgPCPP nanoparticle solution reproducibly reached 99.9% of the temperature (60
°C) achieved the first time, indicating excellent stability of these nanostructures.
Additionally, we found that temperature elevation by AgPCPP is dependent on the
concentration of silver payloads (Figure 5-5C) and laser power density (Figure 5-5D). The
change in temperature increased with increasing laser power output and concentration of
silver in the solution. These results suggest that Ag2S-NP can absorb NIR light and convert
it into thermal energy. Incorporation of these nanoparticles into larger polymeric
nanoparticles can further strengthen their photothermal properties. Thus, AgPCPP have
potential as a photothermal agent that produces enhanced therapeutic effects.
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Figure 5-5 Photothermal activity of Ag2S-NP and AgPCPP.
(a) Heating and cooling curves of AgPCPP nanoparticles, free Ag2S-NP and DI water
under 10 minutes of irradiation (808 nm, 2.0 W/cm2). (b) Photostability of AgPCPP under
four cycles of irradiation/cooling for a total duration of 20 minutes (808 nm, 2.0 W/cm 2).
Temperature elevations by AgPCPP are dependent on (c) the concentration of silver in
the solution and (d) laser power density (at a concentration of 0.25 mg Ag per ml).

186

5.4.5 In vitro biocompatibility and photothermal therapy
To assess the biocompatibility of Ag2S-NP and AgPCPP, they were incubated with
human breast cancer cells (MDA-MB-231) for 24 hours. Since we propose to detect and
treat breast cancer with AgPCPP, we selected this cell line as a clinically relevant model
of highly aggressive, late-stage breast cancer.48 The effects on cell viability were
measured using the MTS assay. As shown in Figure 5-6 (solid color bars), incubation with
Ag2S-NP and AgPCPP did not affect cell viability at concentrations up to 0.5 mg Ag/ml.
Both nanoparticle types were found to be biocompatible at each concentration with no
statistically significant differences compared to control (media only). The lowest mean cell
viability values observed from free Ag2S-NP and AgPCPP were 99 ± 2% and 96 ± 3% at
the highest treatment concentration. The results attest to the non-toxic properties of PCPP
polymers38,

49

and the inert and insoluble nature of silver sulfide.27,

28, 50, 51

Therefore,

nanoparticles that are made of this metal core and formed from this polymer do not have
significant safety issues, within the conditions tested.
In parallel experiments, we evaluated the photothermal effects of Ag2S-NP and
AgPCPP on the viability of breast cancer cells. Cells were incubated with increasing
concentrations of Ag2S-NP or AgPCPP, after which the cells were subjected to 5 minutes
of laser irradiation at a power of 1.5 W. Cellular viability was quantified by MTS assay. As
shown in Figure 5-6 (hatched color bars), treatment with media or free Ag2S-NP in the
presence of laser irradiation did not adversely affect cell viability. A slight reduction in
viability (94 ± 7%) was observed from free Ag2S-NP at the highest silver concentration.
This is not statistically significant when compared to non-irradiated control. However, laser
irradiation treatment with AgPCPP resulted in a significant decrease in cell viability. A
sharp drop in viability occurred at a concentration threshold of 0.25 mg Ag/ml. This finding
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is consistent with the fact that AgPCPP can elevate temperature more effectively than free
Ag2S-NP, thus resulting in greater photothermal killing. The results suggest that AgPCPP
produce potent photothermal therapeutic effects and have potential for eliminating laser
irradiated tumor tissues.

Figure 5-6 Biocompatibility and photothermal killing of Ag2S-NP and AgPCPP.
Viability of cells incubated with varying concentrations of (a) Ag2S-NP and (b) AgPCPP in
darkness and under 808 nm laser irradiation. Error bars are one standard deviation. *
indicates P < 0.05 compared to media only control group (one-way ANOVA with Dunnett’s
multiple comparisons test).
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5.4.6 Contrast generation in CT imaging
We next determined the CT contrast properties of Ag2S-NP and AgPCPP using
both a µCT scanner and a clinical CT system. A MILabs µCT scanner operated at a tube
voltage of 50 kVp was used to scan phantom samples of both formulations (Figure 5-7A)
and control materials (i.e., silver salt and iodine). The samples of increasing concentration
were suspended in agar gel. All materials produced CT contrast that was linearly
correlated between attenuation and concentration as expected, with R2 values > 0.99 in
each case. We found that silver nitrate, Ag2S-NP and AgPCPP had statistically
significantly higher attenuation rates than iopamidol (Figure 5-7B). The attenuation rates
among all silver-based contrast materials were not found to be statistically significantly
different.

Figure 5-7 Contrast generation of Ag2S-NP and AgPCPP in µCT imaging.
(a) Phantom image of Ag2S-NP and AgPCPP from a MILabs µCT scanner. (b) Attenuation
rates of both nanoparticle formulations and control materials. Error bars are one standard
deviation. * indicates P < 0.05 (one-way ANOVA with Tukey’s multiple comparisons test).
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The same phantom samples were scanned in a SOMATOM Force clinical CT
scanner at four different tube voltages. The samples were scanned in a clinically relevant
anthropomorphic phantom body that closely represents a patient’s thorax. Axial plane
images of the phantom body containing both nanoparticle formulations at tube voltage of
80 kVp are shown in Figure 5-8A. We clearly observed an increase in CT contrast with
increasing concentrations of the payload. A strong linear correlation between the
attenuation and the concentration was found for all agents. As expected, the attenuation
rates of all silver-based contrast materials are lower and statistically significantly different
than that of iopamidol at each tube voltage (Figure 5-8B). The attenuation rates of silver
salt, Ag2S-NP and AgPCPP were not found to be significantly different. For all agents, the
highest CT attenuation rate occurred at 80 kVp and the rates decreased as the tube
voltage increased to 140 kVp. On the contrary, silver has a higher attenuation rate than
iodine in µCT imaging, which can be attributed to the lower peak tube voltage used in µCT,
thus bringing the mean photon energy closer to silver’s k-edge.

Figure 5-8 Contrast generation of Ag2S-NP and AgPCPP in clinical CT imaging.
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(a) Phantom images of Ag2S-NP and AgPCPP samples taken by a clinical CT scanner.
(b) Attenuation rates of both nanoparticle formulations and control materials at different
tube voltage settings. Error bars are one standard deviation. *indicates P < 0.05 (one-way
ANOVA with Tukey’s multiple comparisons test).

5.4.7 Contrast generation in optical imaging
To assess the potential of AgPCPP as an enhanced optical agent, we first
evaluated the PA contrast properties of AgPCPP by loading samples of increasing
concentrations in a PVCP phantom. The PA images were acquired using a laser frequency
of 700 nm and a PA gain of 24 dB (Figure 5-9A). PA signals were generated based on
thermoelastic expansion from silver sulfide metal cores. AgPCPP generated a significantly
higher PA signal than free Ag2S-NP (Figure 5-9B) due to aggregation induced red shift in
their UV-visible absorption spectrum. This finding is also consistent with the results from
photothermal conversion activity experiments, where higher temperature elevations were
achieved by AgPCPP. AgPCPP produced contrast that is linearly correlated with
concentration (R2 = 0.99). However, Ag2S-NP samples did not produce a significant PA
signal, likely due to their low absorption of NIR light. It is difficult to determine any trend in
PA signal since Ag2S-NP produced minimal signal over the same range of silver
concentrations. Therefore, AgPCPP have potential to serve as a PA contrast agent with
enhanced PA imaging performance.
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Figure 5-9 PA contrast properties of Ag2S-NP and AgPCPP.
(a) PA intensity of AgPCPP compared to Ag2S-NP. (b) Relationship between PA contrast
and Ag concentration in AgPCPP and Ag2S-NP. Error bars are one standard deviation.
Some error bars are smaller than the data point marker and are thus not visible.

We next examined the NIRF contrast properties of AgPCPP using an IVIS
Spectrum imaging system with a 710/820 nm filter pair (Figure 5-10A). For both Ag2S-NP
and AgPCPP formulations, the fluorescence intensity observed becomes greater with
increasing silver concentrations. The fluorescence intensity begins to plateau at the
concentration of 2 mg Ag/ml (Figure 5-10B). Moreover, AgPCPP produced higher NIR
fluorescence signal than Ag2S-NP over the same range of silver concentrations. At the
highest concentration, the signal output from polymer encapsulated Ag2S-NP is at least 5fold higher than that of free Ag2S-NP. Interestingly, the aggregation of Ag2S-NP into the
polymer matrix did not induce drastic quenching of Ag2S-NP. Therefore, AgPCPP may
have use as a NIR fluorescent imaging probe for imaging of deeper tissues with improved
signal-to-noise ratio.
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Figure 5-10 NIR-I fluorescence contrast properties of Ag2S-NP and AgPCPP.
(a) NIRF phantom image of both nanoparticle formulations. Scale bar in units of radiant
efficiency (x107 (p/s/cm2/sr)/μW/cm2). (b) Relationship between NIRF intensity and Ag
concentration. Error bars are one standard deviation. Some error bars are smaller than
the data point marker and are thus not visible.

Since we determined that AgPCPP have superior NIRF contrast properties, we
then assessed their suitability as a fluorescence image-guided surgery agent using the
Vet-FLARE system. Samples of increasing concentrations were loaded in PCR tubes and
placed in the center of the light-tight enclosure under the handheld imaging head. Figure
5-11A shows the resulting color, NIR 700, NIR 800 and merged (with pseudo colors)
images. The color video images show the samples in real time under white light. As
expected, no contrast is observed in the NIR 700 images since both Ag2S-NP and
AgPCPP have an emission peak above 800 nm. In the NIR 800 images, AgPCPP showed
significantly higher (by 3-fold) fluorescence signal intensity than free Ag2S-NP over the
same concentration range (Figure 5-11B). The intensity starts to plateau at the
concentration of 2 mg Ag/ml, which is similar to the finding from IVIS Spectrum imaging
experiments. Grayscale NIRF images were overlaid onto the color video images with
visible pseudo colors (i.e., blue for NIR 700 and green for NIR 800). In the merged images,
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AgPCPP samples appear to be visibly green due to their bright 800 nm NIRF signal.
Notably, another fluorescent agent that emits at wavelengths below 800 nm may be used
concurrently to visualize surrounding structures, such as nerves, during surgical
procedures.52 This can ensure the tumor is resected completely without causing damages
to nearby normal tissues. In addition, a phantom body that closely simulates the NIR light
absorption and scattering properties of breast tissues and tumors could be used to further
assess AgPCPP’s NIRF contrast production. Overall, AgPCPP have potential use as a
NIR fluorescent contrast agent for real-time, intraoperative image-guided surgery.

Figure 5-11 Phantom imaging of Ag2S-NP and AgPCPP with FLARE system.
(a) Color, NIR 700, NIR 800 and merged images of both nanoparticle formulations. (b)
Quantification of fluorescence signal intensity from both NIR imaging channels and both
nanoparticle types as each silver concentration. Error bars are one standard deviation.
Some error bars are smaller than the data point marker and are thus not visible. Blue point
markers overlap with and mask the green point markers.

194

5.5 Discussion
In this study, we have incorporated small quantum dots composed of silver sulfide
metal cores into large polymeric nanoparticles made of both PCPP and novel PEGylated
PCPP polymers. We chose Ag2S-NP as the contrast generating material since they are
known to produce tunable NIRF emissions and convert NIR light into heat.23, 44, 51 We have
recently found that Ag2S-NP produce strong contrast in DEM and CT.27, 28 The ultralow
solubility of Ag2S-NP (i.e., Ksp = 6.3 x 10-50) prevents the release of toxic silver cations,
resulting in high stability and biocompatibility in biological media.53 Next, we chose PCPP
as a matrix for this platform because it can carry hydrophilic payloads and maintain its
structure for some time before degrading into small hydrophilic parts for renal excretion.
PCPP is biocompatible and has been used in many biomedical applications, such as drug
carriers and immunoadjuvants.31-36 Thus, by combining Ag2S-NP and PCPP polymers, we
have developed a “one-for-all” approach for designing biocompatible and biodegradable
contrast agents with multiple functionalities to improve the diagnosis and treatment of
breast cancer.
Our previous reports have utilized PEG-PLL block copolymer to adjust the PCPP
nanoparticle size.38-40 In comparison with previous work, the platform described herein is
the first to use PEGylated PCPP copolymer to tune the size of PCPP nanoparticles.
Nanoparticle size modulation by PEG-PCPP is likely due to the stabilizing steric
hinderance effect from the hydration sphere created by PEG chains.30 AgPCPP are
formed via hydrogen bonding and electrostatic interactions among the functional groups
of the cross-linker (amines of spermine), polymers (carboxylic acids of PCPP and PEGPCPP) and Ag2S-NP payload (carboxylic acid of 2MPA). Anionic PEG-PCPP is used in
the current instance; however, it is possible to use cationic PEG-PCPP in the synthesis,
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which could potentially eliminate the need for spermine or other cationic cross-linkers due
to more favorable ionic interactions. Lastly, the degradation rate of AgPCPP can be finely
tuned by adjusting the molecular weight of PCPP and the ratio of PEG chains on PCPP.30
For example, PCPP with higher molecular weights or longer PEG chains could be used to
slow the degradation process. Spermine cross-linker can also be replaced with alternative
polypeptides with varying degree of amine groups or cations to control bioerosion.
Other groups have developed imaging agents based on aggregates of fluorescent
quantum dots. For example, Fan et al. encapsulated hydrophobic cadmium-based
quantum dots in a polymer matrix material. The polymeric nanosphere has a mean
diameter of 27 nm and contains about 300 quantum dots.54 Chen et al. used siloxane
surfactant to encapsulate quantum dots of the same type, forming micelles with core sizes
ranging between 50 to 130 nm.55 Each micelle contains over 100 quantum dots. Both
studies found that the composite nanostructure produces stronger fluorescence signals
than individual quantum dots. The enhancement in optical properties is likely due to
surface modification that prevents surface oxidation and exciton dissociation, and thus
promotes radiative decay pathways.56 Furthermore, some of the photons absorbed by
quantum dots can be converted into thermal energy (or sound energy via thermoelastic
expansion) through nonradiative decay, a process that is partly dependent on nanoparticle
structure.57 Previous reports have indicated that an increase in nanoparticle size would
result in a red shift in the absorption onset as well as an improvement in photothermal
conversion efficiency.24, 37 In this study, we have demonstrated good synthetic control over
the size of the aggregate, which is important in designing nanoparticle agents for specific
applications. We have observed significant improvement to the optical and
photoconversion characteristics of small Ag2S-NP after being incorporated into large
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polymeric nanoparticles. AgPCPP, or aggregates of Ag2S-NP, exhibit increased
absorption of NIR light with high photostability, resulting in more radiative and nonradiative
decay events. Therefore, AgPCPP show enhanced PTT performance as well as stronger
PA and NIRF contrast compared to free Ag2S-NP. Overall, this is an innovative approach
to improving an agent’s diagnostic and therapeutic effects.
In our design of AgPCPP, we have loaded hydrophilic core nanoparticles of the
same type in PCPP polymers. PCPP nanoparticles can also be loaded with other payloads
in place of or in combination with Ag2S-NP. Such payloads may include hydrophilic drugs,
nanoparticles of high Z element for multi-energy CT imaging, agents for other imaging
modalities (i.e., iron oxide nanoparticles for MRI), silver telluride nanoparticles for
enhanced DEM imaging, or gold nanoparticles for radiotherapy.58 Other platforms such as
liposomes, micelles, and nanoemulsions are effective carriers of contrast payloads.59 In
particular, liposomes are capable of carrying both hydrophobic and hydrophilic payloads,
further expanding the array of payload materials for synthesis of AgPCPP. Additionally,
we can synthesize Ag2S-NP with fluorescence emission in the second NIR window for
imaging of deep tissues without significant effects from tissue absorption and background
autofluorescence.
For future work, a suite of in vivo experiments will be conducted in breast cancer
models to test the potential of AgPCPP as an agent for multimodality tumor detection,
intraoperative tumor margin delineation and photothermal tumor ablation. AgPCPP
formulations will be developed as a long circulating agent for increased tumor
accumulation. The resected tumor tissues will be assessed for margin status by
pathologists, and the animals will be monitored for survival and residual tumor growth
following image-guided surgery and photothermal therapy. Safety of AgPCPP will be
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thoroughly examined via in vivo pharmacokinetics, toxicological studies (e.g.,
histopathology, clinical blood chemistry, etc.), longer biodistribution timepoints, and
degradation/excretion assessments over a range of timepoints. Lastly, synthetic
parameters (e.g., surface ligands) of Ag2S-NP will be closely studied to formulate AgPCPP
with high payload yield in order to decrease the polymer used in synthesis and thus reduce
the viscosity of the solution suitable for eventual human subject injection.

5.6 Conclusion
In summary, we have developed a unique, multifunctional “one-for-all” contrast
agent based on polymer encapsulated small, NIR fluorescent Ag2S-NP. For the first time,
we have demonstrated the use of PEGylated PCPP copolymer in modulating the size of
PCPP nanoparticles and for encapsulating contrast payloads. We have demonstrated
good synthetic control of AgPCPP, efficient loading of hydrophilic payloads and desired
degradation rate in vitro. We have shown that the AgPCPP formulation is a robust contrast
agent for X-ray and optical-based imaging modalities. AgPCPP are also advantageous
over individual Ag2S-NP because AgPCPP produce enhanced PA and NIRF contrast as
well as greater photothermal heating due to increased NIR absorbance. The viability of
breast cancer cells was effectively reduced by AgPCPP under NIR laser irradiation.
Therefore, our promising results suggest that AgPCPP represent a biocompatible and
biodegradable theranostic platform with potential translational impact. In the next chapter,
we summarize the major discussion points of this dissertation work and provide potential
avenues for future projects.
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Chapter 6 : Discussion and future directions
6.1 Overall discussion
Contrast agents specifically designed and optimized for dual energy X-ray breast
imaging methods have only begun to be studied. The research work conducted in this
thesis has led to several key findings that will be highlighted in the chapter. While these
points have been discussed in depth in previous chapters, the most significant results will
be emphasized including: (i) a multimodal nanoprobe based on Ag2S-NP to detect breast
tumors in vivo using a range of imaging modalities, (ii) reducing the nanoparticle size and
examining ligand integrity for efficient renal clearance, and (iii) the design of a
biodegradable polymeric nanoparticle with both diagnostic and therapeutic functions. The
limitations as well as potential strategies to address them will also be discussed in each
of the conclusions.
In Chapter 2, I designed a multimodal “all-in-one” nanoparticle (AION) contrast
agent, which was based on the encapsulation of hydrophobic Ag2S-NP, IO-NP, and DiR
fluorophores in PEGylated micelles, for noninvasive breast cancer detection with DEM,
CT, MRI and NIRF imaging modalities. Multimodal contrast agents, which combine the
unique advantages of each imaging technique, can offset the limitations of a single
imaging modality, provide flexibility in cancer screening, and offer more detailed
information for accurate diagnosis. These agents offer improvements in patient care,
reduce costs, and ensure safety by limiting the number of contrast agent administrations.
The highly insoluble nature of Ag2S-NP prevented the leaching of toxic silver cations,
which improved the overall biocompatibility. AION (HD > 100 nm) accumulated in the
breast tumors and allowed the tumors to be detected in vivo with a range of imaging
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modalities. Both the nanoparticle size and PEGylation of the nanoparticle surface
facilitated accumulation in the tumors to some degree. These results are promising but
higher retention in the RES organs, which is not an atypical finding, could raise concerns.
There are several strategies to further increase the accumulation of AION in tumors,
thereby lowering the uptake in normal tissues. The overall nanoparticle size could be
reduced (i.e., 30-50 nm) to maintain a long blood circulation time, while achieving deep
tumor penetration.1 However, precise size control is limited by the use of the ultrasonic
emulsification procedure to form AION. In addition, surface PEGylation could be modified
to slow their clearance by the RES organs. I could use higher molecular weight PEG (e.g.,
5k) or increase PEG density to provide more substantial stealth characteristics for
deterring serum protein opsonization and evading the RES organs.2 Lastly, targeting
moieties could be conjugated to the nanoparticle surface to improve specificity and
selectivity and thus increase retention at the tumor site.3
Nanoparticles larger than 5 nm have been shown to retain in the body, potentially
for days or even years,4 whereas nanoparticles smaller than 5 nm can be swiftly excreted
via the kidneys and the urine.5 The long-term retention of contrast agents would be a
concern that would likely prevent their eventual clinical application. As I found in Chapter
2, the large size of AION prevented them from being renally cleared, which resulted in
some accumulation in the liver and spleen. In addition, hydrophobic Ag2S-NP must
undergo metabolic biotransformation to increase their hydrophilicity for elimination through
the renal system. Overall, this formulation is not ideal for direct kidney filtration. Therefore,
in Chapter 3, I developed sub-5 nm, hydrophilic Ag2S-NP via a one-pot, high temperature
approach. Ag2S-NP were formed by thermally decomposing silver nitrate and glutathione
in ethylene glycol. Glutathione served as both the capping ligand and sulfide ion donor.
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The viscous reaction medium slows the nucleation and growth of Ag2S-NP and further
tunes the size based on reaction time. As expected, the release of silver ions from these
hydrophilic Ag2S-NP was minimal, and the viability of two normal cell types was not
affected over a range of Ag2S-NP concentrations. Successful urinary excretion of 3 nm
Ag2S-NP was evidenced by the high contrast enhancement in the kidneys and bladder in
post-injection CT images. In addition, Ag2S-NP remained in circulation much longer than
iodinated small molecules, indicating the advantage of Ag2S-NP as a potential cancer
screening agent. Most importantly, I determined that 85% of ID was cleared within 24
hours of intravenous injection, which is one of the best clearance values of heavy metal
nanoparticles reported to date. Their rapid clearance via the urine yielded low retention in
the body, supporting the translational potential of these agents. Despite the promising
results, 15% of ID was still retained in the body (mainly in the liver and spleen), requiring
further toxicity and excretion analyses at longer biodistribution time points. I included
histopathology as the initial toxicity assessment, but more detailed toxicology (i.e., blood
chemistry panel) should be done to confirm the safety of these agents, which is necessary
for eventual clinical translation. Lastly, in Chapter 1, I mentioned that iodine can lead to
contrast-media induced nephropathy in those with pre-existing renal complications. Thus,
it is imperative to probe the biocompatibility and excretion characteristics of these contrast
agents in a model of chronic kidney disease.
A review of current literature revealed that only 20-75% of ID of heavy metal
nanoparticles designed for renal clearance was excreted within 24 hours for most
formulations. Moreover, complete clearance was not achieved at longer time points.
Despite the relatively extensive clearance that I observed for Ag2S-NP, better excretion is
needed for clinical translation. I hypothesized that the glutathione ligands used as surface
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coatings might be degraded or altered during the nanoparticle formation process,
especially in the case of thermal decomposition of molecular precursors as in the
previously used synthesis. For more efficient renal clearance, the glutathione ligands
should remain unchanged in order to carry out their functions of providing stability in
biological media, deterring protein adsorption and avoiding sequestration from phagocytic
cells. As a result, I developed a microfluidics method to form Ag2S-NP under ambient
conditions. This synthesis is designed to include a primary sulfur donor (i.e., sodium
sulfide), allowing the reaction to occur at room temperature. In this case, the reagents are
not subjected to heating, which may help to maintain the structural integrity of the ligands
used. Using NMR and TGA, I found that glutathione ligands remained intact on the
nanoparticle surface. The intact coating shell improved the clearance of Ag2S-NP by
reducing liver uptake by nearly 5% of ID and shifting the nanoparticle distribution into the
hepatocytes. Nanoparticles must first evade the resident liver macrophages, or Kupffer
cells, to access the hepatobiliary clearance pathway. Thus, more clearance via the feces
could be achieved at later time points since hepatic clearance is inefficient and slow.
However, this study has limitations, for example I only examined the silver content in
hepatocytes and Kupffer cells. There is evidence for nanoparticle uptake by other
phagocytic cell types in the liver, such as hepatic B cells.6 I did not further separate LSEC
from Kupffer cells through flow cytometry sorting, so the reported values also include
uptake by LSEC. Although LSEC is the most abundant non-parenchymal cell type, more
nanoparticles are phagocytosed by Kupffer cells compared to LSEC. Furthermore, I
should analyze for the state of surface ligand molecules of renally excreted nanoparticles
via mass spectrometry or liquid chromatography. This would help us to understand the
degree of ligand displacement or substitution in vivo or probe other factors that govern
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renal clearance of inorganic nanoparticles. With this information, I can better design
nanoparticle formulations that are resistant to RES uptake and promote excretion through
kidney filtration.
In the above sections, I have extensively demonstrated the use of Ag2S-NP in Xray imaging applications. Ag2S-NP have also been widely studied for PA and NIRF
imaging and photothermal therapy (PTT) applications due to their exceptional
biocompatibility and optical properties, such as high photostability, tunable NIRF
emissions, and photoconversion activities. In Chapter 5, I focused on the development of
a novel multifunctional “one-for-all” contrast agent based on the encapsulation of sub-5
nm Ag2S-NP in biodegradable, PEGylated polymers. This agent can be used
preoperatively for multimodality breast cancer detection (i.e., DEM, CT, PA and NIRF
imaging), intraoperatively for NIRF image-guided surgery, and postoperatively for
photothermal cancer treatment. The platform is uniquely designed to break down and
allow quick elimination from the body once the diagnostic, surgical and therapeutic tasks
are fulfilled, thus providing good prospects for translation to clinical use. I found that
loading of Ag2S-NP in polymers increased their absorbance in the NIR region, resulting in
enhanced PA and NIRF contrast as well as photothermal killing in vitro. This is an
innovative approach to improving an agent’s diagnostic and therapeutic performance.
However, this study has limitations, for example I have only performed in vitro
experiments. A breast tumor model should be employed to test the potential of this agent
for multimodality tumor detection, intraoperative tumor margin delineation, and
photothermal tumor ablation in vivo. Moreover, the formulation should be further optimized
to improve the yield of silver, thus decreasing the amount of polymers used in synthesis
and reducing the viscosity of the solution. Lastly, a phantom that closely mimics the NIR
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light absorption and scattering characteristics of breast tissues could be used to better
assess the agent’s optical properties.
In summary, I have demonstrated the design and synthesis of silver sulfide
nanoparticles and investigated their utility as a diagnostic agent for X-ray and optical
imaging and as a therapeutic agent for cancer treatment via photothermal therapy. I have
devised several strategies to improve their prospects for clinical translation. This work
represents the first report of silver sulfide nanoparticles as an X-ray imaging agent and
further expands the list of potential DEM specific contrast agents.

6.2 Future directions
6.2.1 Overview
In my work, I present silver sulfide nanoparticles as a low-cost contrast agent with
potent DEM contrast and excellent biocompatibility for improved breast cancer screening.
I have established various synthetic routes to formulate these nanoparticles and further
developed them into a unique, multifunctional theranostic platform. Here, I discuss future
directions of the work and ideas for possible future projects. I will describe other silverbased chalcogenides that attenuate X-rays more strongly than Ag2S-NP, thus generating
greater contrast for enhanced cancer detection. I will examine alternative ligands and
synthetic methods to produce ultrasmall Ag2S-NP with desired properties for efficient renal
clearance. Additionally, I will explain how the current formulations could have use in other
biomedical applications. Finally, I will discuss the potential use of Ag2S-NP as contrast
agents for emerging mammographic technologies.
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6.2.2 Silver-based chalcogenide nanoparticles
Silver sulfide belongs to the silver chalcogenide group, which also includes silver
selenide and silver telluride. Silver chalcogenide nanoparticles are narrow bandgap
semiconducting quantum dots that have been widely developed as NIR emissive
nanoprobes for in vivo imaging studies.7-10 They have also been utilized in other
biomedical applications, such as sensors for biomolecules detection11, 12 and agents for
photothermal therapy.13-15 Importantly, they have very low solubility product constants (Ksp
< 10-50 M3), thus minimizing the release of toxic silver cations. In particular, silver telluride
nanoparticles (Ag2Te-NP) have the lowest solubility product (Ksp ~10-72 M3) of this family,16
which should provide superb stability and biocompatibility.17 Moreover, the k-edge of
tellurium (31.8 keV, Z = 52) falls within the high energy window of DEM and should
contribute to the overall contrast production. The combination of the two elements
provides greater flexibility in the choice of the energy pairs. Due to the presence of
tellurium, Ag2Te-NP should generate higher X-ray contrast than Ag2S-NP (attenuation of
sulfur is negligible at diagnostic energies) in both DEM and CT. The material costs of
Ag2Te-NP will be modest given the current metal prices. Therefore, Ag2Te-NP can provide
low-cost breast cancer screening options with higher X-ray contrast generation than the
Ag2S-NP formulations described in this work. However, less is known about the synthesis
of Ag2Te-NP as there are only few reports published thus far.
In preliminary experiments, I have synthesized Ag2Te-NP coated with sodium
dodecyl sulfate (SDS) surfactants. These water-soluble nanoparticles are produced
according to a previous report.18 Briefly, SDS (78 mg), sodium tellurite (10 mg) and silver
nitrate (15 mg) were mixed in a glass vial containing 9 ml of DI water. 1 ml of hydrazine
hydrate solution was subsequently injected, and the resultant mixture was heated to 90
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°C for 1 hour under constant stirring. The solution color changed from colorless to dark
brown, indicating the formation of Ag2Te-NP. Finally, the reaction mixture was purified with
excess DI water via repeated centrifugation. The core diameter of Ag2Te-NP was
determined to be 13 ± 2.4 nm (Figure 6-1A). The EDX spectrum showed the expected
stoichiometry (Figure 6-1B), confirming the presence and ratio of silver and tellurium
atoms. I have also performed DEM (Figure 6-2A) and CT (Figure 6-2C) phantom imaging
with these nanoparticles. DE contrast for each agent (Figure 6-2B) showed that Ag2TeNP generate higher contrast than Ag2S-NP at all energy combinations. Ag2Te-NP also
performed well when the low energy voltage is set at 26 kV while varying the high energy
window, which may provide flexibility in choosing the high energy X-ray energy spectrum.
CT attenuation rate (HU/mM) for each agent at each tube voltage (Figure 6-2D) indicated
that Ag2Te-NP attenuate X-rays more strongly than Ag2S-NP as expected. However, this
formulation is not stable in PBS or acidic buffers, likely due to the surfactant coating. To
improve their stability in physiological conditions, surface modification is required to
provide them with coating ligands, such as glutathione and thiol-PEG, that render solubility
in biological media. The size of these nanoparticles should also be made smaller (< 5 nm)
for swift renal excretion. Our group has recently reported the synthesis of PEGylated
Ag2Te-NP based on the aforementioned method and demonstrated their potential to
detect breast tumors in vivo via CT imaging.13 To date, only two groups, including ours,
have reported the X-ray imaging application of Ag2Te-NP in vivo, underscoring the
importance for continued exploration of this nanoparticle type.19
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Figure 6-1 Electron micrograph and EDX spectrum of Ag2Te-NP.

Figure 6-2 DEM and CT phantom imaging with Ag2Te-NP and other agents.
(a) DEM phantom image with (b) quantification of contrast-to-noise ratios. (c) CT phantom
image with (d) quantification of CT attenuation rates.
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In addition to binary silver chalcogenides, ternary silver chalcogenides (i.e., I-IIIVi2 semiconducting quantum dots) are gaining considerable interests in recent years. Most
reported ternary silver chalcogenide nanoparticle formulations are based on silver indium
sulfide (AgInS2) or silver indium telluride (AgInTe2). Indium (Z = 49) is one of the candidate
dual energy contrast elements identified in Chapter 1 and has a k-edge of 27.9 keV, which
lies within the high energy spectrum of DEM. These nanoparticles have strong
fluorescence emissions in the NIR window, making them ideal optical probes for in vivo
bioimaging applications.20-22 These nanoparticles can be prepared via organic and
aqueous solvent based syntheses as well as cation exchange with binary silver
chalcogenide nanoparticles.23-25 For example, Tan et al. synthesized hydrophilic AgInS2
nanoparticles by mixing silver and indium precursors with sulfur-hydrazine hydrate
complex in the presence of polymer ligands.26 This synthesis was performed at room
temperature and resulted in nanoparticles with core sizes between 3 to 7 nm. They found
these nanoparticles to be stable in biological media and are biocompatible with HeLa cells.
They also demonstrated the potential of AgInS2 nanoparticles for in vivo NIR fluorescence
imaging. Furthermore, AgInTe2 nanoparticles contain more X-ray attenuating atoms than
Ag2S-NP, Ag2Te-NP, and AgInS2 nanoparticles and should therefore generate higher Xray contrast in the diagnostic energy range. They have mostly been reported as optical
probes for NIR fluorescence imaging.27, 28 Overall, no reports have examined the X-ray
contrast properties of ternary silver chalcogenide nanoparticles so far. More work should
be done to evaluate their stability and safety profiles in vivo. With further research, the
applicability of this nanoparticle type may extend beyond optical imaging applications.
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6.2.3 Applicability to other biomedical uses
The field of cancer immunotherapy has expanded rapidly in the past decade. Many
strategies, such as immunoadjuvant therapy and immune checkpoint blockade, have been
developed to enhance the body’s immune response to better recognize and fight tumor
cells.29 Some of these treatment strategies have been approved by the FDA for clinical
use, such as chimeric antigen receptor T (CART) cell therapy.30 More recently, several
groups have identified PTT to provide similar immunotherapeutic effects through the
activation of specific immune response.31,

32

As mentioned in Chapter 5, PTT utilizes

photosensitizing nanoparticle agents to convert light energy into heat when irradiated with
NIR laser. PTT enables both precise local control and whole tissue irradiation, while being
a rapid, non-invasive antitumor treatment. Photothermal ablation can directly inhibit tumor
growth via apoptosis or necrosis,33 resulting in immunogenic death of tumor cells.
Immunogenic cell death promotes the release of tumor-associated antigens (TAA), cell
fragments, pro-inflammatory cytokines, and immunogenic intracellular substrates, which
are then captured by adaptive immune cells. This induces the maturation of dendritic cells,
thus activating effector T cells for sustained antigen-specific antitumor immune
responses.34-36 The migration and infiltration of immune cells at the tumor region can
eliminate the recurrence of the primary tumor, and eradicate or delay the growth of residual
and metastatic tumors. Therefore, nanomaterial mediated photothermal treatment is an
emerging immunotherapeutic approach that provides localized tumor control and
produces in situ cancer vaccine-like effects through the release of TAA and subsequent
activation of immune responses.
In Chapter 5, I have demonstrated that Ag2S-NP can generate heat in response to
NIR laser irradiation. Polymer encapsulation of these nanoparticles improves their
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photothermal killing effects by increasing the absorption of NIR light and further elevating
the solution temperature. It has been found that PTT-induced ICD occurs within an optimal
temperature window that typically ranges between 45-60 °C but varies depending on the
cancer type and tumor microenvironment.37, 38 Polymer-encapsulated Ag2S-NP can raise
the temperature higher than small core Ag2S-NP at the same silver concentration, thus
requiring less dose to achieve greater immunotherapeutic effects. Furthermore, previous
reports have noted that the inhibition of tumor growth is limited in the case of a single PTTinduced immune response.39 A recent study by Han et al. has shown that the frequency
of nanoparticle mediated PTT can influence the outcome of cancer immunotherapy. They
demonstrated that multiple PTT cycles over a period of 48 hours can reduce the
proliferation and recurrence of primary tumors as well as stimulate immune response in
vivo, which delayed the growth of distal tumors to a certain extent.40 This can be tested
with our polymeric nanoparticle formulation since these nanoparticles are stable under
several irradiation/cooling cycles and their degradation rates can be tuned to optimize the
effects of PTT immunotherapy. Photo-immunotherapy is especially useful for treating
residual tumors and preventing metastasis of cancer cells in the event of incomplete
surgical resection. Additionally, immunoadjuvants or immune checkpoint inhibitors could
be loaded in the polymeric nanostructures to create a synergistic immunotherapy
nanoprobe for enhancing the antitumor immune response. Immunomodulators, such as
CpG, Imiquimod, and Resiquimod, can promote dendritic cell maturation, mediate immune
activation by interacting with toll-like receptors and ameliorate immunosuppression in the
tumor microenvironment.41-43 Finally, Ag2S-NP have recently been shown to inhibit the
growth of lymphoma cells via photodynamic therapy (PDT).44 PDT eliminates tumor cells
through reactive oxygen species (ROS) generation from NIR light activated
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photosensitizing agents. When combining PDT with PTT, issues with tumor hypoxia can
be alleviated due to increased blood flow from local hyperthermia. The combination of
these two phototherapies can thus further improve the outcome of cancer
immunotherapy.45

6.2.4 Emerging mammographic technologies
As I mentioned in Chapter 1, photon counting digital mammography is a novel
mammography technique that utilizes photon counting detectors to discriminate between
high and low energy X-ray photons via two energy thresholds, thus forming a spectral
mammogram.46, 47 This system has been used to differentiate breast tissue compositions
based on their energy-dependent spectral absorption characteristics.48 For example,
previous studies have demonstrated the use of unenhanced photon counting
mammography to discriminate cystic fluid from solid lesions that would otherwise be
difficult to distinguish on mammography alone.49-51 However, the development of contrast
agents specifically designed for this technique has not been explored. In this thesis, I have
extensively demonstrated the potential of Ag2S-NP as a novel contrast agent for DEM.
Thus, it is likely that this type of contrast material may prove effective for photon counting
mammography since this modality is similar to DEM.
In preliminary work, I synthesized ultrasmall Ag2S-NP using the thermal
decomposition method described in Chapter 3. These nanoparticles were 5 nm in core
diameter, as determined by TEM. To evaluate the potential of Ag2S-NP as a photon
counting mammography contrast agent, a Philips MicroDose SI prototype mammography
system (Kista, Sweden) was used to scan a customized ramp phantom composed of
adipose and glandular tissue-equivalent materials (Figure 6-3A). Several samples of
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Ag2S-NP with concentrations ranging from 1 to 30 mg Ag/ml along with PBS and water
were inserted in the phantom. Spectral mammograms (i.e., low energy, high energy, and
sum images) were acquired at various tube voltages (26 to 40 kV), tube currents (12 to 24
mAs) and high bin fractions (HBF, 0.28 – 0.50). Analysis of the phantom images shows a
linear correlation between Ag2S-NP concentration and CNR at each scanning condition
(Figure 6-3B). The magnitude of CNR also increased with increasing X-ray tube voltages.
An example phantom image obtained at 38 kV with a tube current of 24 mAs and HBF of
0.35 is shown in Figure 6-3C. In a comparative analysis with iodine, I found that the optimal
energy for imaging iodine occurs above the k-edge of iodine, which is beyond the clinical
mammographic energy range.52 The preliminary results indicated that Ag2S-NP produce
higher signal than iodine in photon counting mammography, especially when imaged at
lower energies. Further investigations with this technology will include topics such as
alternative energy binning methods, different silver-based contrast agents, and in vivo
breast tumor imaging.
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Figure 6-3 Phantom imaging with photon counting mammography.
(a) Schematic of the contrast-embedded gradient ramp phantom and arrangement of
Ag2S-NP samples. (b) CNR vs. concentration of Ag2S-NP obtained at different tube
voltages, currents, and HBF. (c) Phantom images from high energy bin, low energy bin
and dual energy subtraction obtained at 38 kV (current = 24 mAs, HBF = 0.35).

6.2.5 Alternative coating ligands and synthetic routes
In Chapters 3 and 4, I have demonstrated the renal clearance of sub-5 nm Ag2SNP via CT imaging and biodistribution analyses. As previously mentioned, these
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nanoparticles were synthesized either via a one-pot, high temperature or a microfluidic,
room temperature (Synthesis B) approach. Glutathione was employed as the nanoparticle
surface coating ligand in both syntheses. Glutathione is a zwitterionic tripeptide that is
abundantly found in the cytoplasm. Zwitterionic ligands contain both positively and
negatively charged functional groups, which can carry charges and provide colloidal
stability over a broad pH range. Glutathione is frequently used to coat heavy metal
nanoparticles owing to the strong binding affinity of thiols toward metal ions and high
stability under physiological conditions. These small peptides can prevent nonspecific
serum protein adsorption that would otherwise increase the overall nanoparticle size.
Thus, many reports have successfully developed renally clearable nanoparticles using
glutathione as the capping ligand.53-56
Other zwitterionic, thiol-containing ligands such as cysteine and penicillamine are
good candidates for developing renally excretable nanoparticles. These ligands are lower
in molecular weights compared to glutathione, which may help to maintain an even smaller
HD. Using cysteine coated quantum dots as the model system, Choi et al. were the first
to establish the nanoparticle size cutoff (HD < 5.5 nm) for glomerular filtration.5 However,
recent reports have shown that cysteine ligands are prone to oxidation and are stable only
for a short period of time in the presence of reducing agents.57, 58 This results in the
aggregation of nanoparticles and an increase in the overall nanoparticle size, which would
render them non-renally clearable. On the other hand, penicillamine is a small molecule
that can form chelates with heavy metal ions and be quickly excreted from the body via
renal filtration. Penicillamine has been applied to treat Wilson’s disease, cystinuria and
lead poisoning.59 It has been found that penicillamine ligands can prevent nanoparticle
aggregation due to steric hinderance by the methyl groups of the -carbon of
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penicillamine.60 The steric constraints effectively reduce the oxidative dimerization of the
thiol groups, thus providing good stability over the physiologically relevant pH range. Few
reports have synthesized penicillamine coated Ag2S-NP using a microwave dielectric
heating process and have focused on their use as a NIR fluorescent probe for in vitro cell
imaging.61,
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To the best of our knowledge, no reports have investigated the in vivo

imaging applications and renal clearance of penicillamine coated Ag2S-NP. Thus, this
could be a potential avenue for future work.
In preliminary experiments, I have successfully synthesized penicillamine coated
Ag2S-NP using the microfluidic, room temperature approach described in Chapter 4 (with
the same molar ratios of reagents). As shown in Figure 6-4A, I have tuned their size by
varying the combined flow speeds. For example, the combined speed was varied between
1 and 3.5 ml/min to obtain an array of Ag2S-NP with core sizes ranging between 5 to 10
nm. I have also followed another literature method to synthesize these nanoparticles with
some modifications.63 Briefly, a sulfur-hydrazine complex was prepared by dissolving
elemental sulfur powder in hydrazine hydrate for 24 hours at room temperature. This
complex served as the primary sulfur donor and was added to a mixture of silver nitrate
and penicillamine in water. Overall, the synthesis was designed to allow the reaction to
proceed at room temperature. The nanoparticle size could be finely tuned by modulating
the reaction time. As shown in Figure 6-4B, the reaction time was varied between 10 and
20 minutes to obtain an array of Ag2S-NP with core sizes ranging between 4 to 11 nm.
Compared to the reported syntheses (i.e., microwave heating method), our synthetic
routes allow nanoparticles to be formed under ambient conditions. Based on our results
in Chapter 4, it is important to use mild synthetic conditions to maintain the integrity of
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nanoparticle surface ligands for improved renal clearance. More work should be done to
reduce the nanoparticle size and investigate their stability in buffers of different pH.

Figure 6-4 Electron micrographs of penicillamine coated Ag2S-NP.
(a) Ag2S-NP were synthesized using the microfluidics, room temperature approach
described in Chapter 4. The combined flow rate was set at (i) 1, (ii) 2.5 and (iii) 3.5 ml/min
to obtain Ag2S-NP with core sizes of 10.4 ± 1.3, 5.9 ± 0.8 and 4.9 ± 0.6 nm, respectively.
(b) Ag2S-NP were synthesized at room temperature using a sulfur-hydrazine hydrate
complex. The reaction was quenched at (i) 10, (ii) 15 and (iii) 20 minutes to obtain Ag 2SNP with core sizes of 10.5 ± 1.7, 6.6 ± 1.0 and 4.6 ± 0.6 nm, respectively. The scale is
indicated in the lower right corner on the rightmost image for each row of images. Scale
bar = 50 nm.

225

6.3 Concluding remarks
This thesis focuses on the development of silver sulfide nanoparticles as a lowcost, biocompatible contrast agent for improved breast imaging with dual energy
mammography and other modalities. Overall, this work represents a significant
advancement in the biomedical uses of this nanoparticle type. Silver sulfide nanoparticles
may now find applications in breast cancer detection with X-ray and optical imaging as
well as treatment with phototherapy. The improvements in mammographic techniques,
especially with the rapid progression of photon counting technologies, may further expand
the utility of these nanoparticles. With more research, they will emerge as a multifunctional
theranostic agent suitable for clinical breast imaging and cancer treatment.
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